1n8z › Citations

Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab.

Cho HS, Mason K, Ramyar KX, Stanley AM, Gabelli SB, Denney DW, Leahy DJ
Nature 421 756-60 (2003)
Cited: 932 times
EuropePMC logo PMID: 12610629

Abstract

HER2 (also known as Neu, ErbB2) is a member of the epidermal growth factor receptor (EGFR; also known as ErbB) family of receptor tyrosine kinases, which in humans includes HER1 (EGFR, ERBB1), HER2, HER3 (ERBB3) and HER4 (ERBB4). ErbB receptors are essential mediators of cell proliferation and differentiation in the developing embryo and in adult tissues, and their inappropriate activation is associated with the development and severity of many cancers. Overexpression of HER2 is found in 20-30% of human breast cancers, and correlates with more aggressive tumours and a poorer prognosis. Anticancer therapies targeting ErbB receptors have shown promise, and a monoclonal antibody against HER2, Herceptin (also known as trastuzumab), is currently in use as a treatment for breast cancer. Here we report crystal structures of the entire extracellular regions of rat HER2 at 2.4 A and human HER2 complexed with the Herceptin antigen-binding fragment (Fab) at 2.5 A. These structures reveal a fixed conformation for HER2 that resembles a ligand-activated state, and show HER2 poised to interact with other ErbB receptors in the absence of direct ligand binding. Herceptin binds to the juxtamembrane region of HER2, identifying this site as a target for anticancer therapies.

Reviews - 1n8z mentioned but not cited (19)

  1. The role of HER2 in cancer therapy and targeted drug delivery. Tai W, Mahato R, Cheng K. J Control Release 146 264-275 (2010)
  2. Structure-based view of epidermal growth factor receptor regulation. Ferguson KM. Annu Rev Biophys 37 353-373 (2008)
  3. Peptide-Based Vaccines: Current Progress and Future Challenges. Malonis RJ, Lai JR, Vergnolle O. Chem Rev 120 3210-3229 (2020)
  4. A structural perspective on the regulation of the epidermal growth factor receptor. Kovacs E, Zorn JA, Huang Y, Barros T, Kuriyan J. Annu Rev Biochem 84 739-764 (2015)
  5. The use of CrossMAb technology for the generation of bi- and multispecific antibodies. Klein C, Schaefer W, Regula JT. MAbs 8 1010-1020 (2016)
  6. Structural and genetic diversity in antibody repertoires from diverse species. de los Rios M, Criscitiello MF, Smider VV. Curr Opin Struct Biol 33 27-41 (2015)
  7. Review: Precision medicine and driver mutations: Computational methods, functional assays and conformational principles for interpreting cancer drivers. Nussinov R, Jang H, Tsai CJ, Cheng F. PLoS Comput Biol 15 e1006658 (2019)
  8. How Structural Biologists and the Protein Data Bank Contributed to Recent FDA New Drug Approvals. Westbrook JD, Burley SK. Structure 27 211-217 (2019)
  9. Engineered Autonomous Human Variable Domains. Nilvebrant J, Tessier PM, Sidhu SS. Curr Pharm Des 22 6527-6537 (2016)
  10. Immunoglobulins or Antibodies: IMGT® Bridging Genes, Structures and Functions. Lefranc MP, Lefranc G. Biomedicines 8 E319 (2020)
  11. Impact of the Protein Data Bank on antineoplastic approvals. Westbrook JD, Soskind R, Hudson BP, Burley SK. Drug Discov Today 25 837-850 (2020)
  12. Selection and characterization of cell binding and internalizing phage antibodies. Zhou Y, Zhao L, Marks JD. Arch Biochem Biophys 526 107-113 (2012)
  13. Thiophene-Based Compounds with Potential Anti-Inflammatory Activity. da Cruz RMD, Mendonça-Junior FJB, de Mélo NB, Scotti L, de Araújo RSA, de Almeida RN, de Moura RO. Pharmaceuticals (Basel) 14 692 (2021)
  14. Bos taurus ultralong CDR H3 antibodies. Vadnais ML, Smider VV. Curr Opin Struct Biol 38 62-67 (2016)
  15. Recent advances in T-cell engineering for use in immunotherapy. Sharma P, Kranz DM. F1000Res 5 F1000 Faculty Rev-2344 (2016)
  16. Homo- and Heterodimerization of Proteins in Cell Signaling: Inhibition and Drug Design. Singh SS, Jois SD. Adv Protein Chem Struct Biol 111 1-59 (2018)
  17. Structural Perspectives on Extracellular Recognition and Conformational Changes of Several Type-I Transmembrane Receptors. Chataigner LMP, Leloup N, Janssen BJC. Front Mol Biosci 7 129 (2020)
  18. Cryo-electron Microscopic Analysis of Single-Pass Transmembrane Receptors. Cai K, Zhang X, Bai XC. Chem Rev 122 13952-13988 (2022)
  19. Challenges in Detection of Serum Oncoprotein: Relevance to Breast Cancer Diagnostics. Lengfeld J, Zhang H, Stoesz S, Murali R, Pass F, Greene MI, Goel PN, Grover P. Breast Cancer (Dove Med Press) 13 575-593 (2021)

Articles - 1n8z mentioned but not cited (157)

  1. TanCAR: A Novel Bispecific Chimeric Antigen Receptor for Cancer Immunotherapy. Grada Z, Hegde M, Byrd T, Shaffer DR, Ghazi A, Brawley VS, Corder A, Schönfeld K, Koch J, Dotti G, Heslop HE, Gottschalk S, Wels WS, Baker ML, Ahmed N. Mol Ther Nucleic Acids 2 e105 (2013)
  2. Redox-based reagents for chemoselective methionine bioconjugation. Lin S, Yang X, Jia S, Weeks AM, Hornsby M, Lee PS, Nichiporuk RV, Iavarone AT, Wells JA, Toste FD, Chang CJ. Science 355 597-602 (2017)
  3. Structural basis of Wnt signaling inhibition by Dickkopf binding to LRP5/6. Ahn VE, Chu ML, Choi HJ, Tran D, Abo A, Weis WI. Dev Cell 21 862-873 (2011)
  4. Potential aggregation prone regions in biotherapeutics: A survey of commercial monoclonal antibodies. Wang X, Das TK, Singh SK, Kumar S. MAbs 1 254-267 (2009)
  5. Chemo- and Regioselective Lysine Modification on Native Proteins. Matos MJ, Oliveira BL, Martínez-Sáez N, Guerreiro A, Cal PMSD, Bertoldo J, Maneiro M, Perkins E, Howard J, Deery MJ, Chalker JM, Corzana F, Jiménez-Osés G, Bernardes GJL. J Am Chem Soc 140 4004-4017 (2018)
  6. Improving B-cell epitope prediction and its application to global antibody-antigen docking. Krawczyk K, Liu X, Baker T, Shi J, Deane CM. Bioinformatics 30 2288-2294 (2014)
  7. PyIgClassify: a database of antibody CDR structural classifications. Adolf-Bryfogle J, Xu Q, North B, Lehmann A, Dunbrack RL. Nucleic Acids Res 43 D432-8 (2015)
  8. Characterisation of an engineered trastuzumab IgE antibody and effector cell mechanisms targeting HER2/neu-positive tumour cells. Karagiannis P, Singer J, Hunt J, Gan SK, Rudman SM, Mechtcheriakova D, Knittelfelder R, Daniels TR, Hobson PS, Beavil AJ, Spicer J, Nestle FO, Penichet ML, Gould HJ, Jensen-Jarolim E, Karagiannis SN. Cancer Immunol Immunother 58 915-930 (2009)
  9. Engineering luminescent biosensors for point-of-care SARS-CoV-2 antibody detection. Elledge SK, Zhou XX, Byrnes JR, Martinko AJ, Lui I, Pance K, Lim SA, Glasgow JE, Glasgow AA, Turcios K, Iyer NS, Torres L, Peluso MJ, Henrich TJ, Wang TT, Tato CM, Leung KK, Greenhouse B, Wells JA. Nat Biotechnol 39 928-935 (2021)
  10. Epitope mapping using combinatorial phage-display libraries: a graph-based algorithm. Mayrose I, Shlomi T, Rubinstein ND, Gershoni JM, Ruppin E, Sharan R, Pupko T. Nucleic Acids Res 35 69-78 (2007)
  11. Improving target cell specificity using a novel monovalent bispecific IgG design. Mazor Y, Oganesyan V, Yang C, Hansen A, Wang J, Liu H, Sachsenmeier K, Carlson M, Gadre DV, Borrok MJ, Yu XQ, Dall'Acqua W, Wu H, Chowdhury PS. MAbs 7 377-389 (2015)
  12. Inhibition of human tumor growth in mice by an oncolytic herpes simplex virus designed to target solely HER-2-positive cells. Menotti L, Nicoletti G, Gatta V, Gatta V, Croci S, Landuzzi L, De Giovanni C, Nanni P, Lollini PL, Campadelli-Fiume G. Proc Natl Acad Sci U S A 106 9039-9044 (2009)
  13. Actionable Activating Oncogenic ERBB2/HER2 Transmembrane and Juxtamembrane Domain Mutations. Pahuja KB, Nguyen TT, Jaiswal BS, Prabhash K, Thaker TM, Senger K, Chaudhuri S, Kljavin NM, Antony A, Phalke S, Kumar P, Mravic M, Stawiski EW, Vargas D, Durinck S, Gupta R, Khanna-Gupta A, Trabucco SE, Sokol ES, Hartmaier RJ, Singh A, Chougule A, Trivedi V, Dutt A, Patil V, Joshi A, Noronha V, Ziai J, Banavali SD, Ramprasad V, DeGrado WF, Bueno R, Jura N, Seshagiri S. Cancer Cell 34 792-806.e5 (2018)
  14. ErbB2 resembles an autoinhibited invertebrate epidermal growth factor receptor. Alvarado D, Klein DE, Lemmon MA. Nature 461 287-291 (2009)
  15. RosettaAntibodyDesign (RAbD): A general framework for computational antibody design. Adolf-Bryfogle J, Kalyuzhniy O, Kubitz M, Weitzner BD, Hu X, Adachi Y, Schief WR, Dunbrack RL. PLoS Comput Biol 14 e1006112 (2018)
  16. A genetically encoded aza-Michael acceptor for covalent cross-linking of protein-receptor complexes. Furman JL, Kang M, Choi S, Cao Y, Wold ED, Sun SB, Smider VV, Schultz PG, Kim CH. J Am Chem Soc 136 8411-8417 (2014)
  17. Comparative oncology: ErbB-1 and ErbB-2 homologues in canine cancer are susceptible to cetuximab and trastuzumab targeting. Singer J, Weichselbaumer M, Stockner T, Mechtcheriakova D, Sobanov Y, Bajna E, Wrba F, Horvat R, Thalhammer JG, Willmann M, Jensen-Jarolim E. Mol Immunol 50 200-209 (2012)
  18. Design of Switchable Chimeric Antigen Receptor T Cells Targeting Breast Cancer. Cao Y, Rodgers DT, Du J, Ahmad I, Hampton EN, Ma JS, Mazagova M, Choi SH, Yun HY, Xiao H, Yang P, Luo X, Lim RK, Pugh HM, Wang F, Kazane SA, Wright TM, Kim CH, Schultz PG, Young TS. Angew Chem Int Ed Engl 55 7520-7524 (2016)
  19. Synergy between trastuzumab and pertuzumab for human epidermal growth factor 2 (Her2) from colocalization: an in silico based mechanism. Fuentes G, Scaltriti M, Baselga J, Verma CS. Breast Cancer Res 13 R54 (2011)
  20. A new tool for monoclonal antibody analysis: application of IdeS proteolysis in IgG domain-specific characterization. An Y, Zhang Y, Mueller HM, Shameem M, Chen X. MAbs 6 879-893 (2014)
  21. An immunosuppressive antibody-drug conjugate. Wang RE, Liu T, Wang Y, Cao Y, Du J, Luo X, Deshmukh V, Kim CH, Lawson BR, Tremblay MS, Young TS, Kazane SA, Wang F, Schultz PG. J Am Chem Soc 137 3229-3232 (2015)
  22. Native mass spectrometry and ion mobility characterization of trastuzumab emtansine, a lysine-linked antibody drug conjugate. Marcoux J, Champion T, Colas O, Wagner-Rousset E, Corvaïa N, Van Dorsselaer A, Beck A, Cianférani S. Protein Sci 24 1210-1223 (2015)
  23. Prediction of antigenic epitopes on protein surfaces by consensus scoring. Liang S, Zheng D, Zhang C, Zacharias M. BMC Bioinformatics 10 302 (2009)
  24. High affinity antigen recognition of the dual specific variants of herceptin is entropy-driven in spite of structural plasticity. Bostrom J, Haber L, Koenig P, Kelley RF, Fuh G. PLoS One 6 e17887 (2011)
  25. Receptor-Targeted Nipah Virus Glycoproteins Improve Cell-Type Selective Gene Delivery and Reveal a Preference for Membrane-Proximal Cell Attachment. Bender RR, Muth A, Schneider IC, Friedel T, Hartmann J, Plückthun A, Maisner A, Buchholz CJ. PLoS Pathog 12 e1005641 (2016)
  26. Automated detection of conformational epitopes using phage display Peptide sequences. Negi SS, Braun W. Bioinform Biol Insights 3 71-81 (2009)
  27. A novel antibody engineering strategy for making monovalent bispecific heterodimeric IgG antibodies by electrostatic steering mechanism. Liu Z, Leng EC, Gunasekaran K, Pentony M, Shen M, Howard M, Stoops J, Manchulenko K, Razinkov V, Liu H, Fanslow W, Hu Z, Sun N, Hasegawa H, Clark R, Foltz IN, Yan W. J Biol Chem 290 7535-7562 (2015)
  28. Potential aggregation-prone regions in complementarity-determining regions of antibodies and their contribution towards antigen recognition: a computational analysis. Wang X, Singh SK, Kumar S. Pharm Res 27 1512-1529 (2010)
  29. Site-specific coupling and sterically controlled formation of multimeric antibody fab fragments with unnatural amino acids. Hutchins BM, Kazane SA, Staflin K, Forsyth JS, Felding-Habermann B, Schultz PG, Smider VV. J Mol Biol 406 595-603 (2011)
  30. Evaluating the Use of Antibody Variable Region (Fv) Charge as a Risk Assessment Tool for Predicting Typical Cynomolgus Monkey Pharmacokinetics. Bumbaca Yadav D, Sharma VK, Boswell CA, Hotzel I, Tesar D, Shang Y, Ying Y, Fischer SK, Grogan JL, Chiang EY, Urban K, Ulufatu S, Khawli LA, Prabhu S, Joseph S, Kelley RF. J Biol Chem 290 29732-29741 (2015)
  31. Her2 activation mechanism reflects evolutionary preservation of asymmetric ectodomain dimers in the human EGFR family. Arkhipov A, Shan Y, Kim ET, Dror RO, Shaw DE. Elife 2 e00708 (2013)
  32. A conformationally constrained peptidomimetic binds to the extracellular region of HER2 protein. Banappagari S, Ronald S, Satyanarayanajois SD. J Biomol Struct Dyn 28 289-308 (2010)
  33. Self-assembled antibody multimers through peptide nucleic acid conjugation. Kazane SA, Axup JY, Kim CH, Ciobanu M, Wold ED, Barluenga S, Hutchins BA, Schultz PG, Winssinger N, Smider VV. J Am Chem Soc 135 340-346 (2013)
  34. Systematic screening of soluble expression of antibody fragments in the cytoplasm of E. coli. Gaciarz A, Veijola J, Uchida Y, Saaranen MJ, Wang C, Hörkkö S, Ruddock LW. Microb Cell Fact 15 22 (2016)
  35. A novel asymmetrical anti-HER2/CD3 bispecific antibody exhibits potent cytotoxicity for HER2-positive tumor cells. Yu S, Zhang J, Yan Y, Yao X, Fang L, Xiong H, Liu Y, Chu Q, Zhou P, Wu K. J Exp Clin Cancer Res 38 355 (2019)
  36. Efficient production of bispecific IgG of different isotypes and species of origin in single mammalian cells. Dillon M, Yin Y, Zhou J, McCarty L, Ellerman D, Slaga D, Junttila TT, Han G, Sandoval W, Ovacik MA, Lin K, Hu Z, Shen A, Corn JE, Spiess C, Carter PJ. MAbs 9 213-230 (2017)
  37. Molecular modeling of nearly full-length ErbB2 receptor. Bagossi P, Horváth G, Vereb G, Szöllösi J, Tözsér J. Biophys J 88 1354-1363 (2005)
  38. Engineering a HER2-specific antibody-drug conjugate to increase lysosomal delivery and therapeutic efficacy. Kang JC, Sun W, Khare P, Karimi M, Wang X, Shen Y, Ober RJ, Ward ES, Ward ES. Nat Biotechnol 37 523-526 (2019)
  39. Pep-3D-Search: a method for B-cell epitope prediction based on mimotope analysis. Huang YX, Bao YL, Guo SY, Wang Y, Zhou CG, Li YX. BMC Bioinformatics 9 538 (2008)
  40. Differential binding patterns of monoclonal antibody 2C4 to the ErbB3-p185her2/neu and the EGFR-p185her2/neu complexes. Cai Z, Zhang G, Zhou Z, Bembas K, Drebin JA, Greene MI, Zhang H. Oncogene 27 3870-3874 (2008)
  41. The effects of Antibody Engineering CH and CL in Trastuzumab and Pertuzumab recombinant models: Impact on antibody production and antigen-binding. Lua WH, Ling WL, Yeo JY, Poh JJ, Lane DP, Gan SK. Sci Rep 8 718 (2018)
  42. Design, synthesis, and docking studies of peptidomimetics based on HER2-herceptin binding site with potential antiproliferative activity against breast cancer cell lines. Satyanarayanajois S, Villalba S, Jianchao L, Lin GM. Chem Biol Drug Des 74 246-257 (2009)
  43. Rapid assessment of oxidation via middle-down LCMS correlates with methionine side-chain solvent-accessible surface area for 121 clinical stage monoclonal antibodies. Yang R, Jain T, Lynaugh H, Nobrega RP, Lu X, Boland T, Burnina I, Sun T, Caffry I, Brown M, Zhi X, Lilov A, Xu Y. MAbs 9 646-653 (2017)
  44. Identification and grafting of a unique peptide-binding site in the Fab framework of monoclonal antibodies. Donaldson JM, Zer C, Avery KN, Bzymek KP, Horne DA, Williams JC. Proc Natl Acad Sci U S A 110 17456-17461 (2013)
  45. Protein Crosslinking by Genetically Encoded Noncanonical Amino Acids with Reactive Aryl Carbamate Side Chains. Xuan W, Shao S, Schultz PG. Angew Chem Int Ed Engl 56 5096-5100 (2017)
  46. Assessment of flexible backbone protein design methods for sequence library prediction in the therapeutic antibody Herceptin-HER2 interface. Babor M, Mandell DJ, Kortemme T. Protein Sci 20 1082-1089 (2011)
  47. Structural insights into the down-regulation of overexpressed p185(her2/neu) protein of transformed cells by the antibody chA21. Zhou H, Zha Z, Liu Y, Zhang H, Zhu J, Hu S, Shen G, Cheng L, Niu L, Greene MI, Teng M, Liu J. J Biol Chem 286 31676-31683 (2011)
  48. Functional human antibody CDR fusions as long-acting therapeutic endocrine agonists. Liu T, Zhang Y, Liu Y, Wang Y, Jia H, Kang M, Luo X, Caballero D, Gonzalez J, Sherwood L, Nunez V, Wang D, Woods A, Schultz PG, Wang F. Proc Natl Acad Sci U S A 112 1356-1361 (2015)
  49. Probing antibody internal dynamics with fluorescence anisotropy and molecular dynamics simulations. Kortkhonjia E, Brandman R, Zhou JZ, Voelz VA, Chorny I, Kabakoff B, Patapoff TW, Dill KA, Swartz TE. MAbs 5 306-322 (2013)
  50. Effect of VH-VL Families in Pertuzumab and Trastuzumab Recombinant Production, Her2 and FcγIIA Binding. Ling WL, Lua WH, Poh JJ, Yeo JY, Lane DP, Gan SK. Front Immunol 9 469 (2018)
  51. Assessment of ab initio models of protein complexes by molecular dynamics. Radom F, Plückthun A, Paci E. PLoS Comput Biol 14 e1006182 (2018)
  52. Assisted Design of Antibody and Protein Therapeutics (ADAPT). Vivcharuk V, Baardsnes J, Deprez C, Sulea T, Jaramillo M, Corbeil CR, Mullick A, Magoon J, Marcil A, Durocher Y, O'Connor-McCourt MD, Purisima EO. PLoS One 12 e0181490 (2017)
  53. Oxetane Grafts Installed Site-Selectively on Native Disulfides to Enhance Protein Stability and Activity In Vivo. Martínez-Sáez N, Sun S, Oldrini D, Sormanni P, Boutureira O, Carboni F, Compañón I, Deery MJ, Vendruscolo M, Corzana F, Adamo R, Bernardes GJL. Angew Chem Int Ed Engl 56 14963-14967 (2017)
  54. Reorienting the Fab domains of trastuzumab results in potent HER2 activators. Scheer JM, Sandoval W, Elliott JM, Shao L, Luis E, Lewin-Koh SC, Schaefer G, Vandlen R. PLoS One 7 e51817 (2012)
  55. Co-occurring gain-of-function mutations in HER2 and HER3 modulate HER2/HER3 activation, oncogenesis, and HER2 inhibitor sensitivity. Hanker AB, Brown BP, Meiler J, Marín A, Jayanthan HS, Ye D, Lin CC, Akamatsu H, Lee KM, Chatterjee S, Sudhan DR, Servetto A, Brewer MR, Koch JP, Sheehan JH, He J, Lalani AS, Arteaga CL. Cancer Cell 39 1099-1114.e8 (2021)
  56. MimoPro: a more efficient Web-based tool for epitope prediction using phage display libraries. Chen WH, Sun PP, Lu Y, Guo WW, Huang YX, Ma ZQ. BMC Bioinformatics 12 199 (2011)
  57. The role of Antibody Vκ Framework 3 region towards Antigen binding: Effects on recombinant production and Protein L binding. Su CT, Ling WL, Lua WH, Poh JJ, Gan SK. Sci Rep 7 3766 (2017)
  58. A High-Throughput Method for Characterizing Novel Chimeric Antigen Receptors in Jurkat Cells. Bloemberg D, Nguyen T, MacLean S, Zafer A, Gadoury C, Gurnani K, Chattopadhyay A, Ash J, Lippens J, Harcus D, Pagé M, Fortin A, Pon RA, Gilbert R, Marcil A, Weeratna RD, McComb S. Mol Ther Methods Clin Dev 16 238-254 (2020)
  59. Combating HER2-overexpressing breast cancer through induction of calreticulin exposure by Tras-Permut CrossMab. Zhang F, Zhang J, Liu M, Zhao L, LingHu R, Feng F, Gao X, Jiao S, Zhao L, Hu Y, Yang J. Oncoimmunology 4 e994391 (2015)
  60. Comparison of Rosetta flexible-backbone computational protein design methods on binding interactions. Loshbaugh AL, Kortemme T. Proteins 88 206-226 (2020)
  61. Efficient Phage Display with Multiple Distinct Non-Canonical Amino Acids Using Orthogonal Ribosome-Mediated Genetic Code Expansion. Oller-Salvia B, Chin JW. Angew Chem Int Ed Engl 58 10844-10848 (2019)
  62. Expression of recombinant multi-coloured fluorescent antibodies in gor -/trxB- E. coli cytoplasm. Markiv A, Beatson R, Burchell J, Durvasula RV, Kang AS. BMC Biotechnol 11 117 (2011)
  63. High throughput cytotoxicity screening of anti-HER2 immunotoxins conjugated with antibody fragments from phage-displayed synthetic antibody libraries. Hou SC, Chen HS, Lin HW, Chao WT, Chen YS, Fu CY, Yu CM, Huang KF, Wang AH, Yang AS. Sci Rep 6 31878 (2016)
  64. Homology modeling and structure-based design improve hydrophobic interaction chromatography behavior of integrin binding antibodies. Jetha A, Thorsteinson N, Jmeian Y, Jeganathan A, Giblin P, Fransson J. MAbs 10 890-900 (2018)
  65. Not all therapeutic antibody isotypes are equal: the case of IgM versus IgG in Pertuzumab and Trastuzumab. Samsudin F, Yeo JY, Gan SK, Bond PJ. Chem Sci 11 2843-2854 (2020)
  66. Structures of the HER2-HER3-NRG1β complex reveal a dynamic dimer interface. Diwanji D, Trenker R, Thaker TM, Wang F, Agard DA, Verba KA, Jura N. Nature 600 339-343 (2021)
  67. Systems analysis of drug-induced receptor tyrosine kinase reprogramming following targeted mono- and combination anti-cancer therapy. Goltsov A, Deeni Y, Khalil HS, Soininen T, Kyriakidis S, Hu H, Langdon SP, Harrison DJ, Bown J. Cells 3 563-591 (2014)
  68. A Tri-part Protein Complementation System Using Antibody-Small Peptide Fusions Enables Homogeneous Immunoassays. Dixon AS, Kim SJ, Baumgartner BK, Krippner S, Owen SC. Sci Rep 7 8186 (2017)
  69. Directed Evolution of Scanning Unnatural-Protease-Resistant (SUPR) Peptides for in Vivo Applications. Fiacco SV, Kelderhouse LE, Hardy A, Peleg Y, Hu B, Ornelas A, Yang P, Gammon ST, Howell SM, Wang P, Takahashi TT, Millward SW, Roberts RW. Chembiochem 17 1643-1651 (2016)
  70. Structural model for the interaction of a designed Ankyrin Repeat Protein with the human epidermal growth factor receptor 2. Epa VC, Dolezal O, Doughty L, Xiao X, Jost C, Plückthun A, Adams TE. PLoS One 8 e59163 (2013)
  71. Conformational Ensembles of Antibodies Determine Their Hydrophobicity. Waibl F, Fernández-Quintero ML, Kamenik AS, Kraml J, Hofer F, Kettenberger H, Georges G, Liedl KR. Biophys J 120 143-157 (2021)
  72. Cryo-EM Structure of HER2-trastuzumab-pertuzumab complex. Hao Y, Yu X, Bai Y, McBride HJ, Huang X. PLoS One 14 e0216095 (2019)
  73. Effect of variable domain charge on in vitro and in vivo disposition of monoclonal antibodies. Liu S, Verma A, Kettenberger H, Richter WF, Shah DK. MAbs 13 1993769 (2021)
  74. A simple strategy for retargeting lentiviral vectors to desired cell types via a disulfide-bond-forming protein-peptide pair. Kasaraneni N, Chamoun-Emanuelli AM, Wright GA, Chen Z. Sci Rep 8 10990 (2018)
  75. Epitope prediction based on random peptide library screening: benchmark dataset and prediction tools evaluation. Sun P, Chen W, Huang Y, Wang H, Ma Z, Lv Y. Molecules 16 4971-4993 (2011)
  76. Predominant structural configuration of natural antibody repertoires enables potent antibody responses against protein antigens. Chen HS, Hou SC, Jian JW, Goh KS, Shen ST, Lee YC, You JJ, Peng HP, Kuo WC, Chen ST, Peng MC, Wang AH, Yu CM, Chen IC, Tung CP, Chen TH, Ping Chiu K, Ma C, Yuan Wu C, Lin SW, Yang AS. Sci Rep 5 12411 (2015)
  77. Bivalent antibody pliers inhibit β-tryptase by an allosteric mechanism dependent on the IgG hinge. Maun HR, Vij R, Walters BT, Morando A, Jackman JK, Wu P, Estevez A, Chen X, Franke Y, Lipari MT, Dennis MS, Kirchhofer D, Ciferri C, Loyet KM, Yi T, Eigenbrot C, Lazarus RA, Koerber JT. Nat Commun 11 6435 (2020)
  78. Cholesterol loading and ultrastable protein interactions determine the level of tumor marker required for optimal isolation of cancer cells. Jain J, Veggiani G, Howarth M. Cancer Res 73 2310-2321 (2013)
  79. DutaFabs are engineered therapeutic Fab fragments that can bind two targets simultaneously. Beckmann R, Jensen K, Fenn S, Speck J, Krause K, Meier A, Röth M, Fauser S, Kimbung R, Logan DT, Steegmaier M, Kettenberger H. Nat Commun 12 708 (2021)
  80. Parallel immunizations of rabbits using the same antigen yield antibodies with similar, but not identical, epitopes. Hjelm B, Forsström B, Löfblom J, Rockberg J, Uhlén M. PLoS One 7 e45817 (2012)
  81. Structure based antibody-like peptidomimetics. Murali R, Greene MI. Pharmaceuticals (Basel) 5 209-235 (2012)
  82. Thermodynamic stability and flexibility characteristics of antibody fragment complexes. Li T, Verma D, Tracka MB, Casas-Finet J, Livesay DR, Jacobs DJ. Protein Pept Lett 21 752-765 (2014)
  83. Antibody-drug conjugates with HER2-targeting antibodies from synthetic antibody libraries are highly potent against HER2-positive human gastric tumor in xenograft models. Kuo WY, Hsu HJ, Wu CY, Chen HS, Chou YC, Tsou YL, Peng HP, Jian JW, Yu CM, Chiu YK, Chen IC, Tung CP, Hsiao M, Lin CL, Wang YA, Wang AH, Yang AS. MAbs 11 153-165 (2019)
  84. Generation and characterization of peptide mimotopes specific for anti ErbB-2 monoclonal antibodies. Witsch EJ, Mahlknecht G, Wakim J, Sertchook R, Bublil E, Yarden Y, Sela M. Int Immunol 23 391-403 (2011)
  85. Human Domain Antibodies to Conserved Epitopes on HER2 Potently Inhibit Growth of HER2-Overexpressing Human Breast Cancer Cells In Vitro. Wang H, Wang Y, Xiao Z, Li W, Dimitrov DS, Chen W. Antibodies (Basel) 8 E25 (2019)
  86. RF1 attenuation enables efficient non-natural amino acid incorporation for production of homogeneous antibody drug conjugates. Yin G, Stephenson HT, Yang J, Li X, Armstrong SM, Heibeck TH, Tran C, Masikat MR, Zhou S, Stafford RL, Yam AY, Lee J, Steiner AR, Gill A, Penta K, Pollitt S, Baliga R, Murray CJ, Thanos CD, McEvoy LM, Sato AK, Hallam TJ. Sci Rep 7 3026 (2017)
  87. Trastuzumab Blocks the Receiver Function of HER2 Leading to the Population Shifts of HER2-Containing Homodimers and Heterodimers. Zhao J, Mohan N, Nussinov R, Ma B, Wu WJ. Antibodies (Basel) 10 7 (2021)
  88. B-cell epitope prediction through a graph model. Zhao L, Wong L, Lu L, Hoi SC, Li J. BMC Bioinformatics 13 Suppl 17 S20 (2012)
  89. Eosinophil peroxidase activates cells by HER2 receptor engagement and β1-integrin clustering with downstream MAPK cell signaling. Hennigan K, Conroy PJ, Walsh MT, Amin M, O'Kennedy R, Ramasamy P, Gleich GJ, Siddiqui Z, Glynn S, McCabe O, Mooney C, Harvey BJ, Costello RW, McBryan J. Clin Immunol 171 1-11 (2016)
  90. Expression Enhancement in Trastuzumab Therapeutic Monoclonal Antibody Production using Genomic Amplification with Methotrexate. Akbarzadeh-Sharbaf S, Yakhchali B, Minuchehr Z, Shokrgozar MA, Zeinali S. Avicenna J Med Biotechnol 5 87-95 (2013)
  91. Prediction of antibody structural epitopes via random peptide library screening and next generation sequencing. Ibsen KN, Daugherty PS. J Immunol Methods 451 28-36 (2017)
  92. A monoclonal antibody targeting ErbB2 domain III inhibits ErbB2 signaling and suppresses the growth of ErbB2-overexpressing breast tumors. Meng Y, Zheng L, Yang Y, Wang H, Dong J, Wang C, Zhang Y, Yu X, Wang L, Xia T, Zhang D, Guo Y, Li B. Oncogenesis 5 e211 (2016)
  93. A phosphorylation pattern-recognizing antibody specifically reacts to RNA polymerase II bound to exons. Han J, Lee JH, Park S, Yoon S, Yoon A, Hwang DB, Lee HK, Kim MS, Lee Y, Yang WJ, Youn HD, Kim H, Chung J. Exp Mol Med 48 e271 (2016)
  94. Crocetin and crocin decreased cholesterol and triglyceride content of both breast cancer tumors and cell lines. Hashemi SA, Bathaie SZ, Mohagheghi MA. Avicenna J Phytomed 10 384-397 (2020)
  95. Cytotoxic Evaluation, Molecular Docking, and 2D-QSAR Studies of Dihydropyrimidinone Derivatives as Potential Anticancer Agents. Altaf R, Nadeem H, Ilyas U, Iqbal J, Paracha RZ, Zafar H, Paiva-Santos AC, Sulaiman M, Raza F. J Oncol 2022 7715689 (2022)
  96. Design Strategy to Create Antibody Mimetics Harbouring Immobilised Complementarity Determining Region Peptides for Practical Use. Kadonosono T, Yimchuen W, Ota Y, See K, Furuta T, Shiozawa T, Kitazawa M, Goto Y, Patil A, Kuchimaru T, Kizaka-Kondoh S. Sci Rep 10 891 (2020)
  97. Engineering a high-affinity peptide binding site into the anti-CEA mAb M5A. Zer C, Avery KN, Meyer K, Goodstein L, Bzymek KP, Singh G, Williams JC. Protein Eng Des Sel 30 409-417 (2017)
  98. High-resolution glycosylation site-engineering method identifies MICA epitope critical for shedding inhibition activity of anti-MICA antibodies. Lombana TN, Matsumoto ML, Berkley AM, Toy E, Cook R, Gan Y, Du C, Schnier P, Sandoval W, Ye Z, Schartner JM, Kim J, Spiess C. MAbs 11 75-93 (2019)
  99. IMGT/Collier-de-Perles: a two-dimensional visualization tool for amino acid domain sequences. Vlachakis D, Feidakis C, Megalooikonomou V, Kossida S. Theor Biol Med Model 10 14 (2013)
  100. Novel Human Antibodies to Insulin Growth Factor 2 Receptor (IGF2R) for Radioimmunoimaging and Therapy of Canine and Human Osteosarcoma. Broqueza J, Prabaharan CB, Andrahennadi S, Allen KJH, Dickinson R, MacDonald-Dickinson V, Dadachova E, Uppalapati M. Cancers (Basel) 13 2208 (2021)
  101. PepMapper: a collaborative web tool for mapping epitopes from affinity-selected peptides. Chen W, Guo WW, Huang Y, Ma Z. PLoS One 7 e37869 (2012)
  102. Rigidity of the extracellular part of HER2: Evidence from engineering subdomain interfaces and shared-helix DARPin-DARPin fusions. Jost C, Stüber JC, Honegger A, Wu Y, Batyuk A, Plückthun A. Protein Sci 26 1796-1806 (2017)
  103. Switchable targeting of solid tumors by BsCAR T cells. Stepanov AV, Kalinin RS, Shipunova VO, Zhang D, Xie J, Rubtsov YP, Ukrainskaya VM, Schulga A, Konovalova EV, Volkov DV, Yaroshevich IA, Moysenovich AM, Belogurov AA, Zhang H, Telegin GB, Chernov AS, Maschan MA, Terekhov SS, Wu P, Deyev SM, Lerner RA, Gabibov AG, Altman S. Proc Natl Acad Sci U S A 119 e2210562119 (2022)
  104. A reinforced merging methodology for mapping unique peptide motifs in members of protein families. Chang HT, Pai TW, Fan TC, Su BH, Wu PC, Tang CY, Chang CT, Liu SH, Chang MD. BMC Bioinformatics 7 38 (2006)
  105. Conformational B-cell epitope prediction method based on antigen preprocessing and mimotopes analysis. Sun P, Ju H, Zhang B, Gu Y, Liu B, Huang Y, Zhang H, Li Y. Biomed Res Int 2015 257030 (2015)
  106. Construction of an immunotoxin via site-specific conjugation of anti-Her2 IgG and engineered Pseudomonas exotoxin A. Lee BS, Lee Y, Park J, Jeong BS, Jo M, Jung ST, Yoo TH. J Biol Eng 13 56 (2019)
  107. In silico design, construction and cloning of Trastuzumab humanized monoclonal antibody: A possible biosimilar for Herceptin. Akbarzadeh-Sharbaf S, Yakhchali B, Minuchehr Z, Shokrgozar MA, Zeinali S. Adv Biomed Res 1 21 (2012)
  108. A meta-learning approach for B-cell conformational epitope prediction. Hu YJ, Lin SC, Lin YL, Lin KH, You SN. BMC Bioinformatics 15 378 (2014)
  109. Binding and functional profiling of antibody mutants guides selection of optimal candidates as antibody drug conjugates. Zwaagstra JC, Sulea T, Baardsnes J, Radinovic S, Cepero-Donates Y, Robert A, O'Connor-McCourt MD, Tikhomirov IA, Jaramillo ML. PLoS One 14 e0226593 (2019)
  110. Disulfide-compatible phage-assisted continuous evolution in the periplasmic space. Morrison MS, Wang T, Raguram A, Hemez C, Liu DR. Nat Commun 12 5959 (2021)
  111. Druggability and Binding Site Interaction Studies of Potential Metabolites Isolated from Marine Sponge Aurora globostellata against Human Epidermal Growth Factor Receptor-2. Sugappriya M, Sudarsanam D, Bhaskaran R, Joseph J, Suresh A. Bioinformation 13 261-268 (2017)
  112. Extensive conformational and physical plasticity protects HER2-HER3 tumorigenic signaling. Campbell MR, Ruiz-Saenz A, Zhang Y, Peterson E, Steri V, Oeffinger J, Sampang M, Jura N, Moasser MM. Cell Rep 38 110285 (2022)
  113. Identification of critical chemical modifications by size exclusion chromatography of stressed antibody-target complexes with competitive binding. Shi RL, Xiao G, Dillon TM, McAuley A, Ricci MS, Bondarenko PV. MAbs 13 1887612 (2021)
  114. Rationally Designed Transgene-Encoded Cell-Surface Polypeptide Tag for Multiplexed Programming of CAR T-cell Synthetic Outputs. Johnson AJ, Wei J, Rosser JM, Künkele A, Chang CA, Reid AN, Jensen MC. Cancer Immunol Res 9 1047-1060 (2021)
  115. Restricted epitope specificity determined by variable region germline segment pairing in rodent antibody repertoires. Hsiao YC, Chen YJ, Goldstein LD, Wu J, Lin Z, Schneider K, Chaudhuri S, Antony A, Bajaj Pahuja K, Modrusan Z, Seshasayee D, Seshagiri S, Hötzel I. MAbs 12 1722541 (2020)
  116. Targeting Phosphotyrosine in Native Proteins with Conditional, Bispecific Antibody Traps. Zhou XX, Bracken CJ, Zhang K, Zhou J, Mou Y, Wang L, Cheng Y, Leung KK, Wells JA. J Am Chem Soc 142 17703-17713 (2020)
  117. Trastuzumab-Peptide interactions: mechanism and application in structure-based ligand design. Sun TY, Wang Q, Zhang J, Wu T, Zhang F. Int J Mol Sci 14 16836-16850 (2013)
  118. All-in-one disulfide bridging enables the generation of antibody conjugates with modular cargo loading. Dannheim FM, Walsh SJ, Orozco CT, Hansen AH, Bargh JD, Jackson SE, Bond NJ, Parker JS, Carroll JS, Spring DR. Chem Sci 13 8781-8790 (2022)
  119. Dynamical Rearrangement of Human Epidermal Growth Factor Receptor 2 upon Antibody Binding: Effects on the Dimerization. Magalhães PR, Machuqueiro M, Almeida JG, Melo A, D S Cordeiro MN, Verde SC, Gümüş ZH, Moreira IS, D G Correia J, Melo R. Biomolecules 9 E706 (2019)
  120. Engineered Amber-Emitting Nano Luciferase and Its Use for Immunobioluminescence Imaging In Vivo. Xiong Y, Zhang Y, Li Z, Reza MS, Li X, Tian X, Ai HW. J Am Chem Soc 144 14101-14111 (2022)
  121. Isotope-Coded Labeling for Accelerated Protein Interaction Profiling Using MS. Venable JD, Steckler C, Ou W, Grünewald J, Agarwalla S, Brock A. Anal Chem 87 7540-7544 (2015)
  122. Structural insights into the non-inhibitory mechanism of the anti-EGFR EgB4 nanobody. Zeronian MR, Doulkeridou S, van Bergen En Henegouwen PMP, Janssen BJC. BMC Mol Cell Biol 23 12 (2022)
  123. The Contorsbody, an antibody format for agonism: Design, structure, and function. Georges GJ, Dengl S, Bujotzek A, Hesse F, Fischer JAA, Gärtner A, Benz J, Lauer ME, Ringler P, Stahlberg H, Plath F, Brinkmann U, Imhof-Jung S. Comput Struct Biotechnol J 18 1210-1220 (2020)
  124. Comparative analysis of evolutionarily conserved motifs of epidermal growth factor receptor 2 (HER2) predicts novel potential therapeutic epitopes. Deng X, Zheng X, Yang H, Moreira JM, Brünner N, Christensen H. PLoS One 9 e106448 (2014)
  125. Computationally-guided design and affinity improvement of a protein binder targeting a specific site on HER2. Kim TY, Cha JS, Kim H, Choi Y, Cho HS, Kim HS. Comput Struct Biotechnol J 19 1325-1334 (2021)
  126. Engineering Bifunctional Calcium Alendronate Gene-Delivery Nanoneedle for Synergistic Chemo/Immuno-Therapy Against HER2 Positive Ovarian Cancer. Chen G, Zeng L, Bi B, Huang X, Qiu M, Chen P, Chen ZY, He Y, Pan Y, Chen Y, Zhao J. Adv Sci (Weinh) 10 e2204654 (2023)
  127. Hydrodynamic and Electrophoretic Properties of Trastuzumab/HER2 Extracellular Domain Complexes as Revealed by Experimental Techniques and Computational Simulations. Ramos J, Vega JF, Cruz V, Sanchez-Sanchez E, Cortes J, Martinez-Salazar J. Int J Mol Sci 20 E1076 (2019)
  128. Improved intratumoral penetration of IL12 immunocytokine enhances the antitumor efficacy. Jung K, Yoo S, Kim JE, Kim W, Kim YS. Front Immunol 13 1034774 (2022)
  129. In Silico Study: Combination of α-Mangostin and Chitosan Conjugated with Trastuzumab against Human Epidermal Growth Factor Receptor 2. Megantara S, Wathoni N, Mohammed AFA, Suhandi C, Ishmatullah MH, Putri MFFD. Polymers (Basel) 14 2747 (2022)
  130. Intra-Domain Cysteines (IDC), a New Strategy for the Development of Original Antibody Fragment-Drug Conjugates (FDCs). Jolivet L, Ait Mohamed Amar I, Horiot C, Boursin F, Colas C, Letast S, Denevault-Sabourin C, Allard-Vannier E, Joubert N, Aubrey N. Pharmaceutics 14 1524 (2022)
  131. Research Support, U.S. Gov't, Non-P.H.S. Molecular explorations of cancer biology and therapeutics at PDB-101. Goodsell DS, Dutta S, Voigt M, Zardecki C, Burley SK. Oncogene 41 4333-4335 (2022)
  132. Recruiting the Immune System Against Disease: Lessons for Clinical and Systems Pharmacology. Vicini P, Standifer N, Hickling TP. CPT Pharmacometrics Syst Pharmacol 8 436-439 (2019)
  133. Single Mutation on Trastuzumab Modulates the Stability of Antibody-Drug Conjugates Built Using Acetal-Based Linkers and Thiol-Maleimide Chemistry. Ferhati X, Jiménez-Moreno E, Hoyt EA, Salluce G, Cabeza-Cabrerizo M, Navo CD, Compañón I, Akkapeddi P, Matos MJ, Salaverri N, Garrido P, Martínez A, Laserna V, Murray TV, Jiménez-Osés G, Ravn P, Bernardes GJL, Corzana F. J Am Chem Soc 144 5284-5294 (2022)
  134. Standardized in-vitro evaluation of CAR-T cells using acellular artificial target particles. Harari-Steinfeld R, Abhinav Ayyadevara VSS, Cuevas L, Marincola F, Roh KH. Front Immunol 13 994532 (2022)
  135. Substitution of Heavy Complementarity Determining Region 3 (CDR-H3) Residues Can Synergistically Enhance Functional Activity of Antibody and Its Binding Affinity to HER2 Antigen. Moon SK, Park SR, Park A, Oh HM, Shin HJ, Jeon EJ, Kim S, Park HJ, Yeon YJ, Yoo YJ. Mol Cells 39 217-228 (2016)
  136. Trastuzumab does not bind rat or mouse ErbB2/neu: implications for selection of non-clinical safety models for trastuzumab-based therapeutics. Lewis Phillips G, Guo J, Kiefer JR, Proctor W, Bumbaca Yadav D, Dybdal N, Shen BQ. Breast Cancer Res Treat 191 303-317 (2022)
  137. Activity-based profiling of cullin-RING E3 networks by conformation-specific probes. Henneberg LT, Singh J, Duda DM, Baek K, Yanishevski D, Murray PJ, Mann M, Sidhu SS, Schulman BA. Nat Chem Biol 19 1513-1523 (2023)
  138. An anti-HER2 biparatopic antibody that induces unique HER2 clustering and complement-dependent cytotoxicity. Weisser NE, Sanches M, Escobar-Cabrera E, O'Toole J, Whalen E, Chan PWY, Wickman G, Abraham L, Choi K, Harbourne B, Samiotakis A, Rojas AH, Volkers G, Wong J, Atkinson CE, Baardsnes J, Worrall LJ, Browman D, Smith EE, Baichoo P, Cheng CW, Guedia J, Kang S, Mukhopadhyay A, Newhook L, Ohrn A, Raghunatha P, Zago-Schmitt M, Schrag JD, Smith J, Zwierzchowski P, Scurll JM, Fung V, Black S, Strynadka NCJ, Gold MR, Presta LG, Ng G, Dixit S. Nat Commun 14 1394 (2023)
  139. Published Erratum Author Correction: The effects of Antibody Engineering CH and CL in Trastuzumab and Pertuzumab recombinant models: Impact on antibody production and antigen-binding. Lua WH, Ling WL, Yeo JY, Poh JJ, Lane DP, Gan SK. Sci Rep 8 11110 (2018)
  140. Binding Affinity of Trastuzumab and Pertuzumab Monoclonal Antibodies to Extracellular HER2 Domain. Cruz VL, Souza-Egipsy V, Gion M, Pérez-García J, Cortes J, Ramos J, Vega JF. Int J Mol Sci 24 12031 (2023)
  141. Co-crystallisation and humanisation of an anti-HER2 single-domain antibody as a theranostic tool. Sawmynaden K, Wong N, Davies S, Cowan R, Brown R, Tang D, Henry M, Tickle D, Matthews D, Carr M, Bakrania P, Hoi Ting H, Hall G. PLoS One 18 e0288259 (2023)
  142. Complementation Dependent Enzyme Prodrug Therapy Enables Targeted Activation of Prodrug on HER2-Positive Cancer Cells. Nervig CS, Hatch ST, Owen SC. ACS Med Chem Lett 13 1769-1775 (2022)
  143. Computation-Aided Design of Albumin Affibody-Inserted Antibody Fragment for the Prolonged Serum Half-Life. Kwon NH, Lee JH, Kwon I. Pharmaceutics 14 1769 (2022)
  144. research-article Contextual protein and antibody encodings from equivariant graph transformers. Mahajan SP, Ruffolo JA, Gray JJ. bioRxiv 2023.07.15.549154 (2023)
  145. Crystal structures of HER3 extracellular domain 4 in complex with the designed ankyrin-repeat protein D5. Radom F, Vonrhein C, Mittl PRE, Plückthun A. Acta Crystallogr F Struct Biol Commun 77 192-201 (2021)
  146. Domain-level epitope mapping of polyclonal antibodies against HER-1 and HER-2 receptors using phage display technology. Pérez-Martínez D, Infante YC, Ramírez BS, Rojas G. Sci Rep 12 12268 (2022)
  147. Generation of bispecific antibodies by structure-guided redesign of IgG constant regions. Iwasaki YW, Tharakaraman K, Subramanian V, Khongmanee A, Hatas A, Fleischer E, Rurak TT, Ngok-Ngam P, Tit-Oon P, Ruchirawat M, Satayavivad J, Fuangthong M, Sasisekharan R. Front Immunol 13 1063002 (2022)
  148. Generation of robust bispecific antibodies through fusion of single-domain antibodies on IgG scaffolds: a comprehensive comparison of formats. Madsen AV, Kristensen P, Buell AK, Goletz S. MAbs 15 2189432 (2023)
  149. Genetic and structural basis of the human anti-α-galactosyl antibody response. Langley DB, Schofield P, Nevoltris D, Jackson J, Jackson KJL, Peters TJ, Burk M, Matthews JM, Basten A, Goodnow CC, van Nunen S, Reed JH, Christ D. Proc Natl Acad Sci U S A 119 e2123212119 (2022)
  150. Glycan Profile Analysis of Engineered Trastuzumab with Rationally Added Glycosylation Sequons Presents Significantly Increased Glycan Complexity. Cruz E, Sifniotis V, Sumer-Bayraktar Z, Reslan M, Wilkinson-White L, Cordwell S, Kayser V. Pharmaceutics 13 1747 (2021)
  151. Hallucinating structure-conditioned antibody libraries for target-specific binders. Mahajan SP, Ruffolo JA, Frick R, Gray JJ. Front Immunol 13 999034 (2022)
  152. In Silico Discovery of Anticancer Peptides from Sanghuang. Liu M, Lv J, Chen L, Li W, Han W. Int J Mol Sci 23 13682 (2022)
  153. Mechanistic insights into the rational design of masked antibodies. Orozco CT, Bersellini M, Irving LM, Howard WW, Hargreaves D, Devine PWA, Siouve E, Browne GJ, Bond NJ, Phillips JJ, Ravn P, Jackson SE. MAbs 14 2095701 (2022)
  154. Molecular Dynamics-Based Design and Biophysical Evaluation of Thermostable Single-Chain Fv Antibody Mutants Derived from Pharmaceutical Antibodies. Okazaki K, Kobashigawa Y, Morita H, Yamauchi S, Fukuda N, Liu C, Toyota Y, Sato T, Morioka H. ACS Omega 8 22945-22954 (2023)
  155. Site-specific DNA functionalization through the tetrazene-forming reaction in ionic liquids. Ishizawa S, Tumurkhuu M, Gross EJ, Ohata J. Chem Sci 13 1780-1788 (2022)
  156. Surface patches induce nonspecific binding and phase separation of antibodies. Ausserwöger H, Krainer G, Welsh TJ, Thorsteinson N, de Csilléry E, Sneideris T, Schneider MM, Egebjerg T, Invernizzi G, Herling TW, Lorenzen N, Knowles TPJ. Proc Natl Acad Sci U S A 120 e2210332120 (2023)
  157. The production of the first functional antibody mimetic in higher plants: the chloroplast makes the DARPin G3 for HER2 imaging in oncology. Ehsasatvatan M, Kohnehrouz BB, Gholizadeh A, Ofoghi H, Shanehbandi D. Biol Res 55 32 (2022)


Reviews citing this publication (243)

  1. ERBB receptors and cancer: the complexity of targeted inhibitors. Hynes NE, Lane HA. Nat Rev Cancer 5 341-354 (2005)
  2. Trastuzumab--mechanism of action and use in clinical practice. Hudis CA. N Engl J Med 357 39-51 (2007)
  3. Epidermal growth factor receptor (EGFR) signaling in cancer. Normanno N, De Luca A, Bianco C, Strizzi L, Mancino M, Maiello MR, Carotenuto A, De Feo G, Caponigro F, Salomon DS. Gene 366 2-16 (2006)
  4. ADAMs: key components in EGFR signalling and development. Blobel CP. Nat Rev Mol Cell Biol 6 32-43 (2005)
  5. Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. Baselga J, Swain SM. Nat Rev Cancer 9 463-475 (2009)
  6. Potent antibody therapeutics by design. Carter PJ. Nat Rev Immunol 6 343-357 (2006)
  7. ErbB receptors and signaling pathways in cancer. Hynes NE, MacDonald G. Curr Opin Cell Biol 21 177-184 (2009)
  8. The ErbB/HER family of protein-tyrosine kinases and cancer. Roskoski R. Pharmacol Res 79 34-74 (2014)
  9. ERBB receptors: from oncogene discovery to basic science to mechanism-based cancer therapeutics. Arteaga CL, Engelman JA. Cancer Cell 25 282-303 (2014)
  10. An open-and-shut case? Recent insights into the activation of EGF/ErbB receptors. Burgess AW, Cho HS, Eigenbrot C, Ferguson KM, Garrett TP, Leahy DJ, Lemmon MA, Sliwkowski MX, Ward CW, Yokoyama S. Mol Cell 12 541-552 (2003)
  11. The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis. Moasser MM. Oncogene 26 6469-6487 (2007)
  12. Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer. Nahta R, Yu D, Hung MC, Hortobagyi GN, Esteva FJ. Nat Clin Pract Oncol 3 269-280 (2006)
  13. The ERBB network: at last, cancer therapy meets systems biology. Yarden Y, Pines G. Nat Rev Cancer 12 553-563 (2012)
  14. ErbB receptors: directing key signaling networks throughout life. Holbro T, Hynes NE. Annu Rev Pharmacol Toxicol 44 195-217 (2004)
  15. Comparing antibody and small-molecule therapies for cancer. Imai K, Takaoka A. Nat Rev Cancer 6 714-727 (2006)
  16. Risk Factors and Preventions of Breast Cancer. Sun YS, Zhao Z, Yang ZN, Xu F, Lu HJ, Zhu ZY, Shi W, Jiang J, Yao PP, Zhu HP. Int J Biol Sci 13 1387-1397 (2017)
  17. The epidermal growth factor receptor family: biology driving targeted therapeutics. Wieduwilt MJ, Moasser MM. Cell Mol Life Sci 65 1566-1584 (2008)
  18. ErbB receptors: from oncogenes to targeted cancer therapies. Zhang H, Berezov A, Wang Q, Zhang G, Drebin J, Murali R, Greene MI. J Clin Invest 117 2051-2058 (2007)
  19. HER2 therapy: molecular mechanisms of trastuzumab resistance. Nahta R, Esteva FJ. Breast Cancer Res 8 215 (2006)
  20. Herceptin: mechanisms of action and resistance. Nahta R, Esteva FJ. Cancer Lett 232 123-138 (2006)
  21. Designed ankyrin repeat proteins (DARPins): binding proteins for research, diagnostics, and therapy. Plückthun A. Annu Rev Pharmacol Toxicol 55 489-511 (2015)
  22. The ErbB/HER receptor protein-tyrosine kinases and cancer. Roskoski R. Biochem Biophys Res Commun 319 1-11 (2004)
  23. The EGFR family: not so prototypical receptor tyrosine kinases. Lemmon MA, Schlessinger J, Ferguson KM. Cold Spring Harb Perspect Biol 6 a020768 (2014)
  24. EGFR family: structure physiology signalling and therapeutic targets. Burgess AW. Growth Factors 26 263-274 (2008)
  25. Chimeric antigen receptor T cells: a novel therapy for solid tumors. Yu S, Li A, Liu Q, Li T, Yuan X, Han X, Wu K. J Hematol Oncol 10 78 (2017)
  26. Protein kinase inhibitors: contributions from structure to clinical compounds. Johnson LN. Q Rev Biophys 42 1-40 (2009)
  27. Role of receptor tyrosine kinase transmembrane domains in cell signaling and human pathologies. Li E, Hristova K. Biochemistry 45 6241-6251 (2006)
  28. Ten things you should know about protein kinases: IUPHAR Review 14. Fabbro D, Cowan-Jacob SW, Moebitz H. Br J Pharmacol 172 2675-2700 (2015)
  29. Anaplastic lymphoma kinase proteins in growth control and cancer. Pulford K, Morris SW, Turturro F. J Cell Physiol 199 330-358 (2004)
  30. Ligand-induced ErbB receptor dimerization. Lemmon MA. Exp Cell Res 315 638-648 (2009)
  31. Anthracyclines/trastuzumab: new aspects of cardiotoxicity and molecular mechanisms. Rochette L, Guenancia C, Gudjoncik A, Hachet O, Zeller M, Cottin Y, Vergely C. Trends Pharmacol Sci 36 326-348 (2015)
  32. Allosteric Modulation as a Unifying Mechanism for Receptor Function and Regulation. Changeux JP, Christopoulos A. Cell 166 1084-1102 (2016)
  33. Toll-like receptors as molecular switches. Gay NJ, Gangloff M, Weber AN. Nat Rev Immunol 6 693-698 (2006)
  34. Emerging targeted therapies for breast cancer. Alvarez RH, Valero V, Hortobagyi GN. J Clin Oncol 28 3366-3379 (2010)
  35. ErbB receptors, their ligands, and the consequences of their activation and inhibition in the myocardium. Fuller SJ, Sivarajah K, Sugden PH. J Mol Cell Cardiol 44 831-854 (2008)
  36. Biosensor technology: recent advances in threat agent detection and medicine. Kirsch J, Siltanen C, Zhou Q, Revzin A, Simonian A. Chem Soc Rev 42 8733-8768 (2013)
  37. Resistance to HER2-directed antibodies and tyrosine kinase inhibitors: mechanisms and clinical implications. Garrett JT, Arteaga CL. Cancer Biol Ther 11 793-800 (2011)
  38. Tyrosine kinase receptors as attractive targets of cancer therapy. Bennasroune A, Gardin A, Aunis D, Crémel G, Hubert P. Crit Rev Oncol Hematol 50 23-38 (2004)
  39. Management of breast cancer with targeted agents: importance of heterogeneity. [corrected]. Di Cosimo S, Baselga J. Nat Rev Clin Oncol 7 139-147 (2010)
  40. Mechanisms of resistance to HER family targeting antibodies. Kruser TJ, Wheeler DL. Exp Cell Res 316 1083-1100 (2010)
  41. A glimpse of structural biology through X-ray crystallography. Shi Y. Cell 159 995-1014 (2014)
  42. Targeting the function of the HER2 oncogene in human cancer therapeutics. Moasser MM. Oncogene 26 6577-6592 (2007)
  43. A high-throughput shotgun mutagenesis approach to mapping B-cell antibody epitopes. Davidson E, Doranz BJ. Immunology 143 13-20 (2014)
  44. Phosphate recognition in structural biology. Hirsch AK, Fischer FR, Diederich F. Angew Chem Int Ed Engl 46 338-352 (2007)
  45. Chimeric Antigen Receptors T Cell Therapy in Solid Tumor: Challenges and Clinical Applications. Mirzaei HR, Rodriguez A, Shepphird J, Brown CE, Badie B. Front Immunol 8 1850 (2017)
  46. Non-genetic engineering of cells for drug delivery and cell-based therapy. Wang Q, Cheng H, Peng H, Zhou H, Li PY, Langer R. Adv Drug Deliv Rev 91 125-140 (2015)
  47. The HER family and cancer: emerging molecular mechanisms and therapeutic targets. Sergina NV, Moasser MM. Trends Mol Med 13 527-534 (2007)
  48. The insulin and EGF receptor structures: new insights into ligand-induced receptor activation. Ward CW, Lawrence MC, Streltsov VA, Adams TE, McKern NM. Trends Biochem Sci 32 129-137 (2007)
  49. Asymmetric tyrosine kinase arrangements in activation or autophosphorylation of receptor tyrosine kinases. Bae JH, Schlessinger J. Mol Cells 29 443-448 (2010)
  50. Anti-HER2 vaccines: new prospects for breast cancer therapy. Ladjemi MZ, Jacot W, Chardès T, Pèlegrin A, Navarro-Teulon I. Cancer Immunol Immunother 59 1295-1312 (2010)
  51. Improving treatment of HER2-positive cancers: opportunities and challenges. Stern HM. Sci Transl Med 4 127rv2 (2012)
  52. Evolving novel anti-HER2 strategies. Jones KL, Buzdar AU. Lancet Oncol 10 1179-1187 (2009)
  53. Pertuzumab: new hope for patients with HER2-positive breast cancer. Capelan M, Pugliano L, De Azambuja E, Bozovic I, Saini KS, Sotiriou C, Loi S, Piccart-Gebhart MJ. Ann Oncol 24 273-282 (2013)
  54. Activating HER2 mutations as emerging targets in multiple solid cancers. Connell CM, Doherty GJ. ESMO Open 2 e000279 (2017)
  55. Progress and Challenges in the Design and Clinical Development of Antibodies for Cancer Therapy. Almagro JC, Daniels-Wells TR, Perez-Tapia SM, Penichet ML. Front Immunol 8 1751 (2017)
  56. Recent research and development of Antrodia cinnamomea. Lu MC, El-Shazly M, Wu TY, Du YC, Chang TT, Chen CF, Hsu YM, Lai KH, Chiu CP, Chang FR, Wu YC. Pharmacol Ther 139 124-156 (2013)
  57. Treatment of HER2-overexpressing breast cancer. Baselga J. Ann Oncol 21 Suppl 7 vii36-40 (2010)
  58. Phage display screening of therapeutic peptide for cancer targeting and therapy. Saw PE, Song EW. Protein Cell 10 787-807 (2019)
  59. Targeting EGFR and HER-2 receptor tyrosine kinases for cancer drug discovery and development. Kamath S, Buolamwini JK. Med Res Rev 26 569-594 (2006)
  60. Interaction of antibodies with ErbB receptor extracellular regions. Schmitz KR, Ferguson KM. Exp Cell Res 315 659-670 (2009)
  61. Mimotope vaccination--from allergy to cancer. Knittelfelder R, Riemer AB, Jensen-Jarolim E. Expert Opin Biol Ther 9 493-506 (2009)
  62. Unnatural amino acid incorporation in E. coli: current and future applications in the design of therapeutic proteins. Wals K, Ovaa H. Front Chem 2 15 (2014)
  63. Antitumor activity of HER-2 inhibitors. Rabindran SK. Cancer Lett 227 9-23 (2005)
  64. Recent advances in novel targeted therapies for HER2-positive breast cancer. Murphy CG, Morris PG. Anticancer Drugs 23 765-776 (2012)
  65. Development and clinical application of anti-HER2 monoclonal and bispecific antibodies for cancer treatment. Yu S, Liu Q, Han X, Qin S, Zhao W, Li A, Wu K. Exp Hematol Oncol 6 31 (2017)
  66. HER2 as a target for breast cancer therapy. Tagliabue E, Balsari A, Campiglio M, Pupa SM. Expert Opin Biol Ther 10 711-724 (2010)
  67. Value and limitations of measuring HER-2 extracellular domain in the serum of breast cancer patients. Leary AF, Hanna WM, van de Vijver MJ, Penault-Llorca F, Rüschoff J, Osamura RY, Bilous M, Dowsett M. J Clin Oncol 27 1694-1705 (2009)
  68. HER2-family signalling mechanisms, clinical implications and targeting in breast cancer. Elster N, Collins DM, Toomey S, Crown J, Eustace AJ, Hennessy BT. Breast Cancer Res Treat 149 5-15 (2015)
  69. Strategies to overcome trastuzumab resistance in HER2-overexpressing breast cancers: focus on new data from clinical trials. Lavaud P, Andre F. BMC Med 12 132 (2014)
  70. Notch-EGFR/HER2 Bidirectional Crosstalk in Breast Cancer. Baker AT, Zlobin A, Osipo C. Front Oncol 4 360 (2014)
  71. Profile of neratinib and its potential in the treatment of breast cancer. Feldinger K, Kong A. Breast Cancer (Dove Med Press) 7 147-162 (2015)
  72. Molecular approach to breast cancer treatment. Yarden Y, Baselga J, Miles D. Semin Oncol 31 6-13 (2004)
  73. Epidermal Growth Factor Receptor Family and its Role in Gastric Cancer. Arienti C, Pignatta S, Tesei A. Front Oncol 9 1308 (2019)
  74. Genetically encoding new bioreactivity. Wang L. N Biotechnol 38 16-25 (2017)
  75. Monoclonal antibody-based targeted therapy in breast cancer: current status and future directions. Bernard-Marty C, Lebrun F, Awada A, Piccart MJ. Drugs 66 1577-1591 (2006)
  76. Perspectives of HER2-targeting in gastric and esophageal cancer. Gerson JN, Skariah S, Denlinger CS, Astsaturov I. Expert Opin Investig Drugs 26 531-540 (2017)
  77. Using Genome Sequence to Enable the Design of Medicines and Chemical Probes. Angelbello AJ, Chen JL, Childs-Disney JL, Zhang P, Wang ZF, Disney MD. Chem Rev 118 1599-1663 (2018)
  78. The ErbB kinase domain: structural perspectives into kinase activation and inhibition. Bose R, Zhang X. Exp Cell Res 315 649-658 (2009)
  79. Therapeutic antibodies against cancer. Adler MJ, Dimitrov DS. Hematol Oncol Clin North Am 26 447-81, vii (2012)
  80. Dynamic equilibrium between multiple active and inactive conformations explains regulation and oncogenic mutations in ErbB receptors. Landau M, Ben-Tal N. Biochim Biophys Acta 1785 12-31 (2008)
  81. Imaging EGFR and HER2 by PET and SPECT: a review. Corcoran EB, Hanson RN. Med Res Rev 34 596-643 (2014)
  82. Preclinical Characteristics of the Irreversible Pan-HER Kinase Inhibitor Neratinib Compared with Lapatinib: Implications for the Treatment of HER2-Positive and HER2-Mutated Breast Cancer. Collins DM, Conlon NT, Kannan S, Verma CS, Eli LD, Lalani AS, Crown J. Cancers (Basel) 11 (2019)
  83. Structure-function relationships of the variable domains of monoclonal antibodies approved for cancer treatment. Magdelaine-Beuzelin C, Kaas Q, Wehbi V, Ohresser M, Jefferis R, Lefranc MP, Watier H. Crit Rev Oncol Hematol 64 210-225 (2007)
  84. Application and potential limitations of animal models utilized in the development of trastuzumab (Herceptin): a case study. Pegram M, Ngo D. Adv Drug Deliv Rev 58 723-734 (2006)
  85. ErbB signaling in cardiac development and disease. Sanchez-Soria P, Camenisch TD. Semin Cell Dev Biol 21 929-935 (2010)
  86. Evolution of anti-HER2 therapies for cancer treatment. Parakh S, Gan HK, Parslow AC, Burvenich IJG, Burgess AW, Scott AM. Cancer Treat Rev 59 1-21 (2017)
  87. HER2 therapy. HER2 (ERBB2): functional diversity from structurally conserved building blocks. Landgraf R. Breast Cancer Res 9 202 (2007)
  88. Effector mechanisms of therapeutic antibodies against ErbB receptors. Peipp M, Dechant M, Valerius T. Curr Opin Immunol 20 436-443 (2008)
  89. Synthetic antibody technologies. Adams JJ, Sidhu SS. Curr Opin Struct Biol 24 1-9 (2014)
  90. Advances in novel drug delivery strategies for breast cancer therapy. Dhankhar R, Vyas SP, Jain AK, Arora S, Rath G, Goyal AK. Artif Cells Blood Substit Immobil Biotechnol 38 230-249 (2010)
  91. Jumping higher: is it still possible? The ALTTO trial challenge. Tomasello G, de Azambuja E, Dinh P, Snoj N, Piccart-Gebhart M. Expert Rev Anticancer Ther 8 1883-1890 (2008)
  92. Role of human epidermal growth factor receptor 2 in gastric cancer: biological and pharmacological aspects. Jørgensen JT. World J Gastroenterol 20 4526-4535 (2014)
  93. Targeted therapy: wave of the future. Pegram MD, Pietras R, Bajamonde A, Klein P, Fyfe G. J Clin Oncol 23 1776-1781 (2005)
  94. Contemporary pre-clinical development of anticancer agents--what are the optimal preclinical models? Damia G, D'Incalci M. Eur J Cancer 45 2768-2781 (2009)
  95. Dual HER2-targeted approaches in HER2-positive breast cancer. Ahn ER, Vogel CL. Breast Cancer Res Treat 131 371-383 (2012)
  96. Recent advances in systemic therapy: Advances in systemic therapy for HER2-positive metastatic breast cancer. Morrow PK, Zambrana F, Esteva FJ. Breast Cancer Res 11 207 (2009)
  97. Roles for neuregulins in human cancer. Stove C, Bracke M. Clin Exp Metastasis 21 665-684 (2004)
  98. Aptamers as drug delivery vehicles. Kruspe S, Mittelberger F, Szameit K, Hahn U. ChemMedChem 9 1998-2011 (2014)
  99. Cancer therapeutic antibodies come of age: targeting minimal residual disease. Ben-Kasus T, Schechter B, Sela M, Yarden Y. Mol Oncol 1 42-54 (2007)
  100. HER2 targeting as a two-sided strategy for breast cancer diagnosis and treatment: Outlook and recent implications in nanomedical approaches. Colombo M, Corsi F, Foschi D, Mazzantini E, Mazzucchelli S, Morasso C, Occhipinti E, Polito L, Prosperi D, Ronchi S, Verderio P. Pharmacol Res 62 150-165 (2010)
  101. ErbB receptors and cell polarity: new pathways and paradigms for understanding cell migration and invasion. Feigin ME, Muthuswamy SK. Exp Cell Res 315 707-716 (2009)
  102. Transmembrane helix-helix interactions involved in ErbB receptor signaling. Cymer F, Schneider D. Cell Adh Migr 4 299-312 (2010)
  103. Colorectal cancer in review: the role of the EGFR pathway. Saif MW. Expert Opin Investig Drugs 19 357-369 (2010)
  104. Peptide vaccines and targeting HER and VEGF proteins may offer a potentially new paradigm in cancer immunotherapy. Kaumaya PT, Foy KC. Future Oncol 8 961-987 (2012)
  105. Targeting signal transduction pathways in metastatic breast cancer: a comprehensive review. Rosen LS, Ashurst HL, Chap L. Oncologist 15 216-235 (2010)
  106. ADAM17: An Emerging Therapeutic Target for Lung Cancer. Saad MI, Rose-John S, Jenkins BJ. Cancers (Basel) 11 E1218 (2019)
  107. Changing strategies for target therapy in gastric cancer. Lee SY, Oh SC. World J Gastroenterol 22 1179-1189 (2016)
  108. Immunotherapy of cancer: from monoclonal to oligoclonal cocktails of anti-cancer antibodies: IUPHAR Review 18. Carvalho S, Levi-Schaffer F, Sela M, Yarden Y. Br J Pharmacol 173 1407-1424 (2016)
  109. Pharmacogenetics of Chemotherapy-Induced Cardiotoxicity. Chang VY, Wang JJ. Curr Oncol Rep 20 52 (2018)
  110. Molecular mechanisms of cardiotoxicity induced by ErbB receptor inhibitor cancer therapeutics. Hervent AS, De Keulenaer GW. Int J Mol Sci 13 12268-12286 (2012)
  111. Pertuzumab and trastuzumab: the rationale way to synergy. Richard S, Selle F, Lotz JP, Khalil A, Gligorov J, Soares DG. An Acad Bras Cienc 88 Suppl 1 565-577 (2016)
  112. Systemic cancer therapy: evolution over the last 60 years. Dy GK, Adjei AA. Cancer 113 1857-1887 (2008)
  113. Prevalence and role of HER2 mutations in cancer. Cocco E, Lopez S, Santin AD, Scaltriti M. Pharmacol Ther 199 188-196 (2019)
  114. Clinical development of CAR T cell therapy in China: 2020 update. Wei J, Guo Y, Wang Y, Wu Z, Bo J, Zhang B, Zhu J, Han W. Cell Mol Immunol 18 792-804 (2021)
  115. ErbB-2 nuclear function in breast cancer growth, metastasis and resistance to therapy. Elizalde PV, Cordo Russo RI, Chervo MF, Schillaci R. Endocr Relat Cancer 23 T243-T257 (2016)
  116. Overcoming treatment resistance in HER2-positive breast cancer: potential strategies. Puglisi F, Minisini AM, De Angelis C, Arpino G. Drugs 72 1175-1193 (2012)
  117. Potential of ErbB4 antibodies for cancer therapy. Hollmén M, Elenius K. Future Oncol 6 37-53 (2010)
  118. Emerging antibody combinations in oncology. Demarest SJ, Hariharan K, Dong J. MAbs 3 338-351 (2011)
  119. HER-2-positive breast cancer: hope beyond trastuzumab. Bartsch R, Wenzel C, Zielinski CC, Steger GG. BioDrugs 21 69-77 (2007)
  120. Targeting ADAMS and ERBBs in lung cancer. Hynes NE, Schlange T. Cancer Cell 10 7-11 (2006)
  121. Emerging Nanotechnologies for Liquid Biopsy: The Detection of Circulating Tumor Cells and Extracellular Vesicles. Li W, Wang H, Zhao Z, Gao H, Liu C, Zhu L, Wang C, Yang Y. Adv Mater 31 e1805344 (2019)
  122. Therapeutic strategies and mechanisms of tumorigenesis of HER2-overexpressing breast cancer. Emde A, Köstler WJ, Yarden Y, Association of Radiotherapy and Oncology of the Mediterranean arEa (AROME). Crit Rev Oncol Hematol 84 Suppl 1 e49-57 (2012)
  123. Allosteric modulation as a unifying mechanism for receptor function and regulation. Changeux JP, Christopoulos A. Diabetes Obes Metab 19 Suppl 1 4-21 (2017)
  124. Drug-biomarker co-development in oncology - 20 years and counting. Twomey JD, Brahme NN, Zhang B. Drug Resist Updat 30 48-62 (2017)
  125. The erbB2/HER2/neu receptor polymorphism Ile655Val and breast cancer risk. Cox DG, Hankinson SE, Hunter DJ. Pharmacogenet Genomics 15 447-450 (2005)
  126. Trastuzumab Mechanism of Action; 20 Years of Research to Unravel a Dilemma. Maadi H, Soheilifar MH, Choi WS, Moshtaghian A, Wang Z. Cancers (Basel) 13 3540 (2021)
  127. Deep Learning in Drug Discovery and Medicine; Scratching the Surface. Dana D, Gadhiya SV, St Surin LG, Li D, Naaz F, Ali Q, Paka L, Yamin MA, Narayan M, Goldberg ID, Narayan P. Molecules 23 E2384 (2018)
  128. Emerging therapies in gastrointestinal cancers. Nautiyal J, Rishi AK, Majumdar AP. World J Gastroenterol 12 7440-7450 (2006)
  129. HER2 targeted therapy in breast cancer...beyond Herceptin. Pal SK, Pegram M. Rev Endocr Metab Disord 8 269-277 (2007)
  130. Pertuzumab for the treatment of ovarian cancer. Langdon SP, Faratian D, Nagumo Y, Mullen P, Harrison DJ. Expert Opin Biol Ther 10 1113-1120 (2010)
  131. Recombinant antibodies for cancer therapy. Deonarain MP. Expert Opin Biol Ther 8 1123-1141 (2008)
  132. Two-in-One antibodies with dual action Fabs. Eigenbrot C, Fuh G. Curr Opin Chem Biol 17 400-405 (2013)
  133. New Biological Insights from Better Structure Models. Touw WG, Joosten RP, Vriend G. J Mol Biol 428 1375-1393 (2016)
  134. Recombinant therapeutic monoclonal antibodies: mechanisms of action in relation to structural and functional duality. Congy-Jolivet N, Probst A, Watier H, Thibault G. Crit Rev Oncol Hematol 64 226-233 (2007)
  135. Resistance to HER2 inhibitors: is addition better than substitution? Rationale for the hypothetical concept of drug sedimentation. Campone M, Juin P, André F, Bachelot T. Crit Rev Oncol Hematol 78 195-205 (2011)
  136. Targeting HER (ERBB) signaling in head and neck cancer: An essential update. Zhang J, Saba NF, Chen GZ, Shin DM. Mol Aspects Med 45 74-86 (2015)
  137. Breast cancer biomarker measurements and standards. Cole KD, He HJ, Wang L. Proteomics Clin Appl 7 17-29 (2013)
  138. Breast cancer therapy and cardiovascular risk: focus on trastuzumab. Sandoo A, Kitas GD, Carmichael AR. Vasc Health Risk Manag 11 223-228 (2015)
  139. CAR T-cells for cancer therapy. Muhammad N, Mao Q, Xia H. Biotechnol Genet Eng Rev 33 190-226 (2017)
  140. ERBB oncogene proteins as targets for monoclonal antibodies. Polanovski OL, Lebedenko EN, Deyev SM. Biochemistry (Mosc) 77 227-245 (2012)
  141. Pharmacodynamics, pharmacokinetics and clinical efficacy of neratinib in HER2-positive breast cancer and breast cancer with HER2 mutations. Kourie HR, Chaix M, Gombos A, Aftimos P, Awada A. Expert Opin Drug Metab Toxicol 12 947-957 (2016)
  142. Tie2 and Eph receptor tyrosine kinase activation and signaling. Barton WA, Dalton AC, Seegar TC, Himanen JP, Nikolov DB. Cold Spring Harb Perspect Biol 6 a009142 (2014)
  143. A long way to the battlefront: CAR T cell therapy against solid cancers. Wang Z, Chen W, Zhang X, Cai Z, Huang W. J Cancer 10 3112-3123 (2019)
  144. Biopharmaceutical Informatics: supporting biologic drug development via molecular modelling and informatics. Kumar S, Plotnikov NV, Rouse JC, Singh SK. J Pharm Pharmacol 70 595-608 (2018)
  145. Novel approaches to target HER2-positive breast cancer: trastuzumab emtansine. Recondo G, de la Vega M, Galanternik F, Díaz-Cantón E, Leone BA, Leone JP. Cancer Manag Res 8 57-65 (2016)
  146. Pertuzumab and breast cancer: another piece in the anti-HER2 puzzle. Gerratana L, Bonotto M, Bozza C, Ongaro E, Fanotto V, Pelizzari G, Puglisi F. Expert Opin Biol Ther 17 365-374 (2017)
  147. The next wave of cellular immunotherapies in pancreatic cancer. Yeo D, Giardina C, Saxena P, Rasko JEJ. Mol Ther Oncolytics 24 561-576 (2022)
  148. The role of ADAM17 in tumorigenesis and progression of breast cancer. Shen H, Li L, Zhou S, Yu D, Yang S, Chen X, Wang D, Zhong S, Zhao J, Tang J. Tumour Biol (2016)
  149. The root cause of drug resistance in HER2-positive breast cancer and the therapeutic approaches to overcoming the resistance. Zhang Y. Pharmacol Ther 218 107677 (2021)
  150. B-cell epitope peptide cancer vaccines: a new paradigm for combination immunotherapies with novel checkpoint peptide vaccine. Kaumaya PT. Future Oncol 16 1767-1791 (2020)
  151. Cell-specific biomarkers and targeted biopharmaceuticals for breast cancer treatment. Liu M, Li Z, Yang J, Jiang Y, Chen Z, Ali Z, He N, Wang Z. Cell Prolif 49 409-420 (2016)
  152. Insulin and epidermal growth factor receptor family members share parallel activation mechanisms. Ferguson KM, Hu C, Lemmon MA. Protein Sci 29 1331-1344 (2020)
  153. Molecular imaging of EGFR/HER2 cancer biomarkers by protein MRI contrast agents. Qiao J, Xue S, Pu F, White N, Jiang J, Liu ZR, Yang JJ. J Biol Inorg Chem 19 259-270 (2014)
  154. Potential use of humanized antibodies in the treatment of breast cancer. Schaefer NG, Pestalozzi BC, Knuth A, Renner C. Expert Rev Anticancer Ther 6 1065-1074 (2006)
  155. Small-molecule inhibitors of the human epidermal receptor family. Carter CA, Kelly RJ, Giaccone G. Expert Opin Investig Drugs 18 1829-1842 (2009)
  156. Small-molecule inhibitors, immune checkpoint inhibitors, and more: FDA-approved novel therapeutic drugs for solid tumors from 1991 to 2021. Wu Q, Qian W, Sun X, Jiang S. J Hematol Oncol 15 143 (2022)
  157. Attenuation of p53 mutant as an approach for treatment Her2-positive cancer. Fedorova O, Daks A, Shuvalov O, Kizenko A, Petukhov A, Gnennaya Y, Barlev N. Cell Death Discov 6 100 (2020)
  158. Can trastuzumab be effective against tumors with low HER2/Neu (ErbB2) receptors? Arteaga CL. J Clin Oncol 24 3722-3725 (2006)
  159. Molecular Mechanisms and Translational Therapies for Human Epidermal Receptor 2 Positive Breast Cancer. Lv Q, Meng Z, Yu Y, Jiang F, Guan D, Guan D, Liang C, Zhou J, Lu A, Zhang G. Int J Mol Sci 17 E2095 (2016)
  160. Pertuzumab: a new targeted therapy for HER2-positive metastatic breast cancer. Malenfant SJ, Eckmann KR, Barnett CM. Pharmacotherapy 34 60-71 (2014)
  161. Regulation of Beclin 1-Mediated Autophagy by Oncogenic Tyrosine Kinases. Vega-Rubín-de-Celis S, Kinch L, Peña-Llopis S. Int J Mol Sci 21 E9210 (2020)
  162. Somatic pharmacogenomics in cancer. Ikediobi ON. Pharmacogenomics J 8 305-314 (2008)
  163. Updates on the Systemic Treatment of Advanced Non-melanoma Skin Cancer. Tanese K, Nakamura Y, Hirai I, Funakoshi T. Front Med (Lausanne) 6 160 (2019)
  164. A review of approaches to 18 F radiolabelling affinity peptides and proteins. Morris O, Fairclough M, Grigg J, Prenant C, McMahon A. J Labelled Comp Radiopharm 62 4-23 (2019)
  165. Breast Cancer Therapeutics and Biomarkers: Past, Present, and Future Approaches. Schick J, Ritchie RP, Restini C. Breast Cancer (Auckl) 15 1178223421995854 (2021)
  166. Cardiotoxicity of Anticancer Drugs: Molecular Mechanisms and Strategies for Cardioprotection. Morelli MB, Bongiovanni C, Da Pra S, Miano C, Sacchi F, Lauriola M, D'Uva G. Front Cardiovasc Med 9 847012 (2022)
  167. Elimination of Osteosarcoma by Necroptosis with Graphene Oxide-Associated Anti-HER2 Antibodies. Xiao H, Jensen PE, Chen X. Int J Mol Sci 20 E4360 (2019)
  168. More than the sum of the parts: Toward full-length receptor tyrosine kinase structures. Diwanji D, Thaker T, Jura N. IUBMB Life 71 706-720 (2019)
  169. Therapeutic targeting of ERBB2 in breast cancer: understanding resistance in the laboratory and combating it in the clinic. Fabi A, Mottolese M, Segatto O. J Mol Med (Berl) 92 681-695 (2014)
  170. A paradigm shift: Cancer therapy with peptide-based B-cell epitopes and peptide immunotherapeutics targeting multiple solid tumor types: Emerging concepts and validation of combination immunotherapy. Kaumaya PT. Hum Vaccin Immunother 11 1368-1386 (2015)
  171. Kinesin spindle protein (KSP) inhibitors in combination with chemotherapeutic agents for cancer therapy. Song H, Zhou S, Wang R, Li S. ChemMedChem 8 1736-1749 (2013)
  172. Piecing it together: Unraveling the elusive structure-function relationship in single-pass membrane receptors. Valley CC, Lewis AK, Sachs JN. Biochim Biophys Acta Biomembr 1859 1398-1416 (2017)
  173. Cdc42: an effector and regulator of ErbB1 as a strategic target in breast cancer therapy. Hirsch DS, Wu WJ. Expert Rev Anticancer Ther 7 147-157 (2007)
  174. Dual HER2 blockade in the neoadjuvant and adjuvant treatment of HER2-positive breast cancer. Advani P, Cornell L, Chumsri S, Moreno-Aspitia A. Breast Cancer (Dove Med Press) 7 321-335 (2015)
  175. Dual HER2 blockade: preclinical and clinical data. Patel TA, Dave B, Rodriguez AA, Chang JC, Perez EA, Colon-Otero G. Breast Cancer Res 16 419 (2014)
  176. HER-dimerization inhibitors: evaluating pertuzumab in women's cancers. Kristjansdottir K, Dizon D. Expert Opin Biol Ther 10 243-250 (2010)
  177. HER3 mRNA as a predictive biomarker in anticancer therapy. Amler LC. Expert Opin Biol Ther 10 1343-1355 (2010)
  178. Mechanisms of Action of EGFR Tyrosine Kinase Receptor Incorporated in Extracellular Vesicles. Zanetti-Domingues LC, Bonner SE, Martin-Fernandez ML, Huber V. Cells 9 E2505 (2020)
  179. Nitrile-containing pharmaceuticals: target, mechanism of action, and their SAR studies. Wang X, Wang Y, Li X, Yu Z, Song C, Du Y. RSC Med Chem 12 1650-1671 (2021)
  180. Role of pertuzumab in the treatment of HER2-positive breast cancer. Hubalek M, Brantner C, Marth C. Breast Cancer (Dove Med Press) 4 65-73 (2012)
  181. Structure-function relationships of ErbB RTKs in the plasma membrane of living cells. Arndt-Jovin DJ, Botelho MG, Jovin TM. Cold Spring Harb Perspect Biol 6 a008961 (2014)
  182. ErbB Proteins as Molecular Target of Dietary Phytochemicals in Malignant Diseases. Filippi A, Ciolac OA, Ganea C, Mocanu MM. J Oncol 2017 1532534 (2017)
  183. Array-based pharmacogenomics of molecular-targeted therapies in oncology. Sanoudou D, Mountzios G, Arvanitis DA, Pectasides D. Pharmacogenomics J 12 185-196 (2012)
  184. Biological considerations and clinical applications of new HER2-targeted agents. Higa GM, Singh V, Abraham J. Expert Rev Anticancer Ther 10 1497-1509 (2010)
  185. Infection risk in breast cancer patients treated with trastuzumab: a systematic review and meta-analysis. Funakoshi T, Suzuki M, Muss HB. Breast Cancer Res Treat 149 321-330 (2015)
  186. A multiscale systems perspective on cancer, immunotherapy, and Interleukin-12. Klinke DJ. Mol Cancer 9 242 (2010)
  187. Bridging oncology and immunology: expanding horizons with innovative peptide vaccines and peptidomimetics. Kaumaya PT. Immunotherapy 5 1159-1163 (2013)
  188. CAR T Cell Therapy in Pancreaticobiliary Cancers: a Focused Review of Clinical Data. Anwar MY, Williams GR, Paluri RK. J Gastrointest Cancer 52 1-10 (2021)
  189. Cell-Free Co-Translational Approaches for Producing Mammalian Receptors: Expanding the Cell-Free Expression Toolbox Using Nanolipoproteins. Shelby ML, He W, Dang AT, Kuhl TL, Coleman MA. Front Pharmacol 10 744 (2019)
  190. Interaction of current cancer treatments and the immune system: implications for breast cancer therapeutics. Tan PH, Lota AS. Expert Opin Pharmacother 9 2639-2660 (2008)
  191. Adding Pertuzumab to Trastuzumab and Taxanes in HER2 positive breast cancer. Gleeson JP, Keegan NM, Morris PG. Expert Opin Biol Ther 18 251-262 (2018)
  192. Antibody therapy for early-stage breast cancer: trastuzumab adjuvant and neoadjuvant trials. Mehra R, Burtness B. Expert Opin Biol Ther 6 951-962 (2006)
  193. Cancer drug related cardiotoxicity during breast cancer treatment. Giordano G, Spagnuolo A, Olivieri N, Corbo C, Campagna A, Spagnoletti I, Pennacchio RM, Campidoglio S, Pancione M, Palladino L, Villari B, Febbraro A. Expert Opin Drug Saf 15 1063-1074 (2016)
  194. Design and evaluation of radiolabeled tracers for tumor imaging. Wållberg H, Ståhl S. Biotechnol Appl Biochem 60 365-383 (2013)
  195. Emerging Biomarkers and Targeted Therapies in Feline Mammary Carcinoma. Gameiro A, Urbano AC, Ferreira F. Vet Sci 8 164 (2021)
  196. Lapatinib: a competitor or companion to trastuzumab? Collins D, Hill AD, Young L. Cancer Treat Rev 35 574-581 (2009)
  197. New drugs for breast cancer. Tookman L, Roylance R. Br Med Bull 96 111-129 (2010)
  198. Pertuzumab for the treatment of metastatic breast cancer. Langdon SP, Cameron DA. Expert Rev Anticancer Ther 13 907-918 (2013)
  199. Recent Advances in Monoclonal Antibody Therapy for Colorectal Cancers. Hwang K, Yoon JH, Lee JH, Lee S. Biomedicines 9 39 (2021)
  200. System properties of ErbB receptor signaling for the understanding of cancer progression. Hatakeyama M. Mol Biosyst 3 111-116 (2007)
  201. The impact of structural biology in medicine illustrated with four case studies. Hu T, Sprague ER, Fodor M, Stams T, Clark KL, Cowan-Jacob SW. J Mol Med (Berl) 96 9-19 (2018)
  202. Advances and Hurdles in CAR T Cell Immune Therapy for Solid Tumors. Boccalatte F, Mina R, Aroldi A, Leone S, Suryadevara CM, Placantonakis DG, Bruno B. Cancers (Basel) 14 5108 (2022)
  203. Drug-resistant HER2-positive breast cancer: Molecular mechanisms and overcoming strategies. Wu X, Yang H, Yu X, Qin JJ. Front Pharmacol 13 1012552 (2022)
  204. Mechanistic insights into differential requirement of receptor dimerization for oncogenic activation of mutant EGFR and its clinical perspective. Cho J. BMB Rep 53 133-141 (2020)
  205. Progress in Treatment of Non-Small Cell Lung Cancer Harboring HER2 Aberrations. Ni J, Zhang L. Onco Targets Ther 14 4087-4098 (2021)
  206. Role of Chimeric Antigen Receptor T Cell Therapy in Glioblastoma Multiforme. Jindal V. Mol Neurobiol 55 8236-8242 (2018)
  207. Syndecans and Their Synstatins: Targeting an Organizer of Receptor Tyrosine Kinase Signaling at the Cell-Matrix Interface. Rapraeger AC. Front Oncol 11 775349 (2021)
  208. Biomarkers in Her2- Positive Disease. Klocker EV, Suppan C. Breast Care (Basel) 15 586-593 (2020)
  209. Cardiotoxicity of anthracycline-free targeted oncological therapies in HER2-positive breast cancer. Guan J, Zhang M. Oncol Lett 21 100 (2021)
  210. Emerging Role of ERBB2 in Targeted Therapy for Metastatic Colorectal Cancer: Signaling Pathways to Therapeutic Strategies. Wang N, Cao Y, Si C, Shao P, Su G, Wang K, Bao J, Yang L. Cancers (Basel) 14 5160 (2022)
  211. HER2 Aberrations in Non-Small Cell Lung Cancer: From Pathophysiology to Targeted Therapy. Vathiotis IA, Charpidou A, Gavrielatou N, Syrigos KN. Pharmaceuticals (Basel) 14 1300 (2021)
  212. Pharmacokinetics, pharmacodynamics and clinical efficacy of pertuzumab in breast cancer therapy. Rocca A, Andreis D, Fedeli A, Maltoni R, Sarti S, Cecconetto L, Pietri E, Schirone A, Bravaccini S, Serra P, Farolfi A, Amadori D. Expert Opin Drug Metab Toxicol 11 1647-1663 (2015)
  213. The prospect of patritumab for treating non-small cell lung cancer. Horinouchi H. Expert Opin Biol Ther 16 1549-1555 (2016)
  214. Neu Perspectives, Therapies, and Challenges for Metastatic HER2-Positive Breast Cancer. Salkeni MA, Rizvi W, Hein K, Higa GM. Breast Cancer (Dove Med Press) 13 539-557 (2021)
  215. Antibody-Drug Conjugates for the Treatment of HER2-Positive Breast Cancer. Najjar MK, Manore SG, Regua AT, Lo HW. Genes (Basel) 13 2065 (2022)
  216. Beyond RAS and BRAF: a target rich disease that is ripe for picking. Friedrich T, Leong S, Lieu CH. J Gastrointest Oncol 7 705-712 (2016)
  217. Current Insights and Advancements in Head and Neck Cancer: Emerging Biomarkers and Therapeutics with Cues from Single Cell and 3D Model Omics Profiling. Jawa Y, Yadav P, Gupta S, Mathan SV, Pandey J, Saxena AK, Kateriya S, Tiku AB, Mondal N, Bhattacharya J, Ahmad S, Chaturvedi R, Tyagi RK, Tandon V, Singh RP. Front Oncol 11 676948 (2021)
  218. Human epidermal growth factor receptor dimerization analysis in breast cancer diagnosis: potential for improving testing accuracy and treatment selection. Spears M, Bartlett JM. Mol Diagn Ther 13 359-365 (2009)
  219. Molecular Pathways and Mechanisms of HER2 in Cancer Therapy. Raghav KPS, Moasser MM. Clin Cancer Res 29 2351-2361 (2023)
  220. Pharmacotherapeutic options for patients with refractory breast cancer. Fedele P, Ciccarese M, Surico G, Cinieri S. Expert Opin Pharmacother 20 851-861 (2019)
  221. Sagacious epitope selection for vaccines, and both antibody-based therapeutics and diagnostics: tips from virology and oncology. Gan SK, Phua SX, Yeo JY. Antib Ther 5 63-72 (2022)
  222. Signaling pathways and therapeutic interventions in gastric cancer. Lei ZN, Teng QX, Tian Q, Chen W, Xie Y, Wu K, Zeng Q, Zeng L, Pan Y, Chen ZS, He Y. Signal Transduct Target Ther 7 358 (2022)
  223. Targeting the EGF receptor ectodomain in the context of cancer. Huang L, De Baetselier P, Beyaert R. Expert Opin Ther Targets 13 1347-1361 (2009)
  224. The potential for targeting HER2 therapeutically in esophageal cancer - a grasp at straws? Uzunoglu FG, Koenig AM, Izbicki JR. Expert Opin Ther Targets 18 1421-1426 (2014)
  225. [Anti-HER2 vaccines: The HER2 immunotargeting future?]. Ladjemi MZ, Jacot W, Pèlegrin A, Navarro-Teulon I. Pathol Biol (Paris) 59 173-182 (2011)
  226. [Pertuzumab (PERJETA(®) intravenous infusion 420 mg/14 mL): pharmacological properties and clinical development overview]. Myobudani H, Ushiyama N, Ichinose R, Takasuka T. Nihon Yakurigaku Zasshi 143 95-102 (2014)
  227. Aptamer Nanomaterials for Ovarian Cancer Target Theranostics. Zhao J, Tan W, Zheng J, Su Y, Cui M. Front Bioeng Biotechnol 10 884405 (2022)
  228. Breast cancer heterogeneity and its implication in personalized precision therapy. Guo L, Kong D, Liu J, Zhan L, Luo L, Zheng W, Zheng Q, Chen C, Sun S. Exp Hematol Oncol 12 3 (2023)
  229. Cancer immune exclusion: breaking the barricade for a successful immunotherapy. Bruni S, Mercogliano MF, Mauro FL, Cordo Russo RI, Schillaci R. Front Oncol 13 1135456 (2023)
  230. Deciphering the Impact of HER2 Alterations on Non-Small-Cell Lung Cancer: From Biological Mechanisms to Therapeutic Approaches. Bontoux C, Benzaquen J, Hofman V, Heeke S, Hannetel P, Capela-Brosseau-Laborde P, Marquette CH, Ilié M, Hofman P. J Pers Med 12 1651 (2022)
  231. From Anti-HER-2 to Anti-HER-2-CAR-T Cells: An Evolutionary Immunotherapy Approach for Gastric Cancer. Sun J, Li X, Chen P, Gao Y. J Inflamm Res 15 4061-4085 (2022)
  232. HER2 and HER3 as Therapeutic Targets in Head and Neck Cancer. Saddawi-Konefka R, Schokrpur S, Lui AJ, Gutkind JS. Cancer J 28 339-345 (2022)
  233. HER3 Alterations in Cancer and Potential Clinical Implications. Kilroy MK, Park S, Feroz W, Patel H, Mishra R, Alanazi S, Garrett JT. Cancers (Basel) 14 6174 (2022)
  234. Herbal Ingredients in the Prevention of Breast Cancer: Comprehensive Review of Potential Molecular Targets and Role of Natural Products. Küpeli Akkol E, Bardakci H, Barak TH, Aschner M, Şeker Karatoprak G, Khan H, Hussain Y. Oxid Med Cell Longev 2022 6044640 (2022)
  235. Management of patients with advanced-stage HER2-positive breast cancer: current evidence and future perspectives. Marra A, Chandarlapaty S, Modi S. Nat Rev Clin Oncol (2024)
  236. New Insights in the Era of Clinical Biomarkers as Potential Predictors of Systemic Therapy-Induced Cardiotoxicity in Women with Breast Cancer: A Systematic Review. Alexandraki A, Papageorgiou E, Zacharia M, Keramida K, Papakonstantinou A, Cipolla CM, Tsekoura D, Naka K, Mazzocco K, Mauri D, Tsiknakis M, Manikis GC, Marias K, Marcou Y, Kakouri E, Konstantinou I, Daniel M, Galazi M, Kampouroglou E, Ribnikar D, Brown C, Karanasiou G, Antoniades A, Fotiadis D, Filippatos G, Constantinidou A. Cancers (Basel) 15 3290 (2023)
  237. On the relevance of defining protein structures in cancer research. Muñoz IG, Blanco FJ, Montoya G. Clin Transl Oncol 10 204-212 (2008)
  238. Peptides Targeting HER2-Positive Breast Cancer Cells and Applications in Tumor Imaging and Delivery of Chemotherapeutics. Cavallaro PA, De Santo M, Belsito EL, Longobucco C, Curcio M, Morelli C, Pasqua L, Leggio A. Nanomaterials (Basel) 13 2476 (2023)
  239. Preclinical and Basic Research Strategies for Overcoming Resistance to Targeted Therapies in HER2-Positive Breast Cancer. Cao Y, Li Y, Liu R, Zhou J, Wang K. Cancers (Basel) 15 2568 (2023)
  240. Rational Design of Constrained Peptides as Protein Interface Inhibitors. Murali R, Zhang H, Cai Z, Lam L, Greene M. Antibodies (Basel) 10 32 (2021)
  241. Targeting Epidermal Growth Factor Receptor for Cancer Treatment: Abolishing Both Kinase-Dependent and Kinase-Independent Functions of the Receptor. Zhang Y. Pharmacol Rev 75 1218-1232 (2023)
  242. The History and Development of HER2 Inhibitors. Xia X, Gong C, Zhang Y, Xiong H. Pharmaceuticals (Basel) 16 1450 (2023)
  243. Tyrosine kinase as molecular target of anti-tumor drug. Maru Y. Nihon Yakurigaku Zasshi 122 473-481 (2003)

Articles citing this publication (513)

  1. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Nagata Y, Lan KH, Zhou X, Tan M, Esteva FJ, Sahin AA, Klos KS, Li P, Monia BP, Nguyen NT, Hortobagyi GN, Hung MC, Yu D. Cancer Cell 6 117-127 (2004)
  2. Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex. Franklin MC, Carey KD, Vajdos FF, Leahy DJ, de Vos AM, Sliwkowski MX. Cancer Cell 5 317-328 (2004)
  3. Structural basis for inhibition of the epidermal growth factor receptor by cetuximab. Li S, Schmitz KR, Jeffrey PD, Wiltzius JJ, Kussie P, Ferguson KM. Cancer Cell 7 301-311 (2005)
  4. Human Epidermal Growth Factor Receptor 2 (HER2) -Specific Chimeric Antigen Receptor-Modified T Cells for the Immunotherapy of HER2-Positive Sarcoma. Ahmed N, Brawley VS, Hegde M, Robertson C, Ghazi A, Gerken C, Liu E, Dakhova O, Ashoori A, Corder A, Gray T, Wu MF, Liu H, Hicks J, Rainusso N, Dotti G, Mei Z, Grilley B, Gee A, Rooney CM, Brenner MK, Heslop HE, Wels WS, Wang LL, Anderson P, Gottschalk S. J Clin Oncol 33 1688-1696 (2015)
  5. Quantum dot ligands provide new insights into erbB/HER receptor-mediated signal transduction. Lidke DS, Nagy P, Heintzmann R, Arndt-Jovin DJ, Post JN, Grecco HE, Jares-Erijman EA, Jovin TM. Nat Biotechnol 22 198-203 (2004)
  6. Architecture and membrane interactions of the EGF receptor. Arkhipov A, Shan Y, Das R, Endres NF, Eastwood MP, Wemmer DE, Kuriyan J, Shaw DE. Cell 152 557-569 (2013)
  7. The distinctive nature of HER2-positive breast cancers. Burstein HJ. N Engl J Med 353 1652-1654 (2005)
  8. Resistance to Trastuzumab in Breast Cancer. Pohlmann PR, Mayer IA, Mernaugh R. Clin Cancer Res 15 7479-7491 (2009)
  9. Phase I clinical study of pertuzumab, a novel HER dimerization inhibitor, in patients with advanced cancer. Agus DB, Gordon MS, Taylor C, Natale RB, Karlan B, Mendelson DS, Press MF, Allison DE, Sliwkowski MX, Lieberman G, Kelsey SM, Fyfe G. J Clin Oncol 23 2534-2543 (2005)
  10. Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer. Junttila TT, Li G, Parsons K, Phillips GL, Sliwkowski MX. Breast Cancer Res Treat 128 347-356 (2011)
  11. Variants of the antibody herceptin that interact with HER2 and VEGF at the antigen binding site. Bostrom J, Yu SF, Kan D, Appleton BA, Lee CV, Billeci K, Man W, Peale F, Ross S, Wiesmann C, Fuh G. Science 323 1610-1614 (2009)
  12. Prognostic significance of human epidermal growth factor receptor positivity for the development of brain metastasis after newly diagnosed breast cancer. Gabos Z, Sinha R, Hanson J, Chauhan N, Hugh J, Mackey JR, Abdulkarim B. J Clin Oncol 24 5658-5663 (2006)
  13. Focus on epithelial ovarian cancer. Ozols RF, Bookman MA, Connolly DC, Daly MB, Godwin AK, Schilder RJ, Xu X, Hamilton TC. Cancer Cell 5 19-24 (2004)
  14. Selective inhibition of tumor growth by clonal NK cells expressing an ErbB2/HER2-specific chimeric antigen receptor. Schönfeld K, Sahm C, Zhang C, Naundorf S, Brendel C, Odendahl M, Nowakowska P, Bönig H, Köhl U, Kloess S, Köhler S, Holtgreve-Grez H, Jauch A, Schmidt M, Schubert R, Kühlcke K, Seifried E, Klingemann HG, Rieger MA, Tonn T, Grez M, Wels WS. Mol Ther 23 330-338 (2015)
  15. Closed state of both binding domains of homodimeric mGlu receptors is required for full activity. Kniazeff J, Bessis AS, Maurel D, Ansanay H, Prézeau L, Pin JP. Nat Struct Mol Biol 11 706-713 (2004)
  16. Functional analysis of receptor tyrosine kinase mutations in lung cancer identifies oncogenic extracellular domain mutations of ERBB2. Greulich H, Kaplan B, Mertins P, Chen TH, Tanaka KE, Yun CH, Zhang X, Lee SH, Cho J, Ambrogio L, Liao R, Imielinski M, Banerji S, Berger AH, Lawrence MS, Zhang J, Pho NH, Walker SR, Winckler W, Getz G, Frank D, Hahn WC, Eck MJ, Mani DR, Jaffe JD, Carr SA, Wong KK, Meyerson M. Proc Natl Acad Sci U S A 109 14476-14481 (2012)
  17. Humanization of a recombinant monoclonal antibody to produce a therapeutic HER dimerization inhibitor, pertuzumab. Adams CW, Allison DE, Flagella K, Presta L, Clarke J, Dybdal N, McKeever K, Sliwkowski MX. Cancer Immunol Immunother 55 717-727 (2006)
  18. Epidermal growth factor receptor dimerization and activation require ligand-induced conformational changes in the dimer interface. Dawson JP, Berger MB, Lin CC, Schlessinger J, Lemmon MA, Ferguson KM. Mol Cell Biol 25 7734-7742 (2005)
  19. Loss of phosphatase and tensin homolog or phosphoinositol-3 kinase activation and response to trastuzumab or lapatinib in human epidermal growth factor receptor 2-overexpressing locally advanced breast cancers. Dave B, Migliaccio I, Gutierrez MC, Wu MF, Chamness GC, Wong H, Narasanna A, Chakrabarty A, Hilsenbeck SG, Huang J, Rimawi M, Schiff R, Arteaga C, Osborne CK, Chang JC. J Clin Oncol 29 166-173 (2011)
  20. Contribution of variable domains to the stability of humanized IgG1 monoclonal antibodies. Ionescu RM, Vlasak J, Price C, Kirchmeier M. J Pharm Sci 97 1414-1426 (2008)
  21. Chimeric Antigen Receptor-Engineered NK-92 Cells: An Off-the-Shelf Cellular Therapeutic for Targeted Elimination of Cancer Cells and Induction of Protective Antitumor Immunity. Zhang C, Oberoi P, Oelsner S, Waldmann A, Lindner A, Tonn T, Wels WS. Front Immunol 8 533 (2017)
  22. Expression of Wnt3 activates Wnt/β-catenin pathway and promotes EMT-like phenotype in trastuzumab-resistant HER2-overexpressing breast cancer cells. Wu Y, Ginther C, Kim J, Mosher N, Chung S, Slamon D, Vadgama JV. Mol Cancer Res 10 1597-1606 (2012)
  23. Trastuzumab has preferential activity against breast cancers driven by HER2 homodimers. Ghosh R, Narasanna A, Wang SE, Liu S, Chakrabarty A, Balko JM, González-Angulo AM, Mills GB, Penuel E, Winslow J, Sperinde J, Dua R, Pidaparthi S, Mukherjee A, Leitzel K, Kostler WJ, Lipton A, Bates M, Arteaga CL. Cancer Res 71 1871-1882 (2011)
  24. A designed ankyrin repeat protein evolved to picomolar affinity to Her2. Zahnd C, Wyler E, Schwenk JM, Steiner D, Lawrence MC, McKern NM, Pecorari F, Ward CW, Joos TO, Plückthun A. J Mol Biol 369 1015-1028 (2007)
  25. The intrinsic contributions of tyrosine, serine, glycine and arginine to the affinity and specificity of antibodies. Birtalan S, Zhang Y, Fellouse FA, Shao L, Schaefer G, Sidhu SS. J Mol Biol 377 1518-1528 (2008)
  26. Molecular recognition by a binary code. Fellouse FA, Li B, Compaan DM, Peden AA, Hymowitz SG, Sidhu SS. J Mol Biol 348 1153-1162 (2005)
  27. Heterogeneity in EGF-binding affinities arises from negative cooperativity in an aggregating system. Macdonald JL, Pike LJ. Proc Natl Acad Sci U S A 105 112-117 (2008)
  28. General strategy for the generation of human antibody variable domains with increased aggregation resistance. Dudgeon K, Rouet R, Kokmeijer I, Schofield P, Stolp J, Langley D, Stock D, Christ D. Proc Natl Acad Sci U S A 109 10879-10884 (2012)
  29. The extracellular region of ErbB4 adopts a tethered conformation in the absence of ligand. Bouyain S, Longo PA, Li S, Ferguson KM, Leahy DJ. Proc Natl Acad Sci U S A 102 15024-15029 (2005)
  30. Mechanism of activation and inhibition of the HER4/ErbB4 kinase. Qiu C, Tarrant MK, Choi SH, Sathyamurthy A, Bose R, Banjade S, Pal A, Bornmann WG, Lemmon MA, Cole PA, Leahy DJ. Structure 16 460-467 (2008)
  31. The growing role of precision and personalized medicine for cancer treatment. Krzyszczyk P, Acevedo A, Davidoff EJ, Timmins LM, Marrero-Berrios I, Patel M, White C, Lowe C, Sherba JJ, Hartmanshenn C, O'Neill KM, Balter ML, Fritz ZR, Androulakis IP, Schloss RS, Yarmush ML. Technology (Singap World Sci) 6 79-100 (2018)
  32. ErbB3/HER3 does not homodimerize upon neuregulin binding at the cell surface. Berger MB, Mendrola JM, Lemmon MA. FEBS Lett 569 332-336 (2004)
  33. Investigation of the dimerization of proteins from the epidermal growth factor receptor family by single wavelength fluorescence cross-correlation spectroscopy. Liu P, Sudhaharan T, Koh RM, Hwang LC, Ahmed S, Maruyama IN, Wohland T. Biophys J 93 684-698 (2007)
  34. Phase I trial of MK-0752 in children with refractory CNS malignancies: a pediatric brain tumor consortium study. Fouladi M, Stewart CF, Olson J, Wagner LM, Onar-Thomas A, Kocak M, Packer RJ, Goldman S, Gururangan S, Gajjar A, Demuth T, Kun LE, Boyett JM, Gilbertson RJ. J Clin Oncol 29 3529-3534 (2011)
  35. Cardiac toxicity and efficacy of trastuzumab combined with pertuzumab in patients with [corrected] human epidermal growth factor receptor 2-positive metastatic breast cancer. Portera CC, Walshe JM, Rosing DR, Denduluri N, Berman AW, Vatas U, Velarde M, Chow CK, Steinberg SM, Nguyen D, Yang SX, Swain SM. Clin Cancer Res 14 2710-2716 (2008)
  36. Distribution of resting and ligand-bound ErbB1 and ErbB2 receptor tyrosine kinases in living cells using number and brightness analysis. Nagy P, Claus J, Jovin TM, Arndt-Jovin DJ. Proc Natl Acad Sci U S A 107 16524-16529 (2010)
  37. High-resolution mapping of linear antibody epitopes using ultrahigh-density peptide microarrays. Buus S, Rockberg J, Forsström B, Nilsson P, Uhlen M, Schafer-Nielsen C. Mol Cell Proteomics 11 1790-1800 (2012)
  38. Structural basis for high-affinity HER2 receptor binding by an engineered protein. Eigenbrot C, Ultsch M, Dubnovitsky A, Abrahmsén L, Härd T. Proc Natl Acad Sci U S A 107 15039-15044 (2010)
  39. Matuzumab binding to EGFR prevents the conformational rearrangement required for dimerization. Schmiedel J, Blaukat A, Li S, Knöchel T, Ferguson KM. Cancer Cell 13 365-373 (2008)
  40. HER2 phosphorylation is maintained by a PKB negative feedback loop in response to anti-HER2 herceptin in breast cancer. Gijsen M, King P, Perera T, Parker PJ, Harris AL, Larijani B, Kong A. PLoS Biol 8 e1000563 (2010)
  41. Cardiac tolerability of pertuzumab plus trastuzumab plus docetaxel in patients with HER2-positive metastatic breast cancer in CLEOPATRA: a randomized, double-blind, placebo-controlled phase III study. Swain SM, Ewer MS, Cortés J, Amadori D, Miles D, Knott A, Clark E, Benyunes MC, Ross G, Baselga J. Oncologist 18 257-264 (2013)
  42. Direct identification of ligand-receptor interactions on living cells and tissues. Frei AP, Jeon OY, Kilcher S, Moest H, Henning LM, Jost C, Plückthun A, Mercer J, Aebersold R, Carreira EM, Wollscheid B. Nat Biotechnol 30 997-1001 (2012)
  43. International Union of Basic and Clinical Pharmacology. XC. multisite pharmacology: recommendations for the nomenclature of receptor allosterism and allosteric ligands. Christopoulos A, Changeux JP, Catterall WA, Fabbro D, Burris TP, Cidlowski JA, Olsen RW, Peters JA, Neubig RR, Pin JP, Sexton PM, Kenakin TP, Ehlert FJ, Spedding M, Langmead CJ. Pharmacol Rev 66 918-947 (2014)
  44. An antibody that locks HER3 in the inactive conformation inhibits tumor growth driven by HER2 or neuregulin. Garner AP, Bialucha CU, Sprague ER, Garrett JT, Sheng Q, Li S, Sineshchekova O, Saxena P, Sutton CR, Chen D, Chen Y, Wang H, Liang J, Das R, Mosher R, Gu J, Huang A, Haubst N, Zehetmeier C, Haberl M, Elis W, Kunz C, Heidt AB, Herlihy K, Murtie J, Schuller A, Arteaga CL, Sellers WR, Ettenberg SA. Cancer Res 73 6024-6035 (2013)
  45. Neratinib overcomes trastuzumab resistance in HER2 amplified breast cancer. Canonici A, Gijsen M, Mullooly M, Bennett R, Bouguern N, Pedersen K, O'Brien NA, Roxanis I, Li JL, Bridge E, Finn R, Siamon D, McGowan P, Duffy MJ, O'Donovan N, Crown J, Kong A. Oncotarget 4 1592-1605 (2013)
  46. FGFR3 dimer stabilization due to a single amino acid pathogenic mutation. Li E, You M, Hristova K. J Mol Biol 356 600-612 (2006)
  47. A single ligand is sufficient to activate EGFR dimers. Liu P, Cleveland TE, Bouyain S, Byrne PO, Longo PA, Leahy DJ. Proc Natl Acad Sci U S A 109 10861-10866 (2012)
  48. Trastuzumab-induced cardiac dysfunction: A 'dual-hit'. Zeglinski M, Ludke A, Jassal DS, Singal PK. Exp Clin Cardiol 16 70-74 (2011)
  49. Phase I study of chimeric antigen receptor modified T cells in treating HER2-positive advanced biliary tract cancers and pancreatic cancers. Feng K, Liu Y, Guo Y, Qiu J, Wu Z, Dai H, Yang Q, Wang Y, Han W. Protein Cell 9 838-847 (2018)
  50. Novel HER2 aptamer selectively delivers cytotoxic drug to HER2-positive breast cancer cells in vitro. Liu Z, Duan JH, Song YM, Ma J, Wang FD, Lu X, Yang XD. J Transl Med 10 148 (2012)
  51. Synthesis of bispecific antibodies using genetically encoded unnatural amino acids. Kim CH, Axup JY, Dubrovska A, Kazane SA, Hutchins BA, Wold ED, Smider VV, Schultz PG. J Am Chem Soc 134 9918-9921 (2012)
  52. Structural basis for EGF receptor inhibition by the therapeutic antibody IMC-11F8. Li S, Kussie P, Ferguson KM. Structure 16 216-227 (2008)
  53. CED: a conformational epitope database. Huang J, Honda W. BMC Immunol 7 7 (2006)
  54. The tethered configuration of the EGF receptor extracellular domain exerts only a limited control of receptor function. Mattoon D, Klein P, Lemmon MA, Lax I, Schlessinger J. Proc Natl Acad Sci U S A 101 923-928 (2004)
  55. ErbB1-4-dependent EGF/neuregulin signals and their cross talk in the central nervous system: pathological implications in schizophrenia and Parkinson's disease. Iwakura Y, Nawa H. Front Cell Neurosci 7 4 (2013)
  56. Imaging of HER2/neu-positive BT-474 human breast cancer xenografts in athymic mice using (111)In-trastuzumab (Herceptin) Fab fragments. Tang Y, Wang J, Scollard DA, Mondal H, Holloway C, Kahn HJ, Reilly RM. Nucl Med Biol 32 51-58 (2005)
  57. Ligand-induced structural transitions in ErbB receptor extracellular domains. Dawson JP, Bu Z, Lemmon MA. Structure 15 942-954 (2007)
  58. Mechanisms of activation of receptor tyrosine kinases: monomers or dimers. Maruyama IN. Cells 3 304-330 (2014)
  59. Structural basis for eliciting a cytotoxic effect in HER2-overexpressing cancer cells via binding to the extracellular domain of HER2. Jost C, Schilling J, Tamaskovic R, Schwill M, Honegger A, Plückthun A. Structure 21 1979-1991 (2013)
  60. Tumor-targeted gene delivery via anti-HER2 antibody (trastuzumab, Herceptin) conjugated polyethylenimine. Chiu SJ, Ueno NT, Lee RJ. J Control Release 97 357-369 (2004)
  61. HER3 signaling and targeted therapy in cancer. Mishra R, Patel H, Alanazi S, Yuan L, Garrett JT. Oncol Rev 12 355 (2018)
  62. A system for quantifying dynamic protein interactions defines a role for Herceptin in modulating ErbB2 interactions. Wehrman TS, Raab WJ, Casipit CL, Doyonnas R, Pomerantz JH, Blau HM. Proc Natl Acad Sci U S A 103 19063-19068 (2006)
  63. Aglycosylated antibodies and antibody fragments produced in a scalable in vitro transcription-translation system. Yin G, Garces ED, Yang J, Zhang J, Tran C, Steiner AR, Roos C, Bajad S, Hudak S, Penta K, Zawada J, Pollitt S, Murray CJ. MAbs 4 217-225 (2012)
  64. Epigen, the last ligand of ErbB receptors, reveals intricate relationships between affinity and mitogenicity. Kochupurakkal BS, Harari D, Di-Segni A, Maik-Rachline G, Lyass L, Gur G, Kerber G, Citri A, Lavi S, Eilam R, Chalifa-Caspi V, Eshhar Z, Pikarsky E, Pinkas-Kramarski R, Bacus SS, Yarden Y. J Biol Chem 280 8503-8512 (2005)
  65. Pooled analysis of cardiac safety in patients with cancer treated with pertuzumab. Lenihan D, Suter T, Brammer M, Neate C, Ross G, Baselga J. Ann Oncol 23 791-800 (2012)
  66. Rationale for fixed dosing of pertuzumab in cancer patients based on population pharmacokinetic analysis. Ng CM, Lum BL, Gimenez V, Kelsey S, Allison D. Pharm Res 23 1275-1284 (2006)
  67. Prognostic and predictive values of EGFR overexpression and EGFR copy number alteration in HER2-positive breast cancer. Lee HJ, Seo AN, Kim EJ, Jang MH, Kim YJ, Kim JH, Kim SW, Ryu HS, Park IA, Im SA, Gong G, Jung KH, Kim HJ, Park SY. Br J Cancer 112 103-111 (2015)
  68. Size-Dependent Segregation Controls Macrophage Phagocytosis of Antibody-Opsonized Targets. Bakalar MH, Joffe AM, Schmid EM, Son S, Podolski M, Fletcher DA. Cell 174 131-142.e13 (2018)
  69. The FRET signatures of noninteracting proteins in membranes: simulations and experiments. King C, Sarabipour S, Byrne P, Leahy DJ, Hristova K. Biophys J 106 1309-1317 (2014)
  70. Domain-level antibody epitope mapping through yeast surface display of epidermal growth factor receptor fragments. Cochran JR, Kim YS, Olsen MJ, Bhandari R, Wittrup KD. J Immunol Methods 287 147-158 (2004)
  71. FN1, SPARC, and SERPINE1 are highly expressed and significantly related to a poor prognosis of gastric adenocarcinoma revealed by microarray and bioinformatics. Li L, Zhu Z, Zhao Y, Zhang Q, Wu X, Miao B, Cao J, Fei S. Sci Rep 9 7827 (2019)
  72. A phase IIa dose-finding and safety study of first-line pertuzumab in combination with trastuzumab, capecitabine and cisplatin in patients with HER2-positive advanced gastric cancer. Kang YK, Rha SY, Tassone P, Barriuso J, Yu R, Szado T, Garg A, Bang YJ. Br J Cancer 111 660-666 (2014)
  73. Cellular studies of binding, internalization and retention of a radiolabeled EGFR-binding affibody molecule. Nordberg E, Friedman M, Göstring L, Adams GP, Brismar H, Nilsson FY, Ståhl S, Glimelius B, Carlsson J. Nucl Med Biol 34 609-618 (2007)
  74. The functional capacity of the natural amino acids for molecular recognition. Birtalan S, Fisher RD, Sidhu SS. Mol Biosyst 6 1186-1194 (2010)
  75. Differential impact of Cetuximab, Pertuzumab and Trastuzumab on BT474 and SK-BR-3 breast cancer cell proliferation. Brockhoff G, Heckel B, Schmidt-Bruecken E, Plander M, Hofstaedter F, Vollmann A, Diermeier S. Cell Prolif 40 488-507 (2007)
  76. Mechanics of EGF receptor/ErbB2 kinase activation revealed by luciferase fragment complementation imaging. Macdonald-Obermann JL, Piwnica-Worms D, Pike LJ. Proc Natl Acad Sci U S A 109 137-142 (2012)
  77. Plant viral nanoparticles-based HER2 vaccine: Immune response influenced by differential transport, localization and cellular interactions of particulate carriers. Shukla S, Myers JT, Woods SE, Gong X, Czapar AE, Commandeur U, Huang AY, Levine AD, Steinmetz NF. Biomaterials 121 15-27 (2017)
  78. Phase I active immunotherapy with combination of two chimeric, human epidermal growth factor receptor 2, B-cell epitopes fused to a promiscuous T-cell epitope in patients with metastatic and/or recurrent solid tumors. Kaumaya PT, Foy KC, Garrett J, Rawale SV, Vicari D, Thurmond JM, Lamb T, Mani A, Kane Y, Balint CR, Chalupa D, Otterson GA, Shapiro CL, Fowler JM, Grever MR, Bekaii-Saab TS, Carson WE. J Clin Oncol 27 5270-5277 (2009)
  79. Letter Genetically encoding an electrophilic amino acid for protein stapling and covalent binding to native receptors. Chen XH, Xiang Z, Hu YS, Lacey VK, Cang H, Wang L. ACS Chem Biol 9 1956-1961 (2014)
  80. Molecular Mechanisms of Trastuzumab-Based Treatment in HER2-Overexpressing Breast Cancer. Nahta R. ISRN Oncol 2012 428062 (2012)
  81. Stepwise prediction of conformational discontinuous B-cell epitopes using the Mapitope algorithm. Bublil EM, Freund NT, Mayrose I, Penn O, Roitburd-Berman A, Rubinstein ND, Pupko T, Gershoni JM. Proteins 68 294-304 (2007)
  82. Bispecific small molecule-antibody conjugate targeting prostate cancer. Kim CH, Axup JY, Lawson BR, Yun H, Tardif V, Choi SH, Zhou Q, Dubrovska A, Biroc SL, Marsden R, Pinstaff J, Smider VV, Schultz PG. Proc Natl Acad Sci U S A 110 17796-17801 (2013)
  83. Muc4-ErbB2 complex formation and signaling in polarized CACO-2 epithelial cells indicate that Muc4 acts as an unorthodox ligand for ErbB2. Ramsauer VP, Pino V, Farooq A, Carothers Carraway CA, Salas PJ, Carraway KL. Mol Biol Cell 17 2931-2941 (2006)
  84. A phase I-II study of combined blockade of the ErbB receptor network with trastuzumab and gefitinib in patients with HER2 (ErbB2)-overexpressing metastatic breast cancer. Arteaga CL, O'Neill A, Moulder SL, Pins M, Sparano JA, Sledge GW, Davidson NE. Clin Cancer Res 14 6277-6283 (2008)
  85. Antibody Distance from the Cell Membrane Regulates Antibody Effector Mechanisms. Cleary KLS, Chan HTC, James S, Glennie MJ, Cragg MS. J Immunol 198 3999-4011 (2017)
  86. EGFR over-expression and activation in high HER2, ER negative breast cancer cell line induces trastuzumab resistance. Dua R, Zhang J, Nhonthachit P, Penuel E, Petropoulos C, Parry G. Breast Cancer Res Treat 122 685-697 (2010)
  87. EGFR, pMAPK, pAkt and PTEN status by immunohistochemistry: correlation with clinical outcome in HER2-positive metastatic breast cancer patients treated with trastuzumab. Gori S, Sidoni A, Colozza M, Ferri I, Mameli MG, Fenocchio D, Stocchi L, Foglietta J, Ludovini V, Minenza E, De Angelis V, Crinò L. Ann Oncol 20 648-654 (2009)
  88. A putative mechanism for downregulation of the catalytic activity of the EGF receptor via direct contact between its kinase and C-terminal domains. Landau M, Fleishman SJ, Ben-Tal N. Structure 12 2265-2275 (2004)
  89. ADAM10 mediates trastuzumab resistance and is correlated with survival in HER2 positive breast cancer. Feldinger K, Generali D, Kramer-Marek G, Gijsen M, Ng TB, Wong JH, Strina C, Cappelletti M, Andreis D, Li JL, Bridges E, Turley H, Leek R, Roxanis I, Capala J, Murphy G, Harris AL, Kong A. Oncotarget 5 6633-6646 (2014)
  90. Caveolin-1 mediates cellular distribution of HER2 and affects trastuzumab binding and therapeutic efficacy. Pereira PMR, Sharma SK, Carter LM, Edwards KJ, Pourat J, Ragupathi A, Janjigian YY, Durack JC, Lewis JS. Nat Commun 9 5137 (2018)
  91. Hsp90 inhibitor 17-AAG reduces ErbB2 levels and inhibits proliferation of the trastuzumab resistant breast tumor cell line JIMT-1. Zsebik B, Citri A, Isola J, Yarden Y, Szöllosi J, Vereb G. Immunol Lett 104 146-155 (2006)
  92. Regression of cutaneous tumor lesions in patients intratumorally injected with a recombinant single-chain antibody-toxin targeted to ErbB2/HER2. Azemar M, Djahansouzi S, Jäger E, Solbach C, Schmidt M, Maurer AB, Mross K, Unger C, von Minckwitz G, Dall P, Groner B, Wels WS. Breast Cancer Res Treat 82 155-164 (2003)
  93. Activating Mutations in ERBB2 and Their Impact on Diagnostics and Treatment. Herter-Sprie GS, Greulich H, Wong KK. Front Oncol 3 86 (2013)
  94. Inhibition of doxorubicin-induced HER3-PI3K-AKT signalling enhances apoptosis of ovarian cancer cells. Bezler M, Hengstler JG, Ullrich A. Mol Oncol 6 516-529 (2012)
  95. Optimization of therapeutic antibodies by predicting antigen specificity from antibody sequence via deep learning. Mason DM, Friedensohn S, Weber CR, Jordi C, Wagner B, Meng SM, Ehling RA, Bonati L, Dahinden J, Gainza P, Correia BE, Reddy ST. Nat Biomed Eng 5 600-612 (2021)
  96. Site-specific protein transamination using N-methylpyridinium-4-carboxaldehyde. Witus LS, Netirojjanakul C, Palla KS, Muehl EM, Weng CH, Iavarone AT, Francis MB. J Am Chem Soc 135 17223-17229 (2013)
  97. Her4 and Her2/neu tyrosine kinase domains dimerize and activate in a reconstituted in vitro system. Monsey J, Shen W, Schlesinger P, Bose R. J Biol Chem 285 7035-7044 (2010)
  98. Use of adjuvant trastuzumab in women with human epidermal growth factor receptor 2 (HER2)-positive breast cancer by race/ethnicity and education within the National Comprehensive Cancer Network. Freedman RA, Hughes ME, Ottesen RA, Weeks JC, He Y, Wong YN, Theriault R, Keating NL. Cancer 119 839-846 (2013)
  99. In vitro selection of RNA aptamer and specific targeting of ErbB2 in breast cancer cells. Kim MY, Jeong S. Nucleic Acid Ther 21 173-178 (2011)
  100. Inhibition of ErbB2/neuregulin signaling augments paclitaxel-induced cardiotoxicity in adult ventricular myocytes. Pentassuglia L, Timolati F, Seifriz F, Abudukadier K, Suter TM, Zuppinger C. Exp Cell Res 313 1588-1601 (2007)
  101. Macrophage-Mediated Trogocytosis Leads to Death of Antibody-Opsonized Tumor Cells. Velmurugan R, Challa DK, Ram S, Ober RJ, Ward ES. Mol Cancer Ther 15 1879-1889 (2016)
  102. Phase I clinical study of the recombinant antibody toxin scFv(FRP5)-ETA specific for the ErbB2/HER2 receptor in patients with advanced solid malignomas. von Minckwitz G, Harder S, Hövelmann S, Jäger E, Al-Batran SE, Loibl S, Atmaca A, Cimpoiasu C, Neumann A, Abera A, Knuth A, Kaufmann M, Jäger D, Maurer AB, Wels WS. Breast Cancer Res 7 R617-26 (2005)
  103. Safety profile of Pertuzumab with Trastuzumab and Docetaxel in patients from Asia with human epidermal growth factor receptor 2-positive metastatic breast cancer: results from the phase III trial CLEOPATRA. Swain SM, Im YH, Im SA, Chan V, Miles D, Knott A, Clark E, Ross G, Baselga J. Oncologist 19 693-701 (2014)
  104. The extracellular domain of fibroblast growth factor receptor 3 inhibits ligand-independent dimerization. Chen L, Placone J, Novicky L, Hristova K. Sci Signal 3 ra86 (2010)
  105. Comment A new therapeutic antibody masks ErbB2 to its partners. Badache A, Hynes NE. Cancer Cell 5 299-301 (2004)
  106. Differential ErbB1 signaling in squamous cell versus basal cell carcinoma of the skin. Rittié L, Kansra S, Stoll SW, Li Y, Gudjonsson JE, Shao Y, Michael LE, Fisher GJ, Johnson TM, Elder JT. Am J Pathol 170 2089-2099 (2007)
  107. Microenvironment-Mediated Mechanisms of Resistance to HER2 Inhibitors Differ between HER2+ Breast Cancer Subtypes. Watson SS, Dane M, Chin K, Tatarova Z, Liu M, Liby T, Thompson W, Smith R, Nederlof M, Bucher E, Kilburn D, Whitman M, Sudar D, Mills GB, Heiser LM, Jonas O, Gray JW, Korkola JE. Cell Syst 6 329-342.e6 (2018)
  108. Structural model of the mAb 806-EGFR complex using computational docking followed by computational and experimental mutagenesis. Sivasubramanian A, Chao G, Pressler HM, Wittrup KD, Gray JJ. Structure 14 401-414 (2006)
  109. Combined Blockade of Activating ERBB2 Mutations and ER Results in Synthetic Lethality of ER+/HER2 Mutant Breast Cancer. Croessmann S, Formisano L, Kinch LN, Gonzalez-Ericsson PI, Sudhan DR, Nagy RJ, Mathew A, Bernicker EH, Cristofanilli M, He J, Cutler RE, Lalani AS, Miller VA, Lanman RB, Grishin NV, Arteaga CL. Clin Cancer Res 25 277-289 (2019)
  110. ERBB2 phosphorylation and trastuzumab sensitivity of breast cancer cell lines. Ginestier C, Adélaïde J, Gonçalvès A, Repellini L, Sircoulomb F, Letessier A, Finetti P, Geneix J, Charafe-Jauffret E, Bertucci F, Jacquemier J, Viens P, Birnbaum D. Oncogene 26 7163-7169 (2007)
  111. Energetics of ErbB1 transmembrane domain dimerization in lipid bilayers. Chen L, Merzlyakov M, Cohen T, Shai Y, Hristova K. Biophys J 96 4622-4630 (2009)
  112. Discovery and characterization of olokizumab: a humanized antibody targeting interleukin-6 and neutralizing gp130-signaling. Shaw S, Bourne T, Bourne T, Meier C, Carrington B, Gelinas R, Henry A, Popplewell A, Adams R, Baker T, Rapecki S, Marshall D, Moore A, Neale H, Lawson A. MAbs 6 774-782 (2014)
  113. Safety and efficacy of vinorelbine in combination with pertuzumab and trastuzumab for first-line treatment of patients with HER2-positive locally advanced or metastatic breast cancer: VELVET Cohort 1 final results. Perez EA, López-Vega JM, Petit T, Zamagni C, Easton V, Kamber J, Restuccia E, Andersson M. Breast Cancer Res 18 126 (2016)
  114. IQGAP1 protein binds human epidermal growth factor receptor 2 (HER2) and modulates trastuzumab resistance. White CD, Li Z, Dillon DA, Sacks DB. J Biol Chem 286 29734-29747 (2011)
  115. Insights into the evolution of the ErbB receptor family and their ligands from sequence analysis. Stein RA, Staros JV. BMC Evol Biol 6 79 (2006)
  116. Molecular basis for sensitivity and acquired resistance to gefitinib in HER2-overexpressing human gastric cancer cell lines derived from liver metastasis. Yokoyama H, Ikehara Y, Kodera Y, Ikehara S, Yatabe Y, Mochizuki Y, Koike M, Fujiwara M, Nakao A, Tatematsu M, Nakanishi H. Br J Cancer 95 1504-1513 (2006)
  117. Conformational HER-2/neu B-cell epitope peptide vaccine designed to incorporate two native disulfide bonds enhances tumor cell binding and antitumor activities. Dakappagari NK, Lute KD, Rawale S, Steele JT, Allen SD, Phillips G, Reilly RT, Kaumaya PT. J Biol Chem 280 54-63 (2005)
  118. Overexpression of the erbB-2 proto-oncogene in canine osteosarcoma cell lines and tumors. Flint AF, U'Ren L, Legare ME, Withrow SJ, Dernell W, Hanneman WH. Vet Pathol 41 291-296 (2004)
  119. Suppression of breast cancer cell growth by a monoclonal antibody targeting cleavable ErbB4 isoforms. Hollmén M, Määttä JA, Bald L, Sliwkowski MX, Elenius K. Oncogene 28 1309-1319 (2009)
  120. The transmembrane domains of ErbB receptors do not dimerize strongly in micelles. Stanley AM, Fleming KG. J Mol Biol 347 759-772 (2005)
  121. HER2 specific delivery of methotrexate by dendrimer conjugated anti-HER2 mAb. Shukla R, Thomas TP, Desai AM, Kotlyar A, Park SJ, Baker JR. Nanotechnology 19 295102 (2008)
  122. Pathogenic activation of receptor tyrosine kinases in mammalian membranes. He L, Hristova K. J Mol Biol 384 1130-1142 (2008)
  123. Three-dimensional nanometry of vesicle transport in living cells using dual-focus imaging optics. Watanabe TM, Sato T, Gonda K, Higuchi H. Biochem Biophys Res Commun 359 1-7 (2007)
  124. erbB2 is required for G protein-coupled receptor signaling in the heart. Negro A, Brar BK, Gu Y, Peterson KL, Vale W, Lee KF. Proc Natl Acad Sci U S A 103 15889-15893 (2006)
  125. Generation, characterization, and maintenance of trastuzumab-resistant HER2+ breast cancer cell lines. Zazo S, González-Alonso P, Martín-Aparicio E, Chamizo C, Cristóbal I, Arpí O, Rovira A, Albanell J, Eroles P, Lluch A, Madoz-Gúrpide J, Rojo F. Am J Cancer Res 6 2661-2678 (2016)
  126. High-throughput biotinylation of proteins. Kay BK, Thai S, Volgina VV. Methods Mol Biol 498 185-196 (2009)
  127. Induction of caspase-dependent extrinsic apoptosis by apigenin through inhibition of signal transducer and activator of transcription 3 (STAT3) signalling in HER2-overexpressing BT-474 breast cancer cells. Seo HS, Jo JK, Ku JM, Choi HS, Choi YK, Woo JK, Kim HI, Kang SY, Lee KM, Nam KW, Park N, Jang BH, Shin YC, Ko SG. Biosci Rep 35 e00276 (2015)
  128. Population pharmacokinetic and covariate analysis of pertuzumab, a HER2-targeted monoclonal antibody, and evaluation of a fixed, non-weight-based dose in patients with a variety of solid tumors. Garg A, Quartino A, Li J, Jin J, Wada DR, Li H, Cortés J, McNally V, Ross G, Visich J, Lum B. Cancer Chemother Pharmacol 74 819-829 (2014)
  129. A human, compact, fully functional anti-ErbB2 antibody as a novel antitumour agent. De Lorenzo C, Tedesco A, Terrazzano G, Cozzolino R, Laccetti P, Piccoli R, D'Alessio G. Br J Cancer 91 1200-1204 (2004)
  130. Imaging of HER2/neu expression in BT-474 human breast cancer xenografts in athymic mice using [(99m)Tc]-HYNIC-trastuzumab (Herceptin) Fab fragments. Tang Y, Scollard D, Chen P, Wang J, Holloway C, Reilly RM. Nucl Med Commun 26 427-432 (2005)
  131. Phase I Immunotherapy Trial with Two Chimeric HER-2 B-Cell Peptide Vaccines Emulsified in Montanide ISA 720VG and Nor-MDP Adjuvant in Patients with Advanced Solid Tumors. Bekaii-Saab T, Wesolowski R, Ahn DH, Wu C, Mortazavi A, Lustberg M, Ramaswamy B, Fowler J, Wei L, Overholser J, Kaumaya PTP. Clin Cancer Res 25 3495-3507 (2019)
  132. Regulation of focal adhesion turnover by ErbB signalling in invasive breast cancer cells. Xu Y, Benlimame N, Su J, He Q, Alaoui-Jamali MA. Br J Cancer 100 633-643 (2009)
  133. Trastuzumab in the management of early and advanced stage breast cancer. Bartsch R, Wenzel C, Steger GG. Biologics 1 19-31 (2007)
  134. Unliganded EphA3 dimerization promoted by the SAM domain. Singh DR, Cao Q, King C, Salotto M, Ahmed F, Zhou XY, Pasquale EB, Hristova K. Biochem J 471 101-109 (2015)
  135. Unraveling trastuzumab and lapatinib inefficiency in gastric cancer: Future steps (Review). Shimoyama S. Mol Clin Oncol 2 175-181 (2014)
  136. Hyperinsulinemia promotes metastasis to the lung in a mouse model of Her2-mediated breast cancer. Ferguson RD, Gallagher EJ, Cohen D, Tobin-Hess A, Alikhani N, Novosyadlyy R, Haddad N, Yakar S, LeRoith D. Endocr Relat Cancer 20 391-401 (2013)
  137. Patterns of chemotherapy, toxicity, and short-term outcomes for older women receiving adjuvant trastuzumab-based therapy. Freedman RA, Vaz-Luis I, Barry WT, Lii H, Lin NU, Winer EP, Keating NL. Breast Cancer Res Treat 145 491-501 (2014)
  138. Trastuzumab improves tumor perfusion and vascular delivery of cytotoxic therapy in a murine model of HER2+ breast cancer: preliminary results. Sorace AG, Quarles CC, Whisenant JG, Hanker AB, McIntyre JO, Sanchez VM, Yankeelov TE. Breast Cancer Res Treat 155 273-284 (2016)
  139. Using breast cancer cell CXCR4 surface expression to predict liposome binding and cytotoxicity. Guo P, You JO, Yang J, Moses MA, Auguste DT. Biomaterials 33 8104-8110 (2012)
  140. Atomistic insights into regulatory mechanisms of the HER2 tyrosine kinase domain: a molecular dynamics study. Telesco SE, Radhakrishnan R. Biophys J 96 2321-2334 (2009)
  141. Molecular architecture of the ErbB2 extracellular domain homodimer. Hu S, Sun Y, Meng Y, Wang X, Yang W, Fu W, Guo H, Qian W, Hou S, Li B, Rao Z, Lou Z, Guo Y. Oncotarget 6 1695-1706 (2015)
  142. HER2 targeted molecular MR imaging using a de novo designed protein contrast agent. Qiao J, Li S, Wei L, Jiang J, Long R, Mao H, Wei L, Wang L, Yang H, Grossniklaus HE, Liu ZR, Yang JJ. PLoS One 6 e18103 (2011)
  143. Inhibition of protein-protein interaction of HER2-EGFR and HER2-HER3 by a rationally designed peptidomimetic. Banappagari S, Corti M, Pincus S, Satyanarayanajois S. J Biomol Struct Dyn 30 594-606 (2012)
  144. Proteolytic processing of ErbB4 in breast cancer. Hollmén M, Liu P, Kurppa K, Wildiers H, Reinvall I, Vandorpe T, Smeets A, Deraedt K, Vahlberg T, Joensuu H, Leahy DJ, Schöffski P, Elenius K. PLoS One 7 e39413 (2012)
  145. Autocrine motility factor promotes HER2 cleavage and signaling in breast cancer cells. Kho DH, Nangia-Makker P, Balan V, Hogan V, Tait L, Wang Y, Raz A. Cancer Res 73 1411-1419 (2013)
  146. Calpain-1 expression is associated with relapse-free survival in breast cancer patients treated with trastuzumab following adjuvant chemotherapy. Storr SJ, Woolston CM, Barros FF, Green AR, Shehata M, Chan SY, Ellis IO, Martin SG. Int J Cancer 129 1773-1780 (2011)
  147. Combining human and rat sequences in her-2 DNA vaccines blunts immune tolerance and drives antitumor immunity. Jacob JB, Quaglino E, Radkevich-Brown O, Jones RF, Piechocki MP, Reyes JD, Weise A, Amici A, Wei WZ. Cancer Res 70 119-128 (2010)
  148. Computational prediction of the cross-reactive neutralizing epitope corresponding to the [corrected] monclonal [corrected] antibody b12 specific for HIV-1 gp120. Bublil EM, Yeger-Azuz S, Gershoni JM. FASEB J 20 1762-1774 (2006)
  149. Generation and characterization of ErbB2-CAR-engineered cytokine-induced killer cells for the treatment of high-risk soft tissue sarcoma in children. Merker M, Pfirrmann V, Oelsner S, Fulda S, Klingebiel T, Wels WS, Bader P, Rettinger E. Oncotarget 8 66137-66153 (2017)
  150. Mutational activation of ErbB2 reveals a new protein kinase autoinhibition mechanism. Fan YX, Wong L, Ding J, Spiridonov NA, Johnson RC, Johnson GR. J Biol Chem 283 1588-1596 (2008)
  151. Proteomic characterization of Her2/neu-overexpressing breast cancer cells. Chen H, Pimienta G, Gu Y, Sun X, Hu J, Kim MS, Chaerkady R, Gucek M, Cole RN, Sukumar S, Pandey A. Proteomics 10 3800-3810 (2010)
  152. The epitope space of the human proteome. Berglund L, Andrade J, Odeberg J, Uhlén M. Protein Sci 17 606-613 (2008)
  153. A growing family: adding mutated Erbb4 as a novel cancer target. Rudloff U, Samuels Y. Cell Cycle 9 1487-1503 (2010)
  154. An in vitro FcRn- dependent transcytosis assay as a screening tool for predictive assessment of nonspecific clearance of antibody therapeutics in humans. Chung S, Nguyen V, Lin YL, Lafrance-Vanasse J, Scales SJ, Lin K, Deng R, Williams K, Sperinde G, Li JJ, Zheng K, Sukumaran S, Tesar D, Ernst JA, Fischer S, Lazar GA, Prabhu S, Song A. MAbs 11 942-955 (2019)
  155. Exploring Site-Specific N-Glycosylation of HEK293 and Plant-Produced Human IgA Isotypes. Göritzer K, Maresch D, Altmann F, Obinger C, Strasser R. J Proteome Res 16 2560-2570 (2017)
  156. Phase 1b/2a study of trastuzumab emtansine (T-DM1), paclitaxel, and pertuzumab in HER2-positive metastatic breast cancer. Krop IE, Modi S, LoRusso PM, Pegram M, Guardino E, Althaus B, Lu D, Strasak A, Elias A. Breast Cancer Res 18 34 (2016)
  157. Study of inhibition effect of herceptin on interaction between heregulin and erbB receptors HER3/HER2 by single-molecule force spectroscopy. Shi X, Xu L, Yu J, Fang X. Exp Cell Res 315 2847-2855 (2009)
  158. The level of HER2 expression is a predictor of antibody-HER2 trafficking behavior in cancer cells. Ram S, Kim D, Ober RJ, Ward ES. MAbs 6 1211-1219 (2014)
  159. Combination of novel HER2-targeting antibody 1E11 with trastuzumab shows synergistic antitumor activity in HER2-positive gastric cancer. Ko BK, Lee SY, Lee YH, Hwang IS, Persson H, Rockberg J, Borrebaeck C, Park D, Kim KT, Uhlen M, Lee JS. Mol Oncol 9 398-408 (2015)
  160. Epitope mapping and structural analysis of an anti-ErbB2 antibody A21: Molecular basis for tumor inhibitory mechanism. Hu S, Zhu Z, Li L, Chang L, Li W, Cheng L, Teng M, Liu J. Proteins 70 938-949 (2008)
  161. Intermolecular biparatopic trapping of ErbB2 prevents compensatory activation of PI3K/AKT via RAS-p110 crosstalk. Tamaskovic R, Schwill M, Nagy-Davidescu G, Jost C, Schaefer DC, Verdurmen WP, Schaefer JV, Honegger A, Plückthun A. Nat Commun 7 11672 (2016)
  162. Matching of trastuzumab (Herceptin) epitope mimics onto the surface of Her-2/neu--a new method of epitope definition. Riemer AB, Kraml G, Scheiner O, Zielinski CC, Jensen-Jarolim E. Mol Immunol 42 1121-1124 (2005)
  163. Presence of HER4 associates with increased sensitivity to Herceptin in patients with metastatic breast cancer. Sassen A, Diermeier-Daucher S, Sieben M, Ortmann O, Hofstaedter F, Schwarz S, Brockhoff G. Breast Cancer Res 11 R50 (2009)
  164. Comment Targeting HER2 in prostate cancer: where to next? Solit DB, Rosen N. J Clin Oncol 25 241-243 (2007)
  165. Bioorthogonal, two-component delivery systems based on antibody and drug-loaded nanocarriers for enhanced internalization of nanotherapeutics. Hapuarachchige S, Zhu W, Kato Y, Artemov D. Biomaterials 35 2346-2354 (2014)
  166. Dimeric HER2-specific affibody molecules inhibit proliferation of the SKBR-3 breast cancer cell line. Ekerljung L, Lindborg M, Gedda L, Frejd FY, Carlsson J, Lennartsson J. Biochem Biophys Res Commun 377 489-494 (2008)
  167. Immune effects of trastuzumab. Nuti M, Bellati F, Visconti V, Napoletano C, Domenici L, Caccetta J, Zizzari IG, Ruscito I, Rahimi H, Benedetti-Panici P, Rughetti A. J Cancer 2 317-323 (2011)
  168. Quantitation of the effect of ErbB2 on epidermal growth factor receptor binding and dimerization. Li Y, Macdonald-Obermann J, Westfall C, Piwnica-Worms D, Pike LJ. J Biol Chem 287 31116-31125 (2012)
  169. Trastuzumab: a novel standard option for patients with HER-2-positive advanced gastric or gastro-oesophageal junction cancer. Okines AF, Cunningham D. Therap Adv Gastroenterol 5 301-318 (2012)
  170. EGF receptor inhibition: attacks on multiple fronts. Hubbard SR. Cancer Cell 7 287-288 (2005)
  171. Effect of deleterious nsSNP on the HER2 receptor based on stability and binding affinity with herceptin: a computational approach. Rajasekaran R, George Priya Doss C, Sudandiradoss C, Ramanathan K, Purohit R, Sethumadhavan R. C R Biol 331 409-417 (2008)
  172. Engineering multivalent antibodies to target heregulin-induced HER3 signaling in breast cancer cells. Kang JC, Poovassery JS, Bansal P, You S, Manjarres IM, Ober RJ, Ward ES. MAbs 6 340-353 (2014)
  173. Enhancement of cell type specificity by quantitative modulation of a chimeric ligand. Cironi P, Swinburne IA, Silver PA. J Biol Chem 283 8469-8476 (2008)
  174. Structure-based Design of Peptides with High Affinity and Specificity to HER2 Positive Tumors. Geng L, Wang Z, Yang X, Li D, Lian W, Xiang Z, Wang W, Bu X, Lai W, Hu Z, Fang Q. Theranostics 5 1154-1165 (2015)
  175. The effects of trastuzumab on HER2-mediated cell signaling in CHO cells expressing human HER2. Maadi H, Nami B, Tong J, Li G, Wang Z. BMC Cancer 18 238 (2018)
  176. A llama single domain anti-idiotypic antibody mimicking HER2 as a vaccine: Immunogenicity and efficacy. Alvarez-Rueda N, Ladjemi MZ, Béhar G, Corgnac S, Pugnière M, Roquet F, Bascoul-Mollevi C, Baty D, Pèlegrin A, Navarro-Teulon I. Vaccine 27 4826-4833 (2009)
  177. Atomic force microscopy study of the effect of HER 2 antibody on EGF mediated ErbB ligand-receptor interaction. Zhang X, Shi X, Xu L, Yuan J, Fang X. Nanomedicine 9 627-635 (2013)
  178. Dynamic analysis of the epidermal growth factor (EGF) receptor-ErbB2-ErbB3 protein network by luciferase fragment complementation imaging. Macdonald-Obermann JL, Adak S, Landgraf R, Piwnica-Worms D, Pike LJ. J Biol Chem 288 30773-30784 (2013)
  179. Engineering of bispecific affinity proteins with high affinity for ERBB2 and adaptable binding to albumin. Nilvebrant J, Åstrand M, Georgieva-Kotseva M, Björnmalm M, Löfblom J, Hober S. PLoS One 9 e103094 (2014)
  180. In vivo examination of (188)Re(I)-tricarbonyl-labeled trastuzumab to target HER2-overexpressing breast cancer. Chen KT, Lee TW, Lo JM. Nucl Med Biol 36 355-361 (2009)
  181. Neoadjuvant breast cancer treatment as a sensitive setting for trastuzumab biosimilar development and extrapolation. Jackisch C, Scappaticci FA, Heinzmann D, Bisordi F, Schreitmüller T, Minckwitz Gv, Cortés J. Future Oncol 11 61-71 (2015)
  182. Production and characterization of monoclonal antibodies sensitive to conformation in the 5HT2c serotonin receptor. Mancia F, Brenner-Morton S, Siegel R, Assur Z, Sun Y, Schieren I, Mendelsohn M, Axel R, Hendrickson WA. Proc Natl Acad Sci U S A 104 4303-4308 (2007)
  183. Two dimensions in targeting HER2. Moasser MM. J Clin Oncol 32 2074-2077 (2014)
  184. Affinity maturation of an ERBB2-targeted SPECT imaging peptide by in vivo phage display. Larimer BM, Thomas WD, Smith GP, Deutscher SL. Mol Imaging Biol 16 449-458 (2014)
  185. Computational modelling of ErbB family phosphorylation dynamics in response to transforming growth factor alpha and heregulin indicates spatial compartmentation of phosphatase activity. Hendriks BS, Cook J, Burke JM, Beusmans JM, Lauffenburger DA, de Graaf D. Syst Biol (Stevenage) 153 22-33 (2006)
  186. Extended and flexible domain solution structure of the extracellular matrix protein anosmin-1 by X-ray scattering, analytical ultracentrifugation and constrained modelling. Hu Y, Sun Z, Eaton JT, Bouloux PM, Perkins SJ. J Mol Biol 350 553-570 (2005)
  187. Nanobody-targeted photodynamic therapy induces significant tumor regression of trastuzumab-resistant HER2-positive breast cancer, after a single treatment session. Deken MM, Kijanka MM, Beltrán Hernández I, Slooter MD, de Bruijn HS, van Diest PJ, van Bergen En Henegouwen PMP, Lowik CWGM, Robinson DJ, Vahrmeijer AL, Oliveira S. J Control Release 323 269-281 (2020)
  188. News Ready to partner. Sliwkowski MX. Nat Struct Biol 10 158-159 (2003)
  189. Testing for HER2 in Breast Cancer: A Continuing Evolution. Shah S, Chen B. Patholog Res Int 2011 903202 (2010)
  190. A modified Trastuzumab antibody for the immunohistochemical detection of HER-2 overexpression in breast cancer. Bussolati G, Montemurro F, Righi L, Donadio M, Aglietta M, Sapino A. Br J Cancer 92 1261-1267 (2005)
  191. A molecular view of anti-ErbB monoclonal antibody therapy. Leahy DJ. Cancer Cell 13 291-293 (2008)
  192. A quantitative systems approach to identify paracrine mechanisms that locally suppress immune response to Interleukin-12 in the B16 melanoma model. Kulkarni YM, Chambers E, McGray AJ, Ware JS, Bramson JL, Klinke DJ. Integr Biol (Camb) 4 925-936 (2012)
  193. Correlation of HER2, p95HER2 and HER3 expression and treatment outcome of lapatinib plus capecitabine in her2-positive metastatic breast cancer. Han SW, Cha Y, Paquet A, Huang W, Weidler J, Lie Y, Sherwood T, Bates M, Haddad M, Park IH, Oh DY, Lee KS, Im SA, Bang YJ, Ro J, Kim TY. PLoS One 7 e39943 (2012)
  194. Dual-Color Bioluminescent Sensor Proteins for Therapeutic Drug Monitoring of Antitumor Antibodies. van Rosmalen M, Ni Y, Vervoort DFM, Arts R, Ludwig SKJ, Merkx M. Anal Chem 90 3592-3599 (2018)
  195. ERBB2 in cat mammary neoplasias disclosed a positive correlation between RNA and protein low expression levels: a model for erbB-2 negative human breast cancer. Santos S, Baptista CS, Abreu RM, Bastos E, Amorim I, Gut IG, Gärtner F, Chaves R. PLoS One 8 e83673 (2013)
  196. Expression of ribosome-binding protein 1 correlates with shorter survival in Her-2 positive breast cancer. Liang X, Sun S, Zhang X, Wu H, Tao W, Liu T, Wei W, Geng J, Pang D. Cancer Sci 106 740-746 (2015)
  197. Identification of prolidase as a high affinity ligand of the ErbB2 receptor and its regulation of ErbB2 signaling and cell growth. Yang L, Li Y, Zhang Y. Cell Death Dis 5 e1211 (2014)
  198. Insights into HER2 signaling from step-by-step optimization of anti-HER2 antibodies. Fu W, Wang Y, Zhang Y, Xiong L, Takeda H, Ding L, Xu Q, He L, Tan W, Bethune AN, Zhou L. MAbs 6 978-990 (2014)
  199. Maximizing human epidermal growth factor receptor 2 inhibition: a new oncologic paradigm in the era of targeted therapy. Olson EM. J Clin Oncol 30 1712-1714 (2012)
  200. Novel anti-HER2 monoclonal antibodies: synergy and antagonism with tumor necrosis factor-α. Ceran C, Cokol M, Cingoz S, Tasan I, Ozturk M, Yagci T. BMC Cancer 12 450 (2012)
  201. SOX2 oncogenes amplified and operate to activate AKT signaling in gastric cancer and predict immunotherapy responsiveness. Tian Y, Jia X, Wang S, Li Y, Zhao P, Cai D, Zhou Z, Wang J, Luo Y, Dong M. J Cancer Res Clin Oncol 140 1117-1124 (2014)
  202. An improved radiolabelled RNA aptamer molecule for HER2 imaging in cancers. Varmira K, Hosseinimehr SJ, Noaparast Z, Abedi SM. J Drug Target 22 116-122 (2014)
  203. Binding affinity prediction of nanobody-protein complexes by scoring of molecular dynamics trajectories. Soler MA, Fortuna S, de Marco A, Laio A. Phys Chem Chem Phys 20 3438-3444 (2018)
  204. Evaluation of the anti-HER2 C6.5 diabody as a PET radiotracer to monitor HER2 status and predict response to trastuzumab treatment. Reddy S, Shaller CC, Doss M, Shchaveleva I, Marks JD, Yu JQ, Robinson MK. Clin Cancer Res 17 1509-1520 (2011)
  205. Heparan sulfate mediates trastuzumab effect in breast cancer cells. Suarez ER, Paredes-Gamero EJ, Del Giglio A, Tersariol IL, Nader HB, Pinhal MA. BMC Cancer 13 444 (2013)
  206. Kinase activator-receiver preference in ErbB heterodimers is determined by intracellular regions and is not coupled to extracellular asymmetry. Ward MD, Leahy DJ. J Biol Chem 290 1570-1579 (2015)
  207. Protective immunity against neu-positive carcinomas elicited by electroporation of plasmids encoding decreasing fragments of rat neu extracellular domain. Rolla S, Marchini C, Malinarich S, Quaglino E, Lanzardo S, Montani M, Iezzi M, Angeletti M, Ramadori G, Forni G, Cavallo F, Amici A. Hum Gene Ther 19 229-240 (2008)
  208. Structure-activity relationship of conformationally constrained peptidomimetics for antiproliferative activity in HER2-overexpressing breast cancer cell lines. Banappagari S, Ronald S, Satyanarayanajois SD. Medchemcomm 2 752-759 (2011)
  209. Targeted antireceptor therapy with monoclonal antibodies leads to the formation of inactivated tetrameric forms of ErbB receptors. Furuuchi K, Berezov A, Kumagai T, Greene MI. J Immunol 178 1021-1029 (2007)
  210. Targeting of antigens to B lymphocytes via CD19 as a means for tumor vaccine development. Ma Y, Xiang D, Sun J, Ding C, Liu M, Hu X, Li G, Kloecker G, Zhang HG, Yan J. J Immunol 190 5588-5599 (2013)
  211. Tissue microarray-based study of patients with lymph node-negative breast cancer shows that HER2/neu overexpression is an important predictive marker of poor prognosis. Choi YH, Ahn JH, Kim SB, Jung KH, Gong GY, Kim MJ, Son BH, Ahn SH, Kim WK. Ann Oncol 20 1337-1343 (2009)
  212. Letter Trastuzumab--mechanism of action and use. Mir O, Berveiller P, Pons G. N Engl J Med 357 1664-5; author reply 1665-6 (2007)
  213. Trastuzumab: a new treatment option for HER2-positive metastatic gastric and gastroesophageal junction cancer. Lordick F. Future Oncol 7 187-199 (2011)
  214. A computational analysis of in vivo VEGFR activation by multiple co-expressed ligands. Clegg LE, Mac Gabhann F. PLoS Comput Biol 13 e1005445 (2017)
  215. CD4(+) T-Helper Type 1 Cytokines and Trastuzumab Facilitate CD8(+) T-cell Targeting of HER2/neu-Expressing Cancers. Datta J, Xu S, Rosemblit C, Smith JB, Cintolo JA, Powell DJ, Czerniecki BJ. Cancer Immunol Res 3 455-463 (2015)
  216. Computational analysis of molecular basis of 1:1 interactions of NRG-1beta wild-type and variants with ErbB3 and ErbB4. Luo C, Xu L, Zheng S, Luo X, Shen J, Jiang H, Liu X, Zhou M. Proteins 59 742-756 (2005)
  217. Discovery of epitopes for targeting the human epidermal growth factor receptor 2 (HER2) with antibodies. Rockberg J, Schwenk JM, Uhlén M. Mol Oncol 3 238-247 (2009)
  218. FGFR3 transmembrane domain interactions persist in the presence of its extracellular domain. Sarabipour S, Hristova K. Biophys J 105 165-171 (2013)
  219. High-throughput selection of transmembrane sequences that enhance receptor tyrosine kinase activation. He L, Hoffmann AR, Serrano C, Hristova K, Wimley WC. J Mol Biol 412 43-54 (2011)
  220. Immunogenicity and antitumor efficacy of a novel human PD-1 B-cell vaccine (PD1-Vaxx) and combination immunotherapy with dual trastuzumab/pertuzumab-like HER-2 B-cell epitope vaccines (B-Vaxx) in a syngeneic mouse model. Kaumaya PTP, Guo L, Overholser J, Penichet ML, Bekaii-Saab T. Oncoimmunology 9 1818437 (2020)
  221. Optimizing fresh specimen staining for rapid identification of tumor biomarkers during surgery. Barth CW, Schaefer JM, Rossi VM, Davis SC, Gibbs SL. Theranostics 7 4722-4734 (2017)
  222. Role of extracellular subdomains of p185c-neu and the epidermal growth factor receptor in ligand-independent association and transactivation. Kumagai T, Katsumata M, Hasegawa A, Furuuchi K, Funakoshi T, Kawase I, Greene MI. Proc Natl Acad Sci U S A 100 9220-9225 (2003)
  223. Structural basis of a novel heterodimeric Fc for bispecific antibody production. Wei H, Cai H, Jin Y, Wang P, Zhang Q, Lin Y, Wang W, Cheng J, Zeng N, Xu T, Zhou A. Oncotarget 8 51037-51049 (2017)
  224. Structural basis of immunosuppression by the therapeutic antibody daclizumab. Yang H, Wang J, Du J, Zhong C, Zhang D, Guo H, Guo Y, Ding J. Cell Res 20 1361-1371 (2010)
  225. Structure-activity relationships of peptidomimetics that inhibit PPI of HER2-HER3. Kanthala S, Gauthier T, Satyanarayanajois S. Biopolymers 101 693-702 (2014)
  226. Targeting human epidermal growth factor receptor signaling with the neuregulin's heparin-binding domain. Ma Z, Li Q, An H, Pankonin MS, Wang J, Loeb JA. J Biol Chem 284 32108-32115 (2009)
  227. The tethering arm of the EGF receptor is required for negative cooperativity and signal transduction. Adak S, DeAndrade D, Pike LJ. J Biol Chem 286 1545-1555 (2011)
  228. A recombinant human protein targeting HER2 overcomes drug resistance in HER2-positive breast cancer. Yang L, Li Y, Bhattacharya A, Zhang Y. Sci Transl Med 11 eaav1620 (2019)
  229. Combinatorial immunotherapy of sorafenib and blockade of programmed death-ligand 1 induces effective natural killer cell responses against hepatocellular carcinoma. Wang Y, Li H, Liang Q, Liu B, Mei X, Ma Y. Tumour Biol 36 1561-1566 (2015)
  230. Directed evolution of anti-HER2 DARPins by SNAP display reveals stability/function trade-offs in the selection process. Houlihan G, Gatti-Lafranconi P, Lowe D, Hollfelder F. Protein Eng Des Sel 28 269-279 (2015)
  231. Flow cytometric FRET analysis of erbB receptor interaction on a cell-by-cell basis. Diermeier-Daucher S, Hasmann M, Brockhoff G. Ann N Y Acad Sci 1130 280-286 (2008)
  232. Gene and protein expression profiling during differentiation of neuroblastoma cells triggered by 13-cis retinoic acid. Yuza Y, Agawa M, Matsuzaki M, Yamada H, Urashima M. J Pediatr Hematol Oncol 25 715-720 (2003)
  233. HER2 monoclonal antibodies that do not interfere with receptor heterodimerization-mediated signaling induce effective internalization and represent valuable components for rational antibody-drug conjugate design. de Goeij BE, Peipp M, de Haij S, van den Brink EN, Kellner C, Riedl T, de Jong R, Vink T, Strumane K, Bleeker WK, Parren PW. MAbs 6 392-402 (2014)
  234. In situ quantitative measurement of HER2mRNA predicts benefit from trastuzumab-containing chemotherapy in a cohort of metastatic breast cancer patients. Vassilakopoulou M, Togun T, Dafni U, Cheng H, Bordeaux J, Neumeister VM, Bobos M, Pentheroudakis G, Skarlos DV, Pectasides D, Kotoula V, Fountzilas G, Rimm DL, Psyrri A. PLoS One 9 e99131 (2014)
  235. Novel agents that downregulate EGFR, HER2, and HER3 in parallel. Ferreira RB, Law ME, Jahn SC, Davis BJ, Heldermon CD, Reinhard M, Castellano RK, Law BK. Oncotarget 6 10445-10459 (2015)
  236. Population PBPK modelling of trastuzumab: a framework for quantifying and predicting inter-individual variability. Malik PRV, Hamadeh A, Phipps C, Edginton AN. J Pharmacokinet Pharmacodyn 44 277-290 (2017)
  237. Site Selection: a Case Study in the Identification of Optimal Cysteine Engineered Antibody Drug Conjugates. Tumey LN, Li F, Rago B, Han X, Loganzo F, Musto S, Graziani EI, Puthenveetil S, Casavant J, Marquette K, Clark T, Bikker J, Bennett EM, Barletta F, Piche-Nicholas N, Tam A, O'Donnell CJ, Gerber HP, Tchistiakova L. AAPS J 19 1123-1135 (2017)
  238. Spontaneous and pronase-induced HER2 truncation increases the trastuzumab binding capacity of breast cancer tissues and cell lines. Recupero D, Daniele L, Marchiò C, Molinaro L, Castellano I, Cassoni P, Righi A, Montemurro F, Sismondi P, Biglia N, Viale G, Risio M, Sapino A. J Pathol 229 390-399 (2013)
  239. Temporal Modulation of HER2 Membrane Availability Increases Pertuzumab Uptake and Pretargeted Molecular Imaging of Gastric Tumors. Pereira PMR, Mandleywala K, Ragupathi A, Carter LM, Goos JACM, Janjigian YY, Lewis JS. J Nucl Med 60 1569-1578 (2019)
  240. The addition of recombinant vaccinia HER2/neu to oncolytic vaccinia-GMCSF given into the tumor microenvironment overcomes MDSC-mediated immune escape and systemic anergy. de Vries CR, Monken CE, Lattime EC. Cancer Gene Ther 22 154-162 (2015)
  241. A HER2-specific Modified Fc Fragment (Fcab) Induces Antitumor Effects Through Degradation of HER2 and Apoptosis. Leung KM, Batey S, Rowlands R, Isaac SJ, Jones P, Drewett V, Carvalho J, Gaspar M, Weller S, Medcalf M, Wydro MM, Pegram R, Mudde GC, Bauer A, Moulder K, Woisetschläger M, Tuna M, Haurum JS, Sun H. Mol Ther 23 1722-1733 (2015)
  242. A SPR strategy for high-throughput ligand screenings based on synthetic peptides mimicking a selected subdomain of the target protein: a proof of concept on HER2 receptor. Monfregola L, Vitale RM, Amodeo P, De Luca S. Bioorg Med Chem 17 7015-7020 (2009)
  243. A phase I/II trial of trastuzumab plus erlotinib in metastatic HER2-positive breast cancer: a dual ErbB targeted approach. Britten CD, Finn RS, Bosserman LD, Wong SG, Press MF, Malik M, Lum BL, Slamon DJ. Clin Breast Cancer 9 16-22 (2009)
  244. Exploring epitopes of antibodies toward the human tryptophanyl-tRNA synthetase. Hjelm B, Fernández CD, Löfblom J, Ståhl S, Johannesson H, Rockberg J, Uhlén M. N Biotechnol 27 129-137 (2010)
  245. Fcab-HER2 Interaction: a Ménage à Trois. Lessons from X-Ray and Solution Studies. Lobner E, Humm AS, Göritzer K, Mlynek G, Puchinger MG, Hasenhindl C, Rüker F, Traxlmayr MW, Djinović-Carugo K, Obinger C. Structure 25 878-889.e5 (2017)
  246. Immunohistochemical expression of HER1, HER3, and HER4 in HER2-positive breast cancer patients treated with trastuzumab-containing neoadjuvant chemotherapy. Yonemori K, Tsuta K, Shimizu C, Hatanaka Y, Hirakawa A, Ono M, Kouno T, Katsumata N, Ando M, Tamura K, Hasegawa T, Kinoshita T, Fujiwara Y. J Surg Oncol 101 222-227 (2010)
  247. In vivo identification of the interaction site of ErbB2 extracellular domain with its autoinhibitor. Hu P, Feng J, Zhou T, Wang J, Jing B, Yu M, Hu M, Zhang X, Shen B, Guo N. J Cell Physiol 205 335-343 (2005)
  248. Inhibition of Cell Growth and Induction of Apoptosis by Antrodia camphorata in HER-2/neu-Overexpressing Breast Cancer Cells through the Induction of ROS, Depletion of HER-2/neu, and Disruption of the PI3K/Akt Signaling Pathway. Lee CC, Yang HL, Way TD, Kumar KJ, Juan YC, Cho HJ, Lin KY, Hsu LS, Chen SC, Hseu YC. Evid Based Complement Alternat Med 2012 702857 (2012)
  249. Label-Free Detection of Cancer Biomarkers Using an In-Line Taper Fiber-Optic Interferometer and a Fiber Bragg Grating. Sun D, Ran Y, Wang G. Sensors (Basel) 17 E2559 (2017)
  250. Longitudinal autoantibody responses against tumor-associated antigens decrease in breast cancer patients according to treatment modality. Evans RL, Pottala JV, Nagata S, Egland KA. BMC Cancer 18 119 (2018)
  251. Masked selection: a straightforward and flexible approach for the selection of binders against specific epitopes and differentially expressed proteins by phage display. Even-Desrumeaux K, Nevoltris D, Lavaut MN, Alim K, Borg JP, Audebert S, Kerfelec B, Baty D, Chames P. Mol Cell Proteomics 13 653-665 (2014)
  252. Plant-made trastuzumab (herceptin) inhibits HER2/Neu+ cell proliferation and retards tumor growth. Komarova TV, Kosorukov VS, Frolova OY, Petrunia IV, Skrypnik KA, Gleba YY, Dorokhov YL. PLoS One 6 e17541 (2011)
  253. Real-time quantitative polymerase chain reaction (qPCR) analysis with fluorescence resonance energy transfer (FRET) probes reveals differential expression of the four ERBB4 juxtamembrane region variants between medulloblastoma and pilocytic astrocytoma. Zeng N, Liu L, McCabe MG, Jones DTW, Ichimura K, Collins VP. Neuropathol Appl Neurobiol 35 353-366 (2009)
  254. Targeting HER2 Positive Breast Cancer with Chemopreventive Agents. Wahler J, Suh N. Curr Pharmacol Rep 1 324-335 (2015)
  255. Whole exome sequencing to identify genetic markers for trastuzumab-induced cardiotoxicity. Udagawa C, Nakamura H, Ohnishi H, Tamura K, Shimoi T, Yoshida M, Yoshida T, Totoki Y, Shibata T, Zembutsu H. Cancer Sci 109 446-452 (2018)
  256. A general approach for receptor and antibody-targeted detection of native proteins utilizing split-luciferase reassembly. Stains CI, Furman JL, Porter JR, Rajagopal S, Li Y, Wyatt RT, Ghosh I. ACS Chem Biol 5 943-952 (2010)
  257. Activation of the unfolded protein response bypasses trastuzumab-mediated inhibition of the PI-3K pathway. Kumandan S, Mahadevan NR, Chiu K, DeLaney A, Zanetti M. Cancer Lett 329 236-242 (2013)
  258. Assembly of bio-nanoparticles for double controlled drug release. Huang W, Zhang J, Dorn HC, Zhang C. PLoS One 8 e74679 (2013)
  259. Effects of radiation on the epidermal growth factor receptor pathway in the heart. Sridharan V, Sharma SK, Moros EG, Corry PM, Tripathi P, Lieblong BJ, Guha C, Hauer-Jensen M, Boerma M. Int J Radiat Biol 89 539-547 (2013)
  260. Expanding the Scope of Protein-Detecting Electrochemical DNA "Scaffold" Sensors. Kang D, Parolo C, Sun S, Ogden NE, Dahlquist FW, Plaxco KW. ACS Sens 3 1271-1275 (2018)
  261. Experimentally-driven mathematical modeling to improve combination targeted and cytotoxic therapy for HER2+ breast cancer. Jarrett AM, Shah A, Bloom MJ, McKenna MT, Hormuth DA, Yankeelov TE, Sorace AG. Sci Rep 9 12830 (2019)
  262. Multiplex epitope mapping using bacterial surface display reveals both linear and conformational epitopes. Hudson EP, Uhlen M, Rockberg J. Sci Rep 2 706 (2012)
  263. Novel Peptidomimetics for Inhibition of HER2:HER3 Heterodimerization in HER2-Positive Breast Cancer. Kanthala S, Banappagari S, Gokhale A, Liu YY, Xin G, Zhao Y, Jois S. Chem Biol Drug Des 85 702-714 (2015)
  264. Protein design of IgG/TCR chimeras for the co-expression of Fab-like moieties within bispecific antibodies. Wu X, Sereno AJ, Huang F, Zhang K, Batt M, Fitchett JR, He D, Rick HL, Conner EM, Demarest SJ. MAbs 7 364-376 (2015)
  265. Pyrotinib treatment on HER2-positive gastric cancer cells promotes the released exosomes to enhance endothelial cell progression, which can be counteracted by apatinib. Gao Z, Song C, Li G, Lin H, Lian X, Zhang N, Cao B. Onco Targets Ther 12 2777-2787 (2019)
  266. Subcutaneous trastuzumab: development of a new formulation for treatment of HER2-positive early breast cancer. Hamizi S, Freyer G, Bakrin N, Henin E, Mohtaram A, Le Saux O, Falandry C. Onco Targets Ther 6 89-94 (2013)
  267. Successful targeting of ErbB2 receptors-is PTEN the key? Crowder RJ, Lombardi DP, Ellis MJ. Cancer Cell 6 103-104 (2004)
  268. Synthesis of site-specific antibody-drug conjugates by ADP-ribosyl cyclases. Dai Z, Zhang XN, Nasertorabi F, Cheng Q, Li J, Katz BB, Smbatyan G, Pei H, Louie SG, Lenz HJ, Stevens RC, Zhang Y. Sci Adv 6 eaba6752 (2020)
  269. Tailoring DNA Vaccines: Designing Strategies Against HER2-Positive Cancers. Marchini C, Kalogris C, Garulli C, Pietrella L, Gabrielli F, Curcio C, Quaglino E, Cavallo F, Amici A. Front Oncol 3 122 (2013)
  270. Trastuzumab-binding peptide display by Tobacco mosaic virus. Frolova OY, Petrunia IV, Komarova TV, Kosorukov VS, Sheval EV, Gleba YY, Dorokhov YL. Virology 407 7-13 (2010)
  271. Trifunctional antibody ertumaxomab: Non-immunological effects on Her2 receptor activity and downstream signaling. Diermeier-Daucher S, Ortmann O, Buchholz S, Brockhoff G. MAbs 4 614-622 (2012)
  272. Vaccination with human anti-trastuzumab anti-idiotype scFv reverses HER2 immunological tolerance and induces tumor immunity in MMTV.f.huHER2(Fo5) mice. Ladjemi MZ, Chardes T, Corgnac S, Garambois V, Morisseau S, Robert B, Bascoul-Mollevi C, Ait Arsa I, Jacot W, Pouget JP, Pelegrin A, Navarro-Teulon I. Breast Cancer Res 13 R17 (2011)
  273. scFv-based "Grababody" as a general strategy to improve recruitment of immune effector cells to antibody-targeted tumors. Cai Z, Fu T, Nagai Y, Lam L, Yee M, Zhu Z, Zhang H. Cancer Res 73 2619-2627 (2013)
  274. A plant-expressed conjugate vaccine breaks CD4(+) tolerance and induces potent immunity against metastatic Her2(+) breast cancer. Chotprakaikiat W, Allen A, Bui-Minh D, Harden E, Jobsri J, Cavallo F, Gleba Y, Stevenson FK, Ottensmeier C, Klimyuk V, Savelyeva N. Oncoimmunology 5 e1166323 (2016)
  275. Direct 99m Tc labeling of Herceptin (trastuzumab) by 99m Tc(I) tricarbonyl ion. Chen WJ, Yen CL, Lo ST, Chen KT, Lo JM. Appl Radiat Isot 66 340-345 (2008)
  276. Growth inhibition of breast cancer cell lines overexpressing Her2/neu by a novel internalized fully human Fab antibody fragment. Belimezi MM, Papanastassiou D, Merkouri E, Baxevanis CN, Mamalaki A. Cancer Immunol Immunother 55 1091-1099 (2006)
  277. Labelling Herceptin with a novel oxaliplatin derivative: a computational approach towards the selective drug delivery. Cerón-Carrasco JP, Cerezo J, Requena A, Zuñiga J, Contreras-García J, Chavan S, Manrubia-Cobo M, Pérez-Sánchez H. J Mol Model 20 2401 (2014)
  278. Lapatinib sensitivities of two novel trastuzumab-resistant HER2 gene-amplified gastric cancer cell lines. Oshima Y, Tanaka H, Murakami H, Ito Y, Furuya T, Kondo E, Kodera Y, Nakanishi H. Gastric Cancer 17 450-462 (2014)
  279. Mathematical modelling of trastuzumab-induced immune response in an in vivo murine model of HER2+ breast cancer. Jarrett AM, Bloom MJ, Godfrey W, Syed AK, Ekrut DA, Ehrlich LI, Yankeelov TE, Sorace AG. Math Med Biol 36 381-410 (2019)
  280. Nectin-4 cis-interacts with ErbB2 and its trastuzumab-resistant splice variants, enhancing their activation and DNA synthesis. Kedashiro S, Sugiura A, Mizutani K, Takai Y. Sci Rep 9 18997 (2019)
  281. New small 99mTc-labeled peptides for HER2 receptor imaging. Sabahnoo H, Noaparast Z, Abedi SM, Hosseinimehr SJ. Eur J Med Chem 127 1012-1024 (2017)
  282. Orchestration of ErbB3 signaling through heterointeractions and homointeractions. McCabe Pryor M, Steinkamp MP, Halasz AM, Chen Y, Yang S, Smith MS, Zahoransky-Kohalmi G, Swift M, Xu XP, Hanein D, Volkmann N, Lidke DS, Edwards JS, Wilson BS. Mol Biol Cell 26 4109-4123 (2015)
  283. Pertuzumab Increases 17-AAG-Induced Degradation of ErbB2, and This Effect Is Further Increased by Combining Pertuzumab with Trastuzumab. Hughes JB, Rødland MS, Hasmann M, Madshus IH, Stang E. Pharmaceuticals (Basel) 5 674-689 (2012)
  284. Pharmacokinetic and exposure-response analyses of pertuzumab in combination with trastuzumab and docetaxel during neoadjuvant treatment of HER2+ early breast cancer. Quartino AL, Li H, Jin JY, Wada DR, Benyunes MC, McNally V, Viganò L, Nijem I, Lum BL, Garg A. Cancer Chemother Pharmacol 79 353-361 (2017)
  285. Rational design of a humanized glucagon-like peptide-1 receptor agonist antibody. Zhang Y, Zou H, Wang Y, Caballero D, Gonzalez J, Chao E, Welzel G, Shen W, Wang D, Schultz PG, Wang F. Angew Chem Int Ed Engl 54 2126-2130 (2015)
  286. Suppression of heregulin β signaling by the single N-glycan deletion mutant of soluble ErbB3 protein. Takahashi M, Hasegawa Y, Ikeda Y, Wada Y, Tajiri M, Ariki S, Takamiya R, Nishitani C, Araki M, Yamaguchi Y, Taniguchi N, Kuroki Y. J Biol Chem 288 32910-32921 (2013)
  287. Targeting ERBB receptors shifts their partners and triggers persistent ERK signaling through a novel ERBB/EFNB1 complex. Vermeer PD, Colbert PL, Wieking BG, Vermeer DW, Lee JH. Cancer Res 73 5787-5797 (2013)
  288. c-erbB-2 (HER-2/neu) immunohistochemistry in invasive breast cancer: is there concordance between standard sections and tissue microarrays? Selvarajan S, Tan SY, Sii LH, Tan PH. Pathology 38 316-320 (2006)
  289. A novel ErbB2 epitope targeted by human antitumor immunoagents. Troise F, Monti M, Merlino A, Cozzolino F, Fedele C, Russo Krauss I, Sica F, Pucci P, D'Alessio G, De Lorenzo C. FEBS J 278 1156-1166 (2011)
  290. Binding of trastuzumab to ErbB2 is inhibited by a high pericellular density of hyaluronan. Váradi T, Mersich T, Auvinen P, Tammi R, Tammi M, Salamon F, Besznyák I, Jakab F, Baranyai Z, Szöllősi J, Nagy P. J Histochem Cytochem 60 567-575 (2012)
  291. Complementarity determining regions and frameworks contribute to the disulfide bond independent folding of intrinsically stable scFv. Gąciarz A, Ruddock LW. PLoS One 12 e0189964 (2017)
  292. Format chain exchange (FORCE) for high-throughput generation of bispecific antibodies in combinatorial binder-format matrices. Dengl S, Mayer K, Bormann F, Duerr H, Hoffmann E, Nussbaum B, Tischler M, Wagner M, Kuglstatter A, Leibrock L, Buldun C, Georges G, Brinkmann U. Nat Commun 11 4974 (2020)
  293. IgE-based Immunotherapy of Cancer -A Comparative Oncology Approach. Singer J, Jensen-Jarolim E. J Carcinog Mutagen 5 1000176 (2014)
  294. Inhibition of ERBB2-overexpressing Tumors by Recombinant Human Prolidase and Its Enzymatically Inactive Mutant. Yang L, Li Y, Bhattacharya A, Zhang Y. EBioMedicine 2 396-405 (2015)
  295. Localisation Microscopy of Breast Epithelial ErbB-2 Receptors and Gap Junctions: Trafficking after γ-Irradiation, Neuregulin-1β, and Trastuzumab Application. Pilarczyk G, Nesnidal I, Gunkel M, Bach M, Bestvater F, Hausmann M. Int J Mol Sci 18 E362 (2017)
  296. Model-based analysis of HER activation in cells co-expressing EGFR, HER2 and HER3. Shankaran H, Zhang Y, Tan Y, Resat H. PLoS Comput Biol 9 e1003201 (2013)
  297. Polyethylene glycol-conjugated HER2-targeted peptides as a nuclear imaging probe for HER2-overexpressed gastric cancer detection in vivo. Guan SS, Wu CT, Chiu CY, Luo TY, Wu JY, Liao TZ, Liu SH. J Transl Med 16 168 (2018)
  298. Strong dimerization of wild-type ErbB2/Neu transmembrane domain and the oncogenic Val664Glu mutant in mammalian plasma membranes. Placone J, He L, Del Piccolo N, Hristova K. Biochim Biophys Acta 1838 2326-2330 (2014)
  299. Targeting EGFR/HER2 heterodimerization with a novel anti-HER2 domain II/III antibody. Yu X, Wang L, Shen Y, Wang C, Zhang Y, Meng Y, Yang Y, Liang B, Zhou B, Wang H, Wei H, Lei C, Hu S, Li B. Mol Immunol 87 300-307 (2017)
  300. Th1 cytokines sensitize HER-expressing breast cancer cells to lapatinib. Showalter LE, Oechsle C, Ghimirey N, Steele C, Czerniecki BJ, Koski GK. PLoS One 14 e0210209 (2019)
  301. The Effects of Pertuzumab and Its Combination with Trastuzumab on HER2 Homodimerization and Phosphorylation. Nami B, Maadi H, Wang Z. Cancers (Basel) 11 E375 (2019)
  302. The HER2-binding affibody molecule (Z(HER2∶342))₂ increases radiosensitivity in SKBR-3 cells. Ekerljung L, Lennartsson J, Gedda L. PLoS One 7 e49579 (2012)
  303. The improvement of an anti-CD22 immunotoxin: conversion to single-chain and disulfide stabilized form and affinity maturation by alanine scan. Kawa S, Onda M, Ho M, Kreitman RJ, Bera TK, Pastan I. MAbs 3 479-486 (2011)
  304. Scutellaria barbata D. Don polysaccharides inhibit the growth of Calu-3 xenograft tumors via suppression of the HER2 pathway and angiogenesis. Yang J, Yang G, Hou G, Liu Q, Hu W, Zhao PU, He YI. Oncol Lett 9 2721-2725 (2015)
  305. Characterization of the native and denatured herceptin by enzyme linked immunosorbent assay and quartz crystal microbalance using a high-affinity single chain fragment variable recombinant antibody. Shang Y, Mernaugh R, Zeng X. Anal Chem 84 8164-8170 (2012)
  306. Decreased Levels of Circulating Cancer-Associated Protein Biomarkers Following Bariatric Surgery. Farey JE, Fisher OM, Levert-Mignon AJ, Forner PM, Lord RV. Obes Surg 27 578-585 (2017)
  307. Design of a doxorubicin-peptidomimetic conjugate that targets HER2-positive cancer cells. Pallerla S, Gauthier T, Sable R, Jois SD. Eur J Med Chem 125 914-924 (2017)
  308. ErbB1 and ErbB3 co-over expression as a prognostic factor in gastric cancer. Moghbeli M, Makhdoumi Y, Soltani Delgosha M, Aarabi A, Dadkhah E, Memar B, Abdollahi A, Abbaszadegan MR. Biol Res 52 2 (2019)
  309. Fluorescence study for selecting specific ligands toward HER2 receptor: an example of receptor fragment approach. Calce E, Monfregola L, Sandomenico A, Saviano M, De Luca S. Eur J Med Chem 61 116-121 (2013)
  310. Inhibitors of thiol-mediated uptake. Cheng Y, Pham AT, Kato T, Lim B, Moreau D, López-Andarias J, Zong L, Sakai N, Matile S. Chem Sci 12 626-631 (2020)
  311. Mannose phosphate isomerase regulates fibroblast growth factor receptor family signaling and glioma radiosensitivity. Cazet A, Charest J, Bennett DC, Sambrooks CL, Contessa JN. PLoS One 9 e110345 (2014)
  312. Proof of concept study with an HER-2 mimotope anticancer vaccine deduced from a novel AAV-mimotope library platform. Singer J, Manzano-Szalai K, Fazekas J, Thell K, Bentley-Lukschal A, Stremnitzer C, Roth-Walter F, Weghofer M, Ritter M, Pino Tossi K, Hörer M, Michaelis U, Jensen-Jarolim E. Oncoimmunology 5 e1171446 (2016)
  313. TRK-A, HER-2/neu, and KIT Expression/Activation Profiles in Salivary Gland Carcinoma. Negri T, Tamborini E, Dagrada GP, Greco A, Staurengo S, Guzzo M, Locati LD, Carbone A, Pierotti MA, Licitra L, Pilotti S. Transl Oncol 1 121-128 (2008)
  314. Targeting HER2 by Combination Therapies. Ruiz-Saenz A, Moasser MM. J Clin Oncol 36 808-811 (2018)
  315. [Trastuzumab emtansine (Kadcyla(®)) approval in HER2-positive metastatic breast cancers]. Guerin M, Sabatier R, Gonçalves A. Bull Cancer 102 390-397 (2015)
  316. A peptidomimetic with a chiral switch is an inhibitor of epidermal growth factor receptor heterodimerization. Kanthala SP, Liu YY, Singh S, Sable R, Pallerla S, Jois SD. Oncotarget 8 74244-74262 (2017)
  317. AllergoOncology: High innate IgE levels are decisive for the survival of cancer-bearing mice. Singer J, Achatz-Straussberger G, Bentley-Lukschal A, Fazekas-Singer J, Achatz G, Karagiannis SN, Jensen-Jarolim E. World Allergy Organ J 12 100044 (2019)
  318. Anti-HER-2 engineering antibody ChA21 inhibits growth and induces apoptosis of SK-OV-3 cells. Zhang A, Xue H, Ling X, Gao Y, Yang F, Cheng L, Liu J, Wu Q. J Exp Clin Cancer Res 29 23 (2010)
  319. Blockade of a key region in the extracellular domain inhibits HER2 dimerization and signaling. Menendez JA, Schroeder B, Peirce SK, Vellon L, Papadimitropoulou A, Espinoza I, Lupu R. J Natl Cancer Inst 107 djv090 (2015)
  320. Calmodulin binds HER2 and modulates HER2 signaling. White CD, Li Z, Sacks DB. Biochim Biophys Acta 1813 1074-1082 (2011)
  321. Coclustering of ErbB1 and ErbB2 revealed by FRET-sensitized acceptor bleaching. Szabó A, Szöllosi J, Nagy P. Biophys J 99 105-114 (2010)
  322. Development and validation of cell-based ELISA for the quantification of trastuzumab in human plasma. Jamieson D, Cresti N, Verrill MW, Boddy AV. J Immunol Methods 345 106-111 (2009)
  323. Engineering an anti-HER2 biparatopic antibody with a multimodal mechanism of action. Kast F, Schwill M, Stüber JC, Pfundstein S, Nagy-Davidescu G, Rodríguez JMM, Seehusen F, Richter CP, Honegger A, Hartmann KP, Weber TG, Kroener F, Ernst P, Piehler J, Plückthun A. Nat Commun 12 3790 (2021)
  324. Extracellular domain determinants of LET-23 (EGF) receptor tyrosine kinase activity in Caenorhabditis elegans. Moghal N, Sternberg PW. Oncogene 22 5471-5480 (2003)
  325. Identification of anti-ErbB2 dual variable domain immunoglobulin (DVD-Ig™) proteins with unique activities. Gu J, Yang J, Chang Q, Lu X, Wang J, Chen M, Ghayur T, Gu J. PLoS One 9 e97292 (2014)
  326. Imaging and monitoring HER2 expression in breast cancer during trastuzumab therapy with a peptide probe 99mTc-HYNIC-H10F. Wu Y, Li L, Wang Z, Shi J, Hu Z, Gao S, Miao W, Ma Q, Dong C, Wang F. Eur J Nucl Med Mol Imaging 47 2613-2623 (2020)
  327. LMO1 is a novel oncogene in lung cancer, and its overexpression is a new predictive marker for anti-EGFR therapy. Zhang Y, Yang J, Wang J, Guo H, Jing N. Med Oncol 31 99 (2014)
  328. Molecular dynamics (MD) investigations of preformed structures of the transmembrane domain of the oncogenic Neu receptor dimer in a DMPC bilayer. Aller P, Voiry L, Garnier N, Genest M. Biopolymers 77 184-197 (2005)
  329. Recombinant plant-derived human IgE glycoproteomics. Montero-Morales L, Maresch D, Castilho A, Turupcu A, Ilieva KM, Crescioli S, Karagiannis SN, Lupinek C, Oostenbrink C, Altmann F, Steinkellner H. J Proteomics 161 81-87 (2017)
  330. T-cell Activating Tribodies as a Novel Approach for Efficient Killing of ErbB2-positive Cancer Cells. Riccio G, Ricardo AR, Passariello M, Saraiva K, Rubino V, Cunnah P, Mertens N, De Lorenzo C. J Immunother 42 1-10 (2019)
  331. Tumor delivery of antisense oligomer using trastuzumab within a streptavidin nanoparticle. Wang Y, Liu X, Chen L, Cheng D, Rusckowski M, Hnatowich DJ. Eur J Nucl Med Mol Imaging 36 1977-1986 (2009)
  332. A common MET polymorphism harnesses HER2 signaling to drive aggressive squamous cell carcinoma. Kong LR, Mohamed Salleh NAB, Ong RW, Tan TZ, Syn NL, Goh RM, Fhu CW, Tan DSW, Iyer NG, Kannan S, Verma CS, Lim YC, Soo R, Ho J, Huang Y, Lim JSJ, Yan BJ, Nga ME, Lim SG, Koeffler HP, Lee SC, Kappei D, Hung HT, Goh BC. Nat Commun 11 1556 (2020)
  333. Circular RNA hsa_circ_0001598 promotes programmed death-ligand-1-mediated immune escape and trastuzumab resistance via sponging miR-1184 in breast cancer cells. Huang L, Ma J, Cui M. Immunol Res 69 558-567 (2021)
  334. Cooperative but distinct early co-signaling events originate from ERBB2 and ERBB1 receptors upon trastuzumab treatment in breast cancer cells. Bagnato P, Castagnino A, Cortese K, Bono M, Grasso S, Bellese G, Daniele T, Lundmark R, Defilippi P, Castagnola P, Tacchetti C. Oncotarget 8 60109-60122 (2017)
  335. Evaluation of analytical similarity between trastuzumab biosimilar CT-P6 and reference product using statistical analyses. Lee J, Kang HA, Bae JS, Kim KD, Lee KH, Lim KJ, Choo MJ, Chang SJ. MAbs 10 547-571 (2018)
  336. Identification of high affinity HER2 binding antibodies using CHO Fab surface display. Nguyen AW, Le KC, Maynard JA. Protein Eng Des Sel 31 91-101 (2018)
  337. Immobilization of a human epidermal growth factor receptor 2 mimotope-derived synthetic peptide on Au and its potential application for detection of herceptin in human serum by quartz crystal microbalance. Shang Y, Singh PR, Chisti MM, Mernaugh R, Zeng X. Anal Chem 83 8928-8936 (2011)
  338. In silico proteomic characterization of human epidermal growth factor receptor 2 (HER-2) for the mapping of high affinity antigenic determinants against breast cancer. Baloria U, Akhoon BA, Gupta SK, Sharma S, Verma V. Amino Acids 42 1349-1360 (2012)
  339. Increased expression of the integral membrane protein ErbB2 in Chinese hamster ovary cells expressing the anti-apoptotic gene Bcl-xL. O'Connor S, Li E, Majors BS, He L, Placone J, Baycin D, Betenbaugh MJ, Hristova K. Protein Expr Purif 67 41-47 (2009)
  340. LMO1 is a novel oncogene in colorectal cancer and its overexpression is a new predictive marker for anti-EGFR therapy. Liu J, Yan P, Jing N, Yang J. Tumour Biol 35 8161-8167 (2014)
  341. Locoregional recurrence in patients with HER2 positive breast cancer. Brollo J, Kneubil MC, Botteri E, Rotmensz N, Duso BA, Fumagalli L, Locatelli MA, Criscitiello C, Lohsiriwat V, Goldhirsch A, Leonardi MC, Orecchia R, Curigliano G. Breast 22 856-862 (2013)
  342. Over-expression of c-erbB-2 correlates with nuclear morphometry and prognosis in breast carcinoma in Asian women. Selvarajan S, Wong KY, Khoo KS, Bay BH, Tan PH. Pathology 38 528-533 (2006)
  343. Single-molecule functional anatomy of endogenous HER2-HER3 heterodimers. Choi B, Cha M, Eun GS, Lee DH, Lee S, Ehsan M, Chae PS, Heo WD, Park Y, Yoon TY. Elife 9 e53934 (2020)
  344. Size and conformational features of ErbB2 and ErbB3 receptors: a TEM and DLS comparative study. Vicente-Alique E, Núñez-Ramírez R, Vega JF, Hu P, Martínez-Salazar J. Eur Biophys J 40 835-842 (2011)
  345. Trastuzumab therapy vs tetracycline controlled ERBB2 downregulation: influence on tumour development in an ERBB2-dependent mouse tumour model. Hermes M, Schormann W, Brulport M, Uhlemann K, Lupatsch F, Horn LC, Schumann A, Allgaier C, Weishaupt M, Engeland K, Müller GA, Mössner J, Bauer A, Schiffer IB, Gebhard S, Schmidt M, Lausch E, Prawitt D, Wilhelm C, Hengstler JG. Br J Cancer 98 1525-1532 (2008)
  346. Letter Trastuzumab--mechanism of action and use. Karamouzis MV, Konstantinopoulos PA, Papavassiliou AG. N Engl J Med 357 1664; author reply 1665-6 (2007)
  347. Bovine herpesvirus 4-based vector delivering a hybrid rat/human HER-2 oncoantigen efficiently protects mice from autochthonous Her-2+ mammary cancer. Jacca S, Rolih V, Quaglino E, Franceschi V, Tebaldi G, Bolli E, Rosamilia A, Ottonello S, Cavallo F, Donofrio G. Oncoimmunology 5 e1082705 (2016)
  348. Combined 3D-QSAR modeling and molecular docking study on multi-acting quinazoline derivatives as HER2 kinase inhibitors. Mirzaie S, Monajjemi M, Hakhamaneshi MS, Fathi F, Jamalan M. EXCLI J 12 130-143 (2013)
  349. Cysteine co-oxidation process driven by native peptide folding: an example on HER2 receptor model system. Calce E, Sandomenico A, Saviano M, Ruvo M, De Luca S. Amino Acids 46 1197-1206 (2014)
  350. Epitope Mapping of Human HER2 Specific Mouse Monoclonal Antibodies Using Recombinant Extracellular Subdomains Hosseini Ghatar R, Soltantoyeh T, Bahadori T, Golara M, Hassannia H, Khosravi Eghbal R, Khoshnoodi J, Judaki MA, Golsaz-Shirazi F, Jeddi-Tehrani M, Amiri MM, Shokri F. Asian Pac J Cancer Prev 18 3103-3110 (2017)
  351. Exploring the dynamics and interaction of a full ErbB2 receptor and Trastuzumab-Fab antibody in a lipid bilayer model using Martini coarse-grained force field. Franco-Gonzalez JF, Ramos J, Cruz VL, Martinez-Salazar J. J Comput Aided Mol Des 28 1093-1107 (2014)
  352. Expression of full-length HER2 protein in Sf9 insect cells and its presentation on the surface of budded virus-like particles. Nika L, Wallner J, Palmberger D, Koczka K, Vorauer-Uhl K, Grabherr R. Protein Expr Purif 136 27-38 (2017)
  353. Growth factor receptors and apoptosis regulators: signaling pathways, prognosis, chemosensitivity and treatment outcomes of breast cancer. Sarkar S, Mandal M. Breast Cancer (Auckl) 3 47-60 (2009)
  354. Narrow escape time to a structured target located on the boundary of a microdomain. Reingruber J, Abad E, Holcman D. J Chem Phys 130 094909 (2009)
  355. Profiling of protein-protein interactions via single-molecule techniques predicts the dependence of cancers on growth-factor receptors. Lee HW, Choi B, Kang HN, Kim H, Min A, Cha M, Ryu JY, Park S, Sohn J, Shin K, Yun MR, Han JY, Shon MJ, Jeong C, Chung J, Lee SH, Im SA, Cho BC, Yoon TY. Nat Biomed Eng 2 239-253 (2018)
  356. Proteolytic cleavages in the extracellular domain of receptor tyrosine kinases by membrane-associated serine proteases. Chen LM, Chai KX. Oncotarget 8 56490-56505 (2017)
  357. Proteolytic single hinge cleavage of pertuzumab impairs its Fc effector function and antitumor activity in vitro and in vivo. Hsiao HC, Fan X, Jordan RE, Zhang N, An Z. Breast Cancer Res 20 43 (2018)
  358. Resistance to receptor-blocking therapies primes tumors as targets for HER3-homing nanobiologics. Sims JD, Taguiam JM, Alonso-Valenteen F, Markman J, Agadjanian H, Chu D, Lubow J, Abrol R, Srinivas D, Jain A, Han B, Qu Y, Mirzadehgan P, Hwang JY, Rentsendorj A, Chung A, Lester J, Karlan BY, Gray HB, Gross Z, Giuliano A, Cui X, Medina-Kauwe LK. J Control Release 271 127-138 (2018)
  359. Selecting Molecular Recognition. What Can Existing Aptamers Tell Us about Their Inherent Recognition Capabilities and Modes of Interaction? Zhang Q, Landgraf R. Pharmaceuticals (Basel) 5 493-513 (2012)
  360. The transmembrane domain of Neu in a lipid bilayer: molecular dynamics simulations. van der Ende BM, Sharom FJ, Davis JH. Eur Biophys J 33 596-610 (2004)
  361. Transmembrane helix packing of ErbB/Neu receptor in membrane environment: a molecular dynamics study. Aller P, Garnier N, Genest M. J Biomol Struct Dyn 24 209-228 (2006)
  362. A betacellulin mutant promotes differentiation of pancreatic acinar AR42J cells into insulin-producing cells with low affinity of binding to ErbB1. Nagaoka T, Fukuda T, Hashizume T, Nishiyama T, Tada H, Yamada H, Salomon DS, Yamada S, Kojima I, Seno M. J Mol Biol 380 83-94 (2008)
  363. Affinity Maturation of Monoclonal Antibody 1E11 by Targeted Randomization in CDR3 Regions Optimizes Therapeutic Antibody Targeting of HER2-Positive Gastric Cancer. Ko BK, Choi S, Cui LG, Lee YH, Hwang IS, Kim KT, Shim H, Lee JS. PLoS One 10 e0134600 (2015)
  364. Affinity maturation of antiHER2 monoclonal antibody MIL5 using an epitope-specific synthetic phage library by computational design. Qiao C, Lv M, Li X, Geng J, Li Y, Zhang J, Lin Z, Feng J, Shen B. J Biomol Struct Dyn 31 511-521 (2013)
  365. Assessment of the Molecular Mechanism of Action of SB3, a Trastuzumab Biosimilar. Paek K, Kim GW, Ahn SY, Lim JH, Jung D, Kim S, Lee JH. BioDrugs 33 661-671 (2019)
  366. Assessment of the methods used to detect HER2-positive advanced extramammary Paget's disease. Hirai I, Tanese K, Nakamura Y, Otsuka A, Fujisawa Y, Yamamoto Y, Hata H, Fujimura T, Matsushita S, Yoshino K, Kameyama K, Amagai M, Funakoshi T. Med Oncol 35 92 (2018)
  367. Co-mutational assessment of circulating tumour DNA (ctDNA) during osimertinib treatment for T790M mutant lung cancer. Xing P, Han X, Wang S, Liu Y, Yang S, Hao X, Wang Y, Liu P, Li J, Wang L, Chang L, Guan Y, Zhang Z, Wu D, Yao J, Yi X, Shi Y. J Cell Mol Med 23 6812-6821 (2019)
  368. Cytokine Activation by Antibody Fragments Targeted to Cytokine-Receptor Signaling Complexes. Kuruganti S, Miersch S, Deshpande A, Speir JA, Harris BD, Schriewer JM, Buller RM, Sidhu SS, Walter MR. J Biol Chem 291 447-461 (2016)
  369. Design of cyclic and d-amino acids containing peptidomimetics for inhibition of protein-protein interactions of HER2-HER3. Pallerla S, Naik H, Singh S, Gauthier T, Sable R, Jois SD. J Pept Sci 24 (2018)
  370. Early response to ErbB2 over-expression in polarized Caco-2 cells involves partial segregation from ErbB3 by relocalization to the apical surface and initiation of survival signaling. Pfister AB, Wood RC, Salas PJ, Zea DL, Ramsauer VP. J Cell Biochem 111 643-652 (2010)
  371. Efficacy and Safety of Gemcitabine With Trastuzumab and Pertuzumab After Prior Pertuzumab-Based Therapy Among Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer: A Phase 2 Clinical Trial. Iyengar NM, Smyth LM, Lake D, Gucalp A, Singh JC, Traina TA, DeFusco P, Fornier MN, Goldfarb S, Jhaveri K, Modi S, Troso-Sandoval T, Patil S, Ulaner GA, Jochelson M, Norton L, Hudis CA, Dang CT. JAMA Netw Open 2 e1916211 (2019)
  372. Efficacy of the eribulin, pertuzumab, and trastuzumab combination therapy for human epidermal growth factor receptor 2-positive advanced or metastatic breast cancer: a multicenter, single arm, phase II study (JBCRG-M03 study). Yamashita T, Kawaguchi H, Masuda N, Kitada M, Narui K, Hattori M, Yoshinami T, Matsunami N, Yanagihara K, Kawasoe T, Nagashima T, Bando H, Yano H, Hasegawa Y, Nakamura R, Kashiwaba M, Morita S, Ohno S, Toi M. Invest New Drugs 39 217-225 (2021)
  373. Epidermal growth factor receptor peptide vaccination induces cross-reactive immunity to human EGFR, HER2, and HER3. Doyle HA, Koski RA, Bonafé N, Bruck RA, Tagliatela SM, Gee RJ, Mamula MJ. Cancer Immunol Immunother 67 1559-1569 (2018)
  374. Identification of relevant conformational epitopes on the HER2 oncoprotein by using Large Fragment Phage Display (LFPD). Gabrielli F, Salvi R, Garulli C, Kalogris C, Arima S, Tardella L, Monaci P, Pupa SM, Tagliabue E, Montani M, Quaglino E, Stramucci L, Curcio C, Marchini C, Amici A. PLoS One 8 e58358 (2013)
  375. Inhibition of p85, the non-catalytic subunit of phosphatidylinositol 3-kinase, exerts potent antitumor activity in human breast cancer cells. Folgiero V, Di Carlo SE, Bon G, Spugnini EP, Di Benedetto A, Germoni S, Pia Gentileschi M, Accardo A, Milella M, Morelli G, Bossi G, Mottolese M, Falcioni R. Cell Death Dis 3 e440 (2012)
  376. Investigating Molecular Mechanisms of Activation and Mutation of the HER2 Receptor Tyrosine Kinase through Computational Modeling and Simulation. Telesco SE, Shih A, Liu Y, Radhakrishnan R. Cancer Res J 4 1-35 (2011)
  377. Is the Improved Efficacy of Trastuzumab and Lapatinib Combination Worth the Added Toxicity? A Discussion of Current Evidence, Recommendations, and Ethical Issues Regarding Dual HER2-Targeted Therapy. Ahn ER, Wang E, Glück S. Breast Cancer (Auckl) 6 191-207 (2012)
  378. Lead exposure and plasma mRNA expression in ERBB2 gene. Ferrante M, Ledda C, Oliveri Conti G, Fiore M, Rapisarda V, Copat C, Sole G, Terzo N, Travali S. Mol Med Rep 15 3361-3365 (2017)
  379. Mechanism of action of the trastuzumab biosimilar CT-P6. Jeong SA, Choi JM, Park JM, Lee JY, Lee SJ, Lee SY, Lee SY, Park YA, Jeong HJ, Song YC, Kim SH, Chang SJ. Expert Opin Biol Ther 19 1085-1095 (2019)
  380. Rational optimization of a bispecific ligand trap targeting EGF receptor family ligands. Jin P, Zhang J, Beryt M, Turin L, Brdlik C, Feng Y, Bai X, Liu J, Jorgensen B, Shepard HM. Mol Med 15 11-20 (2009)
  381. Shotgun Glycomics Identifies Tumor-Associated Glycan Ligands Bound by an Ovarian Carcinoma-Specific Monoclonal Antibody. Liau B, Tan B, Teo G, Zhang P, Choo A, Rudd PM. Sci Rep 7 14489 (2017)
  382. Special Agents Hunting Down Women Silent Killer: The Emerging Role of the p38α Kinase. Grossi V, Simone C. J Oncol 2012 382159 (2012)
  383. Tensor decomposition-based unsupervised feature extraction applied to matrix products for multi-view data processing. Taguchi YH. PLoS One 12 e0183933 (2017)
  384. The breast cancer susceptibility FGFR2 provides an alternate mode of HER2 activation. Wei W, Liu W, Serra S, Asa SL, Ezzat S. Oncogene (2015)
  385. The effects of bufadienolides on HER2 overexpressing breast cancer cells. Wang T, Mu L, Jin H, Zhang P, Wang Y, Ma X, Pan J, Miao J, Yuan Y. Tumour Biol 37 7155-7163 (2016)
  386. 1H, 13C and 15N assignments of the C-terminal intrinsically disordered cytosolic fragment of the receptor tyrosine kinase ErbB2. Wang Y, Pinet L, Assrir N, Elantak L, Guerlesquin F, Badache A, Lescop E, van Heijenoort C. Biomol NMR Assign 12 23-26 (2018)
  387. A Functional Screening Strategy for Engineering Chimeric Antigen Receptors with Reduced On-Target, Off-Tumor Activation. Di Roberto RB, Castellanos-Rueda R, Frey S, Egli D, Vazquez-Lombardi R, Kapetanovic E, Kucharczyk J, Reddy ST. Mol Ther 28 2564-2576 (2020)
  388. A Network Pharmacology Study Based on the Mechanism of Citri Reticulatae Pericarpium-Pinelliae Rhizoma in the Treatment of Gastric Cancer. Song S, Huang W, Lu X, Liu J, Zhou J, Li Y, Shu P. Evid Based Complement Alternat Med 2021 6667560 (2021)
  389. A novel proteotoxic combination therapy for EGFR+ and HER2+ cancers. Wang M, Ferreira RB, Law ME, Davis BJ, Yaaghubi E, Ghilardi AF, Sharma A, Avery BA, Rodriguez E, Chiang CW, Narayan S, Heldermon CD, Castellano RK, Law BK. Oncogene 38 4264-4282 (2019)
  390. Letter Ablation of breast cancer cells using trastuzumab-functionalized multi-walled carbon nanotubes and trastuzumab-diphtheria toxin conjugate. Oraki Kohshour M, Mirzaie S, Zeinali M, Amin M, Said Hakhamaneshi M, Jalili A, Mosaveri N, Jamalan M. Chem Biol Drug Des 83 259-265 (2014)
  391. Conformational flexibility of the ErbB2 ectodomain and trastuzumab antibody complex as revealed by molecular dynamics and principal component analysis. Franco-Gonzalez JF, Cruz VL, Ramos J, Martínez-Salazar J. J Mol Model 19 1227-1236 (2013)
  392. De novo design of ErbB2 epitope targeting fusion protein stabilized by coiled coil structure. Wang J, Feng J, Shi M, Qian L, Chen L, Yu M, Xu R, Shen B, Guo N. Mol Immunol 45 106-116 (2008)
  393. Development and Characterization of a Humanized Anti-HER2 Antibody HuA21 with Potent Anti-Tumor Properties in Breast Cancer Cells. Li R, Hu S, Chang Y, Zhang Z, Zha Z, Huang H, Shen G, Liu J, Song L, Wei W. Int J Mol Sci 17 563 (2016)
  394. Development of a radiolabeled caninized anti-EGFR antibody for comparative oncology trials. Fazekas-Singer J, Berroterán-Infante N, Rami-Mark C, Dumanic M, Matz M, Willmann M, Andreae F, Singer J, Wadsak W, Mitterhauser M, Jensen-Jarolim E. Oncotarget 8 83128-83141 (2017)
  395. Downregulation of epidermal growth factor receptor family receptors and ligands in a mutant K-ras group of patients with colorectal cancer. Nagaoka T, Kitaura K, Miyata Y, Kumagai K, Kaneda G, Kanazawa H, Suzuki S, Hamada Y, Suzuki R. Mol Med Rep 13 3514-3520 (2016)
  396. ERBB2 juxtamembrane domain (trastuzumab binding site) gene mutation is a rare event in invasive breast cancers overexpressing the ERBB2 gene. Khoury T, Mojica W, Hicks D, Starostik P, Ademuyiwa F, Janarthanan B, Cheney RT. Mod Pathol 24 1055-1059 (2011)
  397. Effect of acute acid-base disturbances on ErbB1/2 tyrosine phosphorylation in rabbit renal proximal tubules. Skelton LA, Boron WF. Am J Physiol Renal Physiol 305 F1747-64 (2013)
  398. Identification of a peptide-peptide binding motif in the coating of nab-paclitaxel nanoparticles with clinical antibodies: bevacizumab, rituximab, and trastuzumab. Butterfield JT, Kim H, Knauer DJ, Nevala WK, Markovic SN. Sci Rep 7 14476 (2017)
  399. NRG1/ERBB3/ERBB2 Axis Triggers Anchorage-Independent Growth of Basal-like/Triple-Negative Breast Cancer Cells. Miano C, Morselli A, Pontis F, Bongiovanni C, Sacchi F, Da Pra S, Romaniello D, Tassinari R, Sgarzi M, Pantano E, Ventura C, Lauriola M, D'Uva G. Cancers (Basel) 14 1603 (2022)
  400. Overview on concepts and applications of Fab antibody fragments. Rader C. Curr Protoc Protein Sci Chapter 6 Unit 6.9 (2009)
  401. Quantitating ADCC against adherent cells: Impedance-based detection is superior to release, membrane permeability, or caspase activation assays in resolving antibody dose response. Tóth G, Szöllősi J, Vereb G. Cytometry A 91 1021-1029 (2017)
  402. Simulation of homology models for the extracellular domains (ECD) of ErbB3, ErbB4 and the ErbB2-ErbB3 complex in their active conformations. Franco-Gonzalez JF, Ramos J, Cruz VL, Martínez-Salazar J. J Mol Model 19 931-941 (2013)
  403. Trastuzumab administration during pregnancy: an update. Andrikopoulou A, Apostolidou K, Chatzinikolaou S, Bletsa G, Zografos E, Dimopoulos MA, Zagouri F. BMC Cancer 21 463 (2021)
  404. Trastuzumab inhibits pituitary tumor cell growth modulating the TGFB/SMAD2/3 pathway. Petiti JP, Sosa LDV, Picech F, Moyano Crespo GD, Arevalo Rojas JZ, Pérez PA, Guido CB, Leimgruber C, Sabatino ME, García P, Bengio V, Papalini FR, Estario P, Berhard C, Villarreal M, Gutiérrez S, De Paul AL, Mukdsi JH, Torres AI. Endocr Relat Cancer 25 837-852 (2018)
  405. Antibody response to HER2 extracellular domain and subdomains in mouse following DNA immunization. Sadri-Ardalani F, Shabani M, Amiri MM, Bahadori M, Emami S, Sarrafzadeh AR, Noutash-Haghighat F, Jeddi-Tehrani M, Shokri F. Tumour Biol 37 1217-1227 (2016)
  406. CD19-targeting fusion protein combined with PD1 antibody enhances anti-tumor immunity in mouse models. Lv Z, Zhang P, Li D, Qin M, Nie L, Wang X, Ai L, Feng Z, Odhiambo WO, Ma Y, Ji Y. Oncoimmunology 9 1747688 (2020)
  407. Editorial Could precision-engineered peptide epitopes/vaccines be the key to a cancer cure? Kaumaya PT. Future Oncol 7 807-810 (2011)
  408. Critical roles for EGFR and EGFR-HER2 clusters in EGF binding of SW620 human carcinoma cells. Wollman AJM, Fournier C, Llorente-Garcia I, Harriman O, Payne-Dwyer AL, Shashkova S, Zhou P, Liu TC, Ouaret D, Wilding J, Kusumi A, Bodmer W, Leake MC. J R Soc Interface 19 20220088 (2022)
  409. Deciphering the stepwise binding mode of HRG1β to HER3 by surface plasmon resonance and interaction map. Peess C, von Proff L, Goller S, Andersson K, Gerg M, Malmqvist M, Bossenmaier B, Schräml M. PLoS One 10 e0116870 (2015)
  410. Design and Synthesis of Megamolecule Mimics of a Therapeutic Antibody. Modica JA, Iderzorig T, Mrksich M. J Am Chem Soc 142 13657-13661 (2020)
  411. Design of peptidomimetics for inhibition of HER2 receptor dimerization by a combination of virtual screening, MD simulations, and QSAR in silico methods. Jamalan M, Jamalan M, Zeinali M, Barzegari Asadabadi E. Chem Biol Drug Des 81 455-462 (2013)
  412. Development of a Nanostructured Platform for Identifying HER2-Heterogeneity of Breast Cancer Cells by Surface-Enhanced Raman Scattering. Téllez-Plancarte A, Haro-Poniatowski E, Picquart M, Morales-Méndez JG, Lara-Cruz C, Jiménez-Salazar JE, Damián-Matsumura P, Escobar-Alarcón L, Batina N. Nanomaterials (Basel) 8 E549 (2018)
  413. Development of a novel anti-HER2 scFv by ribosome display and in silico evaluation of its 3D structure and interaction with HER2, alone and after fusion to LAMP2B. Salimi F, Forouzandeh Moghadam M, Rajabibazl M. Mol Biol Rep 45 2247-2256 (2018)
  414. Differential Effects of Inhibitory and Stimulatory Anti-HER2 Monoclonal Antibodies on AKT/ERK Signaling Pathways Soltantoyeh T, Bahadori T, Hosseini-Ghatar R, Khoshnoodi J, Roohi A, Mobini M, Golsaz-Shirazi F, Jeddi-Tehrani M, Amiri MM, Shokri F. Asian Pac J Cancer Prev 19 2255-2262 (2018)
  415. Epigenetic Silencing of HER2 Expression during Epithelial-Mesenchymal Transition Leads to Trastuzumab Resistance in Breast Cancer. Nami B, Ghanaeian A, Black C, Wang Z. Life (Basel) 11 868 (2021)
  416. Flow-induced 2D protein crystallization: characterization of the coupled interfacial and bulk flows. Young JE, Posada D, Lopez JM, Hirsa AH. Soft Matter 11 3618-3628 (2015)
  417. HER3 expression and MEK activation in non-small-cell lung carcinoma. Manickavasagar T, Yuan W, Carreira S, Gurel B, Miranda S, Ferreira A, Crespo M, Riisnaes R, Baker C, O'Brien M, Bhosle J, Popat S, Banerji U, Lopez J, de Bono J, Minchom A. Lung Cancer Manag 10 LMT48 (2021)
  418. Herceptin-platinum(II) binding complexes: novel cancer-cell-specific agents. Gao J, Liu YG, Liu R, Zingaro RA. ChemMedChem 3 954-962 (2008)
  419. Listeria monocytogenes produces a pro-invasive factor that signals via ErbB2/ErbB3 heterodimers. Oliveira MJ, Lauwaet T, De Bruyne G, Mareel M, Leroy A. J Cancer Res Clin Oncol 131 49-59 (2005)
  420. Molecular dynamics simulations of transitions for ECD epidermal growth factor receptors show key differences between human and drosophila forms of the receptors. Perilla JR, Leahy DJ, Woolf TB. Proteins 81 1113-1126 (2013)
  421. Pari passu dimers of dimers. Sliwkowski MX. Proc Natl Acad Sci U S A 109 13140-13141 (2012)
  422. Reconstructing the discontinuous and conformational β1/β3-loop binding site on hFSH/hCG by using highly constrained multicyclic peptides. Smeenk LE, Timmers-Parohi D, Benschop JJ, Puijk WC, Hiemstra H, van Maarseveen JH, Timmerman P. Chembiochem 16 91-99 (2015)
  423. Regulation of the prometastatic neuregulin-MMP13 axis by SRC family kinases: therapeutic implications. Orive-Ramos A, Seoane S, Ocaña A, Pandiella A, Montero JC. Mol Oncol 11 1788-1805 (2017)
  424. Structural identification of an HER2 receptor model binding pocket to optimize lead compounds: a combined experimental and computational approach. Langella E, Calce E, Saviano M, De Luca S. Mol Biosyst 12 2159-2167 (2016)
  425. Structure of HER receptors and intracellular localisation of downstream effector elements gives insight into mechanism of tumour growth promotion. Witton CJ. Breast Cancer Res 5 206-207 (2003)
  426. Synthesis and biochemical characterization of EGF receptor in a water-soluble membrane model system. Scharadin TM, He W, Yiannakou Y, Tomilov AA, Saldana M, Cortopassi GA, Carraway KL, Coleman MA, Henderson PT. PLoS One 12 e0177761 (2017)
  427. Letter Targeting human epidermal growth factor receptor 2: it is time to kill kinase death human epidermal growth factor receptor 3. Menendez JA, Lupu R. J Clin Oncol 25 2496-8; author reply 2499 (2007)
  428. The EGF Domains of MUC4 Oncomucin Mediate HER2 Binding Affinity and Promote Pancreatic Cancer Cell Tumorigenesis. Stoup N, Liberelle M, Schulz C, Cavdarli S, Vasseur R, Magnez R, Lahdaoui F, Skrypek N, Peretti F, Frénois F, Thuru X, Melnyk P, Renault N, Jonckheere N, Lebègue N, Van Seuningen I. Cancers (Basel) 13 5746 (2021)
  429. The HER2 S310F Mutant Can Form an Active Heterodimer with the EGFR, Which Can Be Inhibited by Cetuximab but Not by Trastuzumab as well as Pertuzumab. Shin JW, Kim S, Ha S, Choi B, Kim S, Im SA, Yoon TY, Chung J. Biomolecules 9 E629 (2019)
  430. UCP-2 inhibitor enhanced the efficacy of trastuzumab against HER2 positive breast cancer cells. Hua J, Zhang Z, Zhang L, Sun Y, Yuan Y. Cancer Chemother Pharmacol 88 633-642 (2021)
  431. mAb806 binding to epidermal growth factor receptor: a computational study. Ng YZ, Kannan S, Lane DP, Fuentes G, Verma CS. Proteins 83 153-168 (2015)
  432. A toolkit for studying cell surface shedding of diverse transmembrane receptors. Hayward AN, Aird EJ, Gordon WR. Elife 8 e46983 (2019)
  433. Blocking the Increase of Intracellular Deuterium Concentration Prevents the Expression of Cancer-Related Genes, Tumor Development, and Tumor Recurrence in Cancer Patients. Kovács BZ, Puskás LG, Nagy LI, Papp A, Gyöngyi Z, Fórizs I, Czuppon G, Somlyai I, Somlyai G. Cancer Control 29 10732748211068963 (2022)
  434. Computational design of a CNT carrier for a high affinity bispecific anti-HER2 antibody based on trastuzumab and pertuzumab Fabs. Salazar-Salinas K, Kubli-Garfias C, Seminario JM. J Mol Model 19 2797-2810 (2013)
  435. Differential regulation of human monocytes and NK cells by antibody-opsonized tumors. Yin J, Albers AJ, Smith TS, Riddell GT, Richards JO. Cancer Immunol Immunother 67 1239-1250 (2018)
  436. Direct stimulation of ERBB2 highlights a novel cytostatic signaling pathway driven by the receptor Thr701 phosphorylation. Gaviraghi M, Rabellino A, Andolfo A, Brand M, Brombin C, Bagnato P, De Feudis G, Raimondi A, Locatelli A, Tosoni D, Mazza D, Gianni L, Tonon G, Yarden Y, Tacchetti C, Daniele T. Sci Rep 10 16906 (2020)
  437. Effect of Spatial Inhomogeneities on the Membrane Surface on Receptor Dimerization and Signal Initiation. Kerketta R, Halász ÁM, Steinkamp MP, Wilson BS, Edwards JS. Front Cell Dev Biol 4 81 (2016)
  438. Encoding latent SuFEx reactive meta-fluorosulfate tyrosine to expand covalent bonding of proteins. Klauser PC, Berdan VY, Cao L, Wang L. Chem Commun (Camb) 58 6861-6864 (2022)
  439. Expression and purification of HER2 extracellular domain proteins in Schneider2 insect cells. Kanthala S, Mill CP, Riese DJ, Jaiswal M, Jois S. Protein Expr Purif 125 26-33 (2016)
  440. HER2 Signaling in Breast Cancer. Shin I. Adv Exp Med Biol 1187 53-79 (2021)
  441. Immunological fingerprint of 4CMenB recombinant antigens via protein microarray reveals key immunosignatures correlating with bactericidal activity. Bartolini E, Borgogni E, Bruttini M, Muzzi A, Giuliani M, Iozzi S, Petracca R, Martinelli M, Bonacci S, Marchi S, Brettoni C, Donati C, Torricelli G, Guidotti S, Domina M, Beninati C, Teti G, Felici F, Rappuoli R, Castellino F, Del Giudice G, Masignani V, Pizza M, Maione D. Nat Commun 11 4994 (2020)
  442. Interactions between anti-ErbB2 antibody A21 and the ErbB2 extracellular domain provide a basis for improving A21 affinity. Chang L, Zhou C, Xu M, Liu J. J Comput Aided Mol Des 24 37-47 (2010)
  443. Mycoplasmal lipoprotein p37 binds human protein HER2. Wu J, Wu L, Fang C, Nie R, Wang J, Wang X, Liu W. Microbiol Res 192 253-259 (2016)
  444. Novel Pituitary Actions of Epidermal Growth Factor: Receptor Specificity and Signal Transduction for UTS1, EGR1, and MMP13 Regulation by EGF. Hu Q, Xu S, Ye C, Jia J, Zhou L, Hu G. Int J Mol Sci 20 E5172 (2019)
  445. Optical fiber-based in vivo quantification of growth factor receptors. Thomas TP, Chang YC, Ye JY, Kotlyar A, Cao Z, Shukla R, Qin S, Norris TB, Baker JR. Cancer 118 2148-2156 (2012)
  446. Potential prognostic and diagnostic application of a novel monoclonal antibody against keratinocyte growth factor receptor. Ceccarelli S, Bei R, Vescarelli E, D'Amici S, di Gioia C, Modesti A, Romano F, Redler A, Marchese C, Angeloni A. Mol Biotechnol 56 939-952 (2014)
  447. Recombinant human IgG antibodies recognizing distinct extracellular domains of EGF receptor exhibit different degrees of growth inhibitory effects on human A431 cancer cells. Chang C, Takayanagi A, Yoshida T, Shimizu N. Exp Cell Res 319 1146-1155 (2013)
  448. Regulation and New Treatment Strategies in Breast Cancer. Ferraiuolo RM, Wagner KU. J Life Sci (Westlake Village) 1 23-38 (2019)
  449. Structural and dynamic characterization of the C-terminal tail of ErbB2: Disordered but not random. Pinet L, Wang YH, Deville C, Lescop E, Guerlesquin F, Badache A, Bontems F, Morellet N, Durand D, Assrir N, van Heijenoort C. Biophys J 120 1869-1882 (2021)
  450. Structural basis of a novel heterodimeric Fc for bispecific antibody production. Wei H, Cai H, Jin Y, Wang P, Zhang Q, Lin Y, Wang W, Cheng J, Zeng N, Xu T, Zhou A. Oncotarget (2017)
  451. Targeted Delivery of Deoxycytidine Kinase to Her2-Positive Cells Enhances the Efficacy of the Nucleoside Analog Fludarabine. Koduvayur SP, Su Y, Kay BK, Lavie A. PLoS One 11 e0157114 (2016)
  452. Theme: oncology--molecular mechanisms determining the efficacy of EGF receptor-specific tyrosine kinase inhibitors help to identify biomarker candidates. Yamauchi M, Gotoh N. Biomark Med 3 139-151 (2009)
  453. Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2 (HER2)-positive early-stage breast cancer: A real-world retrospective study in Chinese patients. Guo J, Li Q, Zhang P, Yuan P, Wang J, Ma F, Fan Y, Cai R, Luo Y, Li Q, Xu B. Chin J Cancer Res 31 759-770 (2019)
  454. AlbuCORE: an albumin-based molecular scaffold for multivalent biologics design. Sanches M, D'Angelo I, Jaramillo M, Baardsnes J, Zwaagstra J, Schrag J, Schoenhofen I, Acchione M, Lawn S, Wickman G, Weisser N, Poon DKY, Ng G, Dixit S. MAbs 12 1802188 (2020)
  455. Blocking soluble TNFα sensitizes HER2-positive breast cancer to trastuzumab through MUC4 downregulation and subverts immunosuppression. Bruni S, Mauro FL, Proietti CJ, Cordo-Russo RI, Rivas MA, Inurrigarro G, Dupont A, Rocha D, Fernández EA, Deza EG, Lopez Della Vecchia D, Barchuk S, Figurelli S, Lasso D, Friedrich AD, Santilli MC, Regge MV, Lebersztein G, Levit C, Anfuso F, Castiglione T, Elizalde PV, Mercogliano MF, Schillaci R. J Immunother Cancer 11 e005325 (2023)
  456. Comparison of Antibodies for Immunohistochemistry-based Detection of HER3 in Breast Cancer. Luhtala S, Staff S, Barok M, Tanner M, Isola J. Appl Immunohistochem Mol Morphol 26 212-219 (2018)
  457. Conditions of tumor-associated antigens as a proper target for therapeutic antibodies against solid cancers. Kurosawa Y. J Stem Cells Regen Med 7 14-28 (2011)
  458. Differential localization of ErbB receptor ensembles influences their signaling in hippocampal neurons. Chen J, Tseng HC, Dichter MA, Zhang H, Greene MI. DNA Cell Biol 24 553-562 (2005)
  459. Efficient and Site-specific Antibody Labeling by Strain-promoted Azide-alkyne Cycloaddition. Kim S, Ko W, Park H, Lee HS. J Vis Exp (2016)
  460. HER2 status is positively associated with vessel invasion of colorectal cancer: a retrospective large cohort study. Wang M, Wang X, Li Y, Li Q, Cai S, Li X, Ma M. Int J Colorectal Dis 37 2061-2067 (2022)
  461. HER2-Targeted Antibody-Drug Conjugates Display Potent Antitumor Activities in Preclinical Extramammary Paget's Disease Models: In Vivo and Immunohistochemical Analyses. Tokuchi K, Maeda T, Kitamura S, Yanagi T, Ujiie H. Cancers (Basel) 14 3519 (2022)
  462. Her2/neu Expression in Wilms' Tumor and Correlation With Histopathologic Findings. Babashahi M, Mehrazma M, Nasiri SJ, Azizi Jalilian F, Rezaei-Tavirani M. Iran J Cancer Prev 6 160-164 (2013)
  463. Heregulin-induced cell migration is prevented by trastuzumab and trastuzumab-emtansine in HER2+ breast cancer. Mondaca JM, Guijarro ACC, Flamini MI, Sanchez AM. Breast Cancer Res Treat 186 363-377 (2021)
  464. How Do Modulators Affect the Orthosteric and Allosteric Binding Pockets? Chen CJ, Jiang C, Yuan J, Chen M, Cuyler J, Xie XQ, Feng Z. ACS Chem Neurosci 13 959-977 (2022)
  465. research-article Human epidermal growth factor receptor 2-targeted therapies in breast cancer. Nahta R. Expert Opin Biol Ther 13 949-952 (2013)
  466. Immune microenvironment characteristics and their implications for immune checkpoint inhibitor efficacy in HER2-overexpressing gastric cancer. Cen S, Xu H, Liu Z, Zhao R, Pan H, Han W. Clin Exp Immunol 207 318-328 (2022)
  467. Integrating Network Pharmacology Approaches to Decipher the Multi-Target Pharmacological Mechanism of Microbial Biosurfactants as Novel Green Antimicrobials against Listeriosis. Adnan M, Siddiqui AJ, Noumi E, Hannachi S, Ashraf SA, Awadelkareem AM, Snoussi M, Badraoui R, Bardakci F, Sachidanandan M, Patel M, Patel M. Antibiotics (Basel) 12 5 (2022)
  468. It's all in for the HER family in tumorigenesis. Lee MK, Sharma A, Czerniecki BJ. Expert Rev Vaccines 9 29-34 (2010)
  469. Multiple Bacteriophage Selection Strategies for Improved Affinity of a Peptide Targeting ERBB2. Larimer BM, Quinn JM, Kramer K, Komissarov A, Deutscher SL. Int J Pept Res Ther 21 383-392 (2015)
  470. Nanoparticles (NPs)-mediated systemic mRNA delivery to reverse trastuzumab resistance for effective breast cancer therapy. Dong Z, Huang Z, Li S, Wang Y, Yao Y, Yang X, Xu X. Acta Pharm Sin B 13 955-966 (2023)
  471. Obtaining and characterization of monoclonal antibodies against recombinant extracellular domain of human epidermal growth factor receptor 2. Sarina N, Abeldenov S, Turgimbayeva A, Zhylkibayev A, Ramankulov Y, Khassenov B, Eskendirova S. Hum Antibodies 26 103-111 (2018)
  472. Phase II Study of Weekly Paclitaxel with Trastuzumab and Pertuzumab in Patients with Human Epidermal Growth Receptor 2 Overexpressing Metastatic Breast Cancer: 5-Year Follow-up. Wang R, Smyth LM, Iyengar N, Chandarlapaty S, Modi S, Jochelson M, Patil S, Norton L, Hudis CA, Dang CT. Oncologist 24 e646-e652 (2019)
  473. Roles of androgen-dependent and -independent activation of signal transduction pathways for cell proliferation of prostate cancer cells. Inoue T, Kobayashi T, Terada N, Shimizu Y, Kamoto T, Ogawa O, Nakamura E. Expert Rev Endocrinol Metab 2 689-704 (2007)
  474. Structure and dynamics of the EGFR/HER2 heterodimer. Bai X, Sun P, Wang X, Long C, Liao S, Dang S, Zhuang S, Du Y, Zhang X, Li N, He K, Zhang Z. Cell Discov 9 18 (2023)
  475. The quest for balance between capturing data and model complexity: A quantitative clinical pharmacology approach applied to monoclonal antibodies. Pressly MA, Peletier LA, Zheng S, Sharma VD, Lien YTK, Wang W, Zhou H, Schmidt S. CPT Pharmacometrics Syst Pharmacol 12 639-655 (2023)
  476. Therapeutic effects of pegylated-interferon-α2a in a mouse model of multiple sclerosis. Afraei S, Sedaghat R, Zavareh FT, Aghazadeh Z, Ekhtiari P, Azizi G, Mirshafiey A. Cent Eur J Immunol 43 9-17 (2018)
  477. Trastuzumab-conjugated nanoparticles composed of poly(butylene adipate-co-butylene terephthalate) prepared by electrospraying technique for targeted delivery of docetaxel. Varshosaz J, Ghassami E, Noorbakhsh A, Minaiyan M, Jahanian-Najafabadi A. IET Nanobiotechnol 13 829-833 (2019)
  478. A Novel Mechanism Underlying the Inhibitory Effects of Trastuzumab on the Growth of HER2-Positive Breast Cancer Cells. Maadi H, Wang Z. Cells 11 4093 (2022)
  479. A disruptive clickable antibody design for the generation of antibody-drug conjugates. Rakotoarinoro N, Dyck YFK, Krebs SK, Assi MK, Parr MK, Stech M. Antib Ther 6 298-310 (2023)
  480. A novel nanobody-based HER2-targeting antibody exhibits potent synergistic antitumor efficacy in trastuzumab-resistant cancer cells. Liu X, Luan L, Liu X, Jiang D, Deng J, Xu J, Yuan Y, Xing J, Chen B, Xing D, Huang H. Front Immunol 14 1292839 (2023)
  481. Affinity enhancement of HER2-binding Z(HER2:342) affibody via rational design approach: a molecular dynamics study. Ghaffari MA, Zeinali M, Barzegari Asadabadi E, Jamalan M, Jahandideh S. J Biomol Struct Dyn 32 1919-1928 (2014)
  482. An HER2 DNA vaccine with evolution-selected amino acid substitutions reveals a fundamental principle for cancer vaccine formulation in HER2 transgenic mice. Jones RF, Reyes JD, Gibson HM, Jacob JB, Vaishampayan U, Ratner S, Chen K, Wei WZ. Cancer Immunol Immunother 68 1143-1155 (2019)
  483. An integrated platform for the capture of circulating tumor cells and in situ SERS profiling of membrane proteins through rational spatial organization of multi-functional cyclic RGD nanopatterns. Dong H, Yao D, Zhou Q, Zhang L, Tian Y. Chem Commun (Camb) 55 1730-1733 (2019)
  484. Antibodies and Tyrosine Kinase Inhibitors in Breast Cancer Therapies. Barth J, Jackisch C, Untch M. Breast Care (Basel) 4 46-50 (2009)
  485. Antibody Affinity Maturation Using Computational Methods: From an Initial Hit to Small-Scale Expression of Optimized Binders. Medagli B, Soler MA, De Zorzi R, Fortuna S. Methods Mol Biol 2552 333-359 (2023)
  486. Assembly of Biologically Functional Structures by Nucleic Acid Templating: Implementation of a Strategy to Overcome Inhibition by Template Excess. Lawler MM, Kurnick JT, Fagundes St Pierre L, Newton EE, Rose LB, Dunn IS. Molecules 27 6831 (2022)
  487. Biased activation of the receptor tyrosine kinase HER2. Catapano C, Rahm JV, Omer M, Teodori L, Kjems J, Dietz MS, Heilemann M. Cell Mol Life Sci 80 158 (2023)
  488. Case Reports Case report: Long-term clinical benefit of pyrotinib therapy following trastuzumab resistance in HER2-amplification recurrent mucinous ovarian carcinoma. Fang X, Mou H, Ying X, Hou X, Wang L, Wu Y, Yan N, Guo L, Liao Q. Front Oncol 12 1024677 (2022)
  489. Computational design of fusion proteins against ErbB2-amplified tumors inspired by ricin toxin. Ahmadi Moghaddam Y, Maroufi A, Zareei S, Irani M. Front Mol Biosci 10 1098365 (2023)
  490. Defucosylated Monoclonal Antibody (H2Mab-139-mG2a-f) Exerted Antitumor Activities in Mouse Xenograft Models of Breast Cancers against Human Epidermal Growth Factor Receptor 2. Suzuki H, Ohishi T, Nanamiya R, Kawada M, Kaneko MK, Kato Y. Curr Issues Mol Biol 45 7734-7748 (2023)
  491. Effects of Chemical Fixatives on Kinetic Measurements of Biomolecular Interaction on Cell Membrane. Dong T, Wan S, Wang Y, Fu Y, Wang P. J Membr Biol (2024)
  492. Evaluation of the Expression of the Human Epithelial Receptor 2 (HER2) in Gastric Carcinoma. Cordts Filho RM, Kassab P, Claro LC, Fracassi MT, Colombo-Souza P, Fukuhara DK, Thuler FR, de Freitas Junior WR, Ilias EJ, Malheiros CA. ScientificWorldJournal 2016 7951365 (2016)
  493. Halting ErbB-2 isoforms retrograde transport to the nucleus as a new theragnostic approach for triple-negative breast cancer. Madera S, Izzo F, Chervo MF, Dupont A, Chiauzzi VA, Bruni S, Petrillo E, Merin SS, De Martino M, Montero D, Levit C, Lebersztein G, Anfuso F, Roldán Deamicis A, Mercogliano MF, Proietti CJ, Schillaci R, Elizalde PV, Cordo Russo RI. Cell Death Dis 13 447 (2022)
  494. In vitro evaluation of two polyhedral boron anion derivatives as linkers for attachment of radioiodine to the anti-HER2 monoclonal antibody trastuzumab. Persson M, Sivaev I, Winberg KJ, Gedda L, Malmström PU, Tolmachev V. Cancer Biother Radiopharm 22 585-596 (2007)
  495. Inhibition of HER Receptors Reveals Distinct Mechanisms of Compensatory Upregulation of Other HER Family Members: Basis for Acquired Resistance and for Combination Therapy. Gutsch D, Jenke R, Büch T, Aigner A. Cells 10 272 (2021)
  496. Inhibition of mutationally activated HER2. Collins SJ, Guo J, Rizzo RC, Miller WT. Chem Biol Drug Des 101 87-102 (2023)
  497. Label-free electrochemical cancer cell detection leveraging hemoglobin-encapsulated silver nanoclusters and Cu-MOF nanohybrids on a graphene-assisted dual-modal probe. Zare AA, Naderi-Manesh H, Naghib SM, Shamsipur M, Molaabasi F. Sci Rep 13 21980 (2023)
  498. Lack of a pharmacokinetic interaction between trastuzumab and carboplatin in the presence of docetaxel: results from a phase Ib study in patients with HER2-positive metastatic or locally advanced inoperable solid tumors. Eppler S, Gordon MS, Redfern CH, Trudeau C, Xu N, Han K, Lum BL. Anticancer Drugs 26 448-455 (2015)
  499. Livin participates in resistance to trastuzumab therapy for breast cancer through ERK1/2 and AKT pathways and promotes EMT-like phenotype. Li F, Zhang L, Feng F, Zheng K, Li Y, Wang T, Ren G. RSC Adv 8 28588-28601 (2018)
  500. Methodological quality evaluation of systematic reviews or meta-analysis of trastuzumab-based therapy for breast cancer: A systematic review. Wei H, Zhang YJ, Yu T, Yan XY, Jiang Q. Medicine (Baltimore) 100 e24389 (2021)
  501. MicroRNAs as biomarkers for trastuzumab-based therapy in HER2-positive advanced oesophago-gastric cancer patients. Lote H, Mousoullou F, Vlachogiannis G, Lampis A, Satchwell L, Peckitt C, Fong C, Begum R, Kidd S, Cromarty S, Gordon A, Fribbens C, Rao S, Starling N, Chau I, Cunningham D, Valeri N. Front Oncol 13 1258365 (2023)
  502. Neuregulin 4 Boosts the Efficacy of Anti-ERBB2 Neutralizing Antibodies. Miano C, Romaniello D, Mazzeschi M, Morselli A, Da Pra S, Sacchi F, Bongiovanni C, Sgarzi M, Pantano E, Lauriola M, D'Uva G. Front Oncol 12 831105 (2022)
  503. Novel method for differentiation between Trastuzumab and host adaptive response. Denisova G, Jenkins K, Evelegh C, Bramson J. Mol Immunol 48 1882-1885 (2011)
  504. Optimize the combination regimen of Trastuzumab and Nab-paclitaxel in HER2-positive tumors via modulating Caveolin-1 expression by lovastatin. Yang C, Fan S, Wang X, Liu W, Yang L, He B, Dai W, Zhang H, Wang X, Zhang Q. Asian J Pharm Sci 17 697-712 (2022)
  505. PDGFR dimer-specific activation, trafficking and downstream signaling dynamics. Rogers MA, Campaña MB, Long R, Fantauzzo KA. J Cell Sci 135 jcs259686 (2022)
  506. Pertuzumab Charge Variant Analysis and Complementarity-Determining Region Stability Assessment to Deamidation. Spanov B, Olaleye O, Mesurado T, Govorukhina N, Jungbauer A, van de Merbel NC, Lingg N, Bischoff R. Anal Chem 95 3951-3958 (2023)
  507. Preclinical development of a first-in-class vaccine encoding HER2, Brachyury and CD40L for antibody enhanced tumor eradication. Hinterberger M, Endt K, Bathke B, Habjan M, Heiseke A, Schweneker M, Von Rohrscheidt J, Atay C, Chaplin P, Kalla M, Hausmann J, Schmittwolf C, Lauterbach H, Volkmann A, Hochrein H, Medina-Echeverz J. Sci Rep 13 5162 (2023)
  508. Radioimmunotheranostic Pair Based on the Anti-HER2 Monoclonal Antibody: Influence of Chelating Agents and Radionuclides on Biological Properties. Miranda ACC, Dos Santos SN, Fuscaldi LL, Balieiro LM, Bellini MH, Guimarães MICC, de Araújo EB. Pharmaceutics 13 971 (2021)
  509. Rational Design of Dual Agonist-Antibody Fusions as Long-acting Therapeutic Hormones. Liu Y, Wang Y, Zhang Y, Liu T, Jia H, Zou H, Fu Q, Zhang Y, Lu L, Chao E, Parker H, Nguyen-Tran V, Shen W, Wang D, Schultz PG, Wang F. ACS Chem Biol 11 2991-2995 (2016)
  510. Structural arrangement of the active back-to-back dimer in N-glycosylated ErbB receptors is regulated by heterodimerization. Mashayekh-Poul R, Azimzadeh-Irani M, Masoomi-Nomandan SZ. Mol Biol Res Commun 12 95-107 (2023)
  511. Synthesis and Preliminary Biological Evaluations of Fluorescent or 149Promethium Labeled Trastuzumab-Polyethylenimine. Fitzsimmons J, Nayak T, Cutler C, Atcher R. Biomedicines 4 E1 (2015)
  512. Targeting CXCR4 abrogates resistance to trastuzumab by blocking cell cycle progression and synergizes with docetaxel in breast cancer treatment. Liu S, Xie SM, Liu W, Gagea M, Hanker AB, Nguyen N, Singareeka Raghavendra A, Yang-Kolodji G, Chu F, Neelapu SS, Marchese A, Hanash S, Zimmermann J, Arteaga CL, Tripathy D. Breast Cancer Res 25 62 (2023)
  513. Uptake of Trastuzumab Biosimilars for the Treatment of HER2-Positive Breast Cancer: A Real-World Experience from a Cancer Center. Piezzo M, D'Aniello R, Avallone I, Barba B, Cianniello D, Cocco S, D'Avino A, Di Gioia G, Di Lauro V, Fusco G, Piscitelli R, von Arx C, De Laurentiis M, Maiolino P. Pharmaceutics 13 684 (2021)


Quick links